Full Issue: Volume 12, Number 1 by unknown
The Science Journal of the Lander 
College of Arts and Sciences 
Volume 12 
Number 1 Fall 2018 - 
2018 
Full Issue: Volume 12, Number 1 
Follow this and additional works at: https://touroscholar.touro.edu/sjlcas 
 Part of the Biology Commons, and the Pharmacology, Toxicology and Environmental Health 
Commons 
Recommended Citation 
(2018). Full Issue: Volume 12, Number 1. The Science Journal of the Lander College of Arts and Sciences, 
12(1). Retrieved from https://touroscholar.touro.edu/sjlcas/vol12/iss1/1 
This Full Issue is brought to you for free and open access by the Lander College of Arts and Sciences at Touro 
Scholar. It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an 
authorized editor of Touro Scholar. For more information, please contact touro.scholar@touro.edu. 
The Science Journal
Vol. XII · Number 1 · Fall 2018

The cover illustration, created by Professor Antony O’Hara of the Digital Multimedia Design 
Program, refers to papers by Etta Rubin, Moshe Baitelman, and Maddie Nierman that discuss 
topics related the the brain.
The Relationship between Vertigo, Vestibular  
System Disorders, and Therapy
Etta Rubin  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 5
New Medical Indications for Thalidomide  
and its Derivatives
Chaya Newfield  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 11
Nonsurgical Approaches to Glioblastoma
Moshe Baitelman  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 20
Neuraxial Analgesia and its Effects on  
Neonatal and Maternal Outcomes
Ilana Tokarsky  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 27
The Association Between Type of Fat and the  
Risk of Developing Cardiovascular Diseases
Dovid Leib Glassner .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 32
What Are the Mechanisms and Effects of  
Age-Related Shortening of the Spine?
Joseph Weingarten  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 39
Xenotransplantation:The Science,  
the Advantages, the Ethics
Chana Erlbaum  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 47
Can Somatic Cell Nuclear Transfer Produce Human 
Pluripotent Stem Cells for Regenerative Medicine?
Alexandra Iskhakov  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 53
Relaxin as a Cure for Fibrosis
Sarah Akilov .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 59
Music and the Brain
Maddie Nierman  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 66
UVB Induced Mutation of p53 in  
Non Melanoma Skin Cancer












Shira Toledano  
Charter Executive Editors
Rivka Borger, P.A.
Michelle Gordon-Grunin, Ph.D. 
Layout Advisor and Editor 
Antony O’Hara, MFA
Faculty Reviewers





Robert S. Bressler, Ph.D.
Chairman of Undergraduate  
Biology Programs
Lander College  
of Arts and Sciences 









The relationship between vertigo and vestibular system disorders has been the subject of much research in recent years. The aim 
of this study is to review and analyze the relevant literature regarding this relationship, with emphasis on determining what causes 
the dizziness, how to test for vertigo, and specifically how to treat it. Additionally, while there may be many ways to prevent vertigo, 
the focus will be on how the role of therapy is vital in the future of healthcare, serving as prevention of anxiety and reoccurring 
vestibular disorders.
The Relationship between Vertigo, Vestibular 
System Disorders, and Therapy
Etta Rubin
Etta Rubin graduated in june 2018 with a b.s. degree in biology and is currently attending the physical therapy 
program at Hunter College
Introduction
About forty percent of Americans, will at some point of their 
lives have a balance problem that is disturbing enough that they 
consult a doctor, according to the National Institute of Health 
(Better Balance, 2017). Symptoms of dizziness from seasickness, 
fear of heights, or alcohol consumption were mentioned as 
early as 730 BC in Roman, Greek, and Chinese texts. However, 
due to the lack of scientific evidence at that time, an explana-
tion for this dizziness was not present until mid-19th century 
scientists began to study the somewhat camouflaged vestibular 
system and research its possible correlations to vertigo. There 
are different forms of treatment available for vertigo and vestib-
ular disorders. This review will investigate and determine which 
form of treatment is the most effective for treating vertigo and 
vestibular disorders.
Methods
The information gathered in this paper has been collected 
from numerous sources including databases such as PUBMED, 
Google Scholar, Touro Library, and Nature.com. The information 
was read, analyzed and compared to determine each study’s va-
lidity and standpoint.
Discussion: Defining the Vestibular System 
One’s balance system helps one stand, walk, run, and move with-
out falling. The eyes, inner ear, and body’s muscles and tendons co-
ordinate with the brain, which help one control balance (Tamaki, 
2016). Together the organs that control or sense the signals 
throughout the body are known as the vestibular system. The 
vestibular apparatus found in the inner ear of humans, provides a 
sense of balance and awareness of spatial orientation.  It is made 
up of three semicircular canals, anterior, posterior, and lateral, that 
are sensitive to angular accelerations (head rotations: up-down, 
side to side, and tilting movements). It also includes two labyrinth 
organs, the utricle and the saccule, that are sensitive to linear 
(or straight-line) accelerations by sensing gravity (Tamaki, 2016). 
Information from the vestibular organs of each ear, the eyes, and 
the rest of the body are then integrated in the brain.
The semicircular canals originate from the utricle and are 
positioned at a 90° angle from one another, with the horizon-
tal canal tipped backwards 20-30 degrees (Figure 2). They are 
filled with endolymphatic fluid which exerts pressure against 
the 10–50 micrometer stereocilia, the canal’s sensory hair cell 
receptors (Better Balance, 2017). Calcium carbonate crystals 
called otoconia are attached to both the medial wall of the 
saccule and floor of the utricle.  Thus, under the influence of 
acceleration of a car, for example, it can cause stimulation of the 
hair cells by their movement relative to the endolymphatic fluid. 
The receptors respond by sending impulses to the brain about 
movement from the specific canal that was stimulated. When 
the vestibular organs on both sides of the head are functioning 
properly, they send symmetrical impulses to the brain and let 
the brain know that the car has accelerated. 
Additionally, the Vestibulocochlear Nerve, also known as 
Cranial Nerve VIII, is responsible for a human’s sense of hearing 
and equilibrium (Patel et. al., 2017). It transmits balance-relat-
ed information from the semicircular canals and the labyrinth 
organs to the central nervous system. The superior portion of 
the nerve innervates anterior and horizontal canals and utricle, 
while the inferior portion innervates posterior canal and sac-
cule. When, for example, a rotational head movement occurs, it 
causes the fluid in the semicircular canals to move which causes 
the stereocilia in the saccule, utricle, and the cristae of the semi-
circular canals to bend. When the hair cells bend, they exert a 
mechanical force into electrical nerve action potentials stimu-
lating cranial nerve VIII. However, if one is jumping up and down, 
descending in an elevator, or accelerating on the highway, the 
two labyrinth organs of each ear are activated. Consequently, it 
causes the fluid in the labyrinth organs to move, while otoconia, 
the calcium carbonate crystals, lag behind. The lagging behind of 
the otoconia causes hair cells in the labyrinth organs to bend, 
and the bending of the hair cells stimulates cranial nerve VIII as 
well. Through the help of the cochlea and the vestibular appa-
ratus, cranial nerve VIII sends messages from the inner ear to 
the central nervous system to empower the body’s sensation of 
hearing and balance (Gill-Body, 2001).
History of Vertigo
Descriptions of vertigo and dizziness as a result of seasickness, 
fear of heights, and alcohol consumption were found in Roman, 
Greek, and Chinese texts as early as 730BC –600CE (Huppert 
et al, 2018). One of the earliest references to vertigo and the 
idea of dizziness in relation to fear of heights is found from 
the 5th century BC in the Hippocratic Corpus. In a collection 
of around 60 early Ancient Greek medical works strongly as-
sociated with the physician Hippocrates and his teachings, the 
6
Etta Rubin
Hippocratic Corpus uses Latin keywords of vertigo such as 
caligo, caligare, altitudo, magnitudo, and celsitudo, describing re-
lationship between heights and dizziness (Huppert et al, 2013).
During the sixteenth century the middle ear was described 
in detail and further progress was made between the sixteenth 
and eighteenth century in describing the inner ear. 
Knowledge of the vestibular system and its functions began to 
grow with nineteenth century scientists such as Jan Evangelista 
Purkinje, Ernst Mach, Josef Breuer, Hermann Helmholtz, and 
Alexander Crum-Brown (Huppert et al, 2018). The first text-
book on neurology (Lehrbuch der Nervenkrankheiten des 
Menschen, 1840) by Moritz Romberg contained general de-
scriptions of signs and symptoms of various conditions with the 
key symptom of vertigo, but lacked a definition of vestibular 
disorders. However, in the nineteenth century technological ad-
vancement permitted a description of the cells and structures 
that constituted the cochlea. Von Helmholtz made progress in 
hearing physiology when he postulated his resonance theory, 
and later Von Békésy made progress as well when he observed 
a traveling wave within the cochlea of human cadavers. Brownell 
later made a major advance when he discovered that the ear 
has a mechanism for sound amplification, via outer hair cell elec-
tromotility (Hachmeister, 2003).
Vertigo as a Symptom
Vertigo and dizziness are among the most common complaints 
in neurology clinics. They account for about 13% of patients en-
tering emergency units and are reported as the third most com-
mon major medical symptom in general medical clinics (Brandt, 
Dieterich, 2017). 
Dizziness and vertigo are complex neurological symptoms, 
traditionally categorized as one of four “types” based on symp-
tom quality: (1) vertigo, an illusion of spinning or motion, (2) 
presyncope, feeling faint, (3) disequilibrium, a loss of balance or 
equilibrium when walking, and (4) lightheadedness, wooziness, 
and giddiness, etc. (Newman-Toker, 2007).
Vertigo is a symptom, not necessarily a disease, but it is an 
outcome of a physiological or uncontrolled processes, character-
ized by sudden dizzy spells causing a lot of discomfort (Srinivasan, 
Jebasingh, 2007). Vertigo is often caused by an inner ear problem. 
The sensations from the inner ear, eyes, and throughout the body 
(somatosensory) are mismatched. Humans need the above three 
to regulate their balance (Better Balance, 2012). Any abnormality 
in one or more of these can trigger vertigo. 
Vertigo can also be caused by decreased blood supply to certain 
areas of the brain. This can follow mini-strokes called transient 
ischemic attacks (TIAs) or can happen as a result of a permanent 
stroke (Seiden, 1989). Similarly, head trauma, even a minor blow 
to the head, is a risk factor to cause vertigo (Naguib et al, 2012).
There are different types of vertigo. Rotatory vertigo mimics 
the sensation of being on a merry-go-round, like in vestibular 
neuritis and other disorders, while postural vertigo resembles 
the sensation of riding in a boat. Yet many patients use the term 
“dizziness” for lightheadedness without any sensation of move-
ment (e.g., in drug intoxication). Lightheadedness is the most 
common type of vertigo; it mainly affects older patients and it is 
characterized by brief attacks of rotational vertigo, accompanied 
by vertical positioning nystagmus that rotates toward the lower 
of the two ears and beats toward the forehead. The attacks are 
triggered by reclining the head, or by lateral positioning of the 
head or body, with the affected ear downward. After a change in 
position of one of these types, rotational vertigo and nystagmus 
arise after a latency of a few seconds and last a total of 30 to 60 
seconds (Strupp, Brandt, 2008).
Importance of Treating Vertigo 
According to news from Munich, Germany by NewsRx editors, 
research states, “Vertigo and dizziness are among the most 
common complaints in neurology clinics, and they account for 
about 13% of the patients entering emergency units (Nervous 
system diseases and conditions, 2017). “Some vertigo is so vio-
lent a person can’t get out of bed, sometimes for several days at 
a time. They can’t hold a job or take care of the family or just be 
with the family. Some balance problems can be very debilitating,” 
says Browning, a certified clinical audiologist at Rocky Mountain 
Hearing and Balance in Salt Lake City (Collins, 2007)
The NIH also reports that balance-related falls cause more 
than half of the accidental deaths among the elderly. About forty 
percent of people over age sixty five fall each year, totaling more 
than thirteen million falls a year, resulting in at least 1,600 senior 
citizens’ deaths as a direct or indirect result of falls (Collins, 2007).
Dysfunction of the vestibular system in humans can be severe 
and extremely debilitating, leading one to become housebound 
and lead a very restricted life, with high rates of anxiety disor-
ders and depression. In the United States of America, approx-
imately 35% of people aged 40 and over have suffered from 
some form of vestibular dysfunction [based on a sample of 
5,086] (Smith, 2017).
Vestibular Disorders and Vertigo
Humans can become disoriented if different sensory input re-
ceived from their eyes, muscles, tendons, or vestibular organs 
conflict (Brennan, 2012). For example, Physiological vertigo is 
Vertigo while in moving vehicles, colloquially known as motion 
sickness. This is due to a “sensory conflict” between one’s vi-
sion and the actual movement sensation. In motion sickness, 
it is caused by multi-sensory motions that do not correlate to 
the expected pattern of movement. Many feel better sitting in 
the front seat of the car or bus as it gives them more visual 
input than at the back seat. These individuals are encouraged 
to keep their eyes open as this will let the brain gain more 
information of the movement of the vehicle and decrease the 
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vertigo. Additionally, signal conflicts may occur when a person is 
standing next to a bus that is pulling away from the sidewalk. The 
visual image of the large moving bus may create an illusion for 
the pedestrian that he, rather than the bus, is moving. However, 
at the same time the information from his muscles and joints in-
dicates that he is not actually moving. Sensory information pro-
vided by the vestibular organs helps override sensory conflicts 
(Bedford, 2012). In addition, higher level thinking and memory 
might suggest the person to glance away from the moving bus 
to look down in order to seek visual confirmation that his body 
is not moving relative to the pavement. 
One of the most commonly diagnosed vestibular disorders 
is Benign Paroxysmal Positional Vertigo, also known as BPPV 
(Smith, 2017). BPPV is a mechanical problem in the inner ear 
that is the most frequent cause of dizziness. It occurs when a 
tiny crystal of calcium breaks free from the wall of one of the 
semi cicular canals and moves into the canal of the inner ear, 
causing disruptions in the inner ear signals that are eventually 
sent to the brain about head and body movements (Najeeb, 
2016). Typically, the crystals fall into the posterior semicircular 
canal every time the patient lies down with the affected ear 
down. As a result, the crystals move the fluids of the inner ear, 
activating the sensor of the semicircular canal inappropriate-
ly. This is perceived as vertigo or spinning by the patient and 
lasts less than a minute until the crystals settle down and stop 
moving (Vestibular.org). It can occur suddenly while the sleeping 
person gets into a particular position, yet, the after effects of 
uneasiness and unsteadiness are even more disturbing than the 
original pain (Baloh, 1998). BPPV is called “benign” because it 
usually resolves spontaneously within a few weeks or months; 
in some cases, however, it can last for years. If left untreated, it 
persists in about 30% of patients (Strupp et al, 2008).
The treating physician will perform a simple maneuver called 
the Dix Hallpike to test for the condition. The doctor will ask 
the patient to sit on the exam table and he’ll turn the patient’s 
head 45 degrees to one side and then will help him or her lie 
back quickly so his or her head hangs slightly over the edge of 
the table. This movement may make the loose crystals move 
within the semicircular canals. The doctor will then ask if the 
patient feels symptoms of vertigo and watch his or her eyes 
to see how they move, checking for nystagmus, an involuntary 
movement of the eyeballs, which is a major symptom of vertigo.
Once vertigo is proven, the follow-through procedure would 
be either an Epley maneuver involving rotation of the patient in 
the reclining position with their head hanging down, or Semonts 
or Brandt Daroff maneuvers, which are all equally effective. 
The cure rate for these procedures is more than 95% within a 
few days, as shown by multiple controlled studies (Strupp et al, 
2008). The purpose of these procedures is to displace abnormal 
calcium deposits within the inner ear to an area which prevents 
them from stimulating the nerve cells, which causes vertigo. 
Canalith Repositioning Maneuvers, also known as Epley ma-
neuvers, can be used to treat vertigo. It is a repositioning ma-
neuver involving sequential movement of the head into four po-
sitions, staying in each position for approximately thirty seconds 
to subsequently move the displaced crystals out of the affected 
area (American-hearing.org).
With a series of specific head and body movements for BPPV 
recommended by the American Academy of Neurology, the 
movements are done to move the calcium deposits out of the 
canal into an inner ear chamber so they can be absorbed by the 
body. One will likely have vertigo symptoms during the proce-
dure as the canaliths move. The movements are safe and often 
effective. Commonly, this will be followed by Brandt-Daroff ex-
ercises, which will consist of shaking the crystals within the flu-
ids by alternating body positions and ultimately dissolving them. 
The treatment of benign paroxysmal positioning vertigo with 
the Semont maneuver is as follows: In the initial sitting posi-
tion, the head is turned forty five degrees to the side of the 
unaffected “healthy” ear. Then the patient is laid on the right 
side, i.e., on the side of the affected ear, while the head is kept 
in forty five degrees of rotation to the other side. This induces 
movement of the particulate matter in the posterior semicircu-
lar canal by gravity, leading to rotatory nystagmus toward the 
lower ear that stops after a brief interval. The patient should 
maintain this position for about one minute. While the head 
is still kept in forty five degree of rotation toward the side of 
the healthy ear, the patient is rapidly swung over to the side of 
the unaffected ear, so that the nose now points downward. The 
particulate matter in the semicircular canal now moves toward 
the exit from the canal. This position, too, should be maintained 
for at least one minute. The patient returns slowly to the initial, 
sitting position. The particles settle in the utricular space, where 
it can no longer induce rotatory vertigo. The above sequence 
should be performed three times in a row three times per day, 
in the morning, at noon, and at night. Most patients are free of 
symptoms after doing this for three days (Strupp et al, 2008).
If one is diagnosed with BPPV, one should get treatment from 
a physical therapist. Physical therapy has a success rate with the 
symptoms usually resolving within one or two treatments. The 
physical therapist guides the patient through a series of move-
ments that will relocate the crystals to their place of origin 
or to an area of the ear that is not affected by their presence 
(Kelowna Capital News, 2008).
Another kind of vertigo is vestibular vertigo. Vestibular vertigo 
is the leaking of inner ear fluid, vestibular failure, infection of 
the vestibule, and tumors. Vestibules are sensitive to the move-
ment of the head, and any type of irritation or damage to the 
vestibules can cause confusion in the brain, resulting in vertigo. 
Vestibular nerve inflammation, which is mostly viral in nature, is 
self- limiting and almost always resolves by itself. 
Similarly, Labyrinthitis and Vestibular Neuritis are vestibular 
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disorders resulting from an infection that inflames the inner 
ear or the nerves connecting the inner ear to the brain. This 
inflammation disrupts the transmission of sensory information 
from the ear to the brain. Vertigo, dizziness, and difficulties with 
balance, vision, or hearing may result. This is explained from the 
inner ear organs and the balance signals sent through the ves-
tibulocochlear nerve. When one ear is infected, it sends faulty 
signals and thus the brain receives mismatched information, re-
sulting in dizziness or vertigo.
Lastly, Meniere’s disease is a chronic, incurable vestibular 
disorder defined in 1995 by the Committee on Hearing and 
Equilibrium of the American Academy of Otolaryngology. It pro-
duces a recurring set of symptoms as a result of abnormally large 
amounts of endolymph fluid collecting in the inner ear. Meniere’s 
disease can develop at any age, but it is more likely to happen to 
adults between 40 and 60 years of age (Agrup Et. Al., 2007).
Vertigo is often triggered by a change in the position of one’s 
head. Within seconds, one can experience an awful sensation, 
as if the entire environment has begun to spin or that one is 
spinning against a stationary environment. One may feel nause-
ated, have a headache, and have abnormal jerky eye movements 
(Brandt, 2000). Ringing in the ears or hearing loss symptoms can 
last a few minutes to a few hours or more and may come and 
go. Another symptom may be nystagmus, which is involuntary 
movement of the eyeballs. One will not see it in the mirror 
because once one fixes their vision in the mirror, nystagmus 
disappears. Additionally, hemi spatial neglect (failure to be aware 
of one side of space), room tilt illusion, loss of spatial memory, 
and ultimately pusher syndrome, a loss of postural balance are 
all symptoms of vertigo. It is important to note that most of 
the peripheral vestibular disorders have a clinical diagnosis, and 
therefore medical history is important.
Testing for Vertigo
The Head Impulse Test (HIT) is one of the many tests to do to find 
the possible cause of vertigo. During the Head Impulse Test, the pa-
tient is asked to fix his or her eyes on a target (e.g. the examiner’s 
nose). The examiner will then generate a rapid head impulse while 
monitoring the patient’s eyes for a corrective or compensatory 
saccade (CS) response. Individuals with normal vestibular function 
should not generate a compensatory saccade after a head impulse, 
rather the eyes should stay fixed on the target. 
Ocular Motor Testing looks at the systems responsible for 
integrating balance, vision, and movement. Four categories of 
ocular motor functions: stability of gaze; smooth pursuit eye 
movements,optokinetic nystagmus; and saccadic eye move-
ments are used to determine spontaneous and gaze-evoked 
nystagmus. Nystagmus often results in reduced vision and depth 
perception and can affect balance and coordination. This testing 
can also be used to determine skew deviation- wherein the eyes 
move upward (hypertropia), but in opposite directions. Skew 
deviation is caused by abnormal prenuclear vestibular input to 
the ocular motor nuclei, most commonly due to brainstem or 
cerebellar stroke.
Frenzel goggles are extremely useful in evaluation of patients 
with vestibular disorders. They were termed by the German 
otolaryngologist Herman Frenzel from Gottingen, Germany in 
the 1950’s, and have been used as an examination tool to disable 
the patient’s ability to visually fixate on an object while at the 
same time allowing the examiner to adequately visualize the 
eye. In essence, they consist of the combination of magnifying 
glasses and a lighting system. When Frenzel goggles are placed 
on the patient and the room lights darkened, nystagmus can 
easily be seen because the patient’s eyes are well illuminated 
and magnified, and because fixation is removed as the patient 
can hardly focus through magnifying glasses on a dark room. The 
Frenzel goggles reduce visual fixation by means of the magnifi-
cation glasses of about sixteen diopters (a unit of measurement 
of the optical power of a lens or curved mirror), and also allow 
a better examination of the eye movements, specifically nystag-
mus (Strupp, et. Al., 2014).
Despite these tests, sometimes one may feel dizzy or 
light-headed but it’s not truly vertigo. This is common in people 
with panic disorders or low blood sugar count, or when one 
suddenly stands up from a lying or seated position or is intox-
icated with drugs or alcohol. Alcohol interferes with the com-
munication between nerve cells and cell receptors that send 
messages between the body and the brain. As a result, the cere-
bellum, the part of the brain that usually creates nerve impulses 
that control an individual’s balance and other fine movements 
for balance, cannot function properly due to the uncoordinated 
nerve signals. Ultimately, the muscle movements become unco-
ordinated and one can lose his or her balance (Susanto, 2014).
Treatment
Vertigo is a symptom, so finding its cause is the key to treating 
it. For some, treatment from an audiologist, physical therapist, 
or occupational therapist for balance treatment is needed. In 
many cases, vertigo goes away without any treatment. This is 
because one’s brain is able to adapt, at least in part, to the inner 
ear changes, relying on other mechanisms (Phillips, 2011). For 
example, if one is at a very loud concert, the brain adapts and 
contracts the inner ear muscles to protect the inner ear from 
damage. Similarly, the brain relies on sight as well as the muscu-
loskeletal system to help with balance when one is walking along 
a beach. Stepping on sand may not be as sturdy as pavement, but 
with the help of the eyes and muscles, one can maintain his or 
her balance even on uneven surfaces. 
“Vestibular Rehabilitation” may be recommended if one has 
recurrent bouts of vertigo. This is a type of physical therapy 
aimed at helping strengthen the vestibular system. It helps train 
the other senses to compensate for vertigo or learn ways to 
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turn one’s head or move without getting dizzy. It includes im-
proving balance and stability while in motion, improving neuro-
muscular coordination and decreasing anxiety due to vestibular 
disorientation, and minimizing falls (Merlingolda, 2013).
Medicine can be another treatment towards vertigo discom-
fort. In some cases, medication may be given to relieve symp-
toms such as nausea or motion sickness associated with vertigo. 
Antihistamines such as meclizine (Antivert) may offer short-
term relief from vertigo in addition to anti-nausea medications 
(Donaldson et al, 2008). If vertigo is caused by an infection or 
inflammation, antibiotics or steroids may reduce swelling and 
cure the infection. 
In a few cases when medical treatment is not effective in 
controlling vertigo, surgery may be considered to repair or 
stabilize the inner ear function (Strupp et al, 2008). There are 
destructive treatments that are designed to eliminate vertigo, 
possibly sacrificing hearing. These procedures are appropriate 
for consideration when medical treatment and vestibular reha-
bilitation has failed to control vertigo symptoms. For example, 
labyrinthectomy is a destructive procedure used for Ménière’s 
disease. Labyrinthectomy is appropriate for patients in whom 
there is no hearing in the ear which is causing vertigo and thus 
offers excellent control of vertigo (Hain 2012). The balance end 
organs, namely the semicircular canals and two otolith organs, 
are removed so that the brain no longer receives signals from 
the parts of the inner ear that sense gravity and motion changes. 
It is important to note the hearing organ, the cochlea, is also 
sacrificed with this procedure. Ultrasound surgery at times may 
also be used to destroy the balance end organs so that the brain 
no longer receives signals from the parts of the ear that sense 
gravity and motion changes (vestibular.org).
After an estimated half a million people have received cochlear 
implants by 2016, several decades since the first cochlear implant 
was performed in 1961 (Smith, 2017), the success of cochlear 
implant technology has naturally encouraged researchers to 
consider other forms of bionic implants that can substitute for 
lost sensory function. The development of the ‘vestibular implant 
or prosthesis’, which aims to replace a missing or dysfunctional 
vestibular system, has been given to groups of patients since 2007 
and considerable progress has been made in this area. 
It is important to note, if vertigo is caused by a more serious 
underlying problem, such as a brain tumor or injury to the brain 
or neck, initial treatment for those conditions may help to alle-
viate its chain reaction vertigo as well.
Conclusion
Through the analysis and research shown throughout the paper, 
it leaves one empowered by what may be the best future health-
care treatment for one who has vertigo and other vestibular 
disorders. There are many types of treatment for vestibular dis-
orders, but where does the future for best healthcare treatment 
of vertigo and vestibular disorders lie? According to the above 
research discussed, doctors and healthcare providers should be 
weary of surgery and medication as solutions to vertigo, for 
many times the vertigo symptoms may prove to be invalid or 
subside over time and these treatments are short term and 
destructive to nearby organs in the body. As a healthier and 
longer lasting alternative, Vestibular Rehabilitation via Epley, 
Sermont, or Brandt Daroff Maneuvers will not only help control 
the dizziness, but also strengthen other senses in the body to 
compensate for vertigo.  As a result of the therapy, it will not 
only prove strengthening of the vestibular system, but will also 
decrease the anxiety and the symptoms of disorientation that 
occur as a result of vestibular disorders.
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Thalidomide is an anti-inflammatory and an anti-angiogenesis drug that is being used around the world for a variety of malig-
nant and inflammatory diseases. Is it justified to continue prescribing and developing thalidomide given the discovery of many 
well-known side effects including catastrophic birth defects? To answer this question, this paper will discuss the pharmacology 
and history of thalidomide, as well as many of its proposed mechanisms of action. The medical indications for the current use of 
thalidomide as well as for several newer and more potent derivatives are mentioned for their therapeutic results, as well as their 
adverse side effects. 
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Introduction to Thalidomide
“Thalidomide remains, arguably, the greatest disaster in medical 
history” (Greener, 2011). Thalidomide was introduced in 1957 
by a German pharmaceutical company as a sedative and hypnot-
ic drug. It was also widely used in several countries to alleviate 
morning sickness in early pregnancy. It was sold in more than 
forty-six countries without any testing for teratogenicity, as was 
common practice for new drugs at that time. More than 10,000 
children around the world developed severe birth defects, espe-
cially shortening or absence of limbs. There was also an increase 
in miscarriages and infant mortality. Remarkably, the United States 
Food and Drug Administration did not approve sale of thalido-
mide despite five requests from manufacturers. As a result, only 
seventeen babies were affected in the United States, probably 
from thalidomide purchased in Canada (Huang, et. al. 2008).
By 1961 production and distribution of thalidomide were 
banned worldwide. Due to the risk of teratogenicity, almost no 
research into the use of thalidomide took place for the next 
decade. The first new indication for thalidomide was in treating 
a complication of leprosy known as erythema nodosum lepro-
sum (ENL) (Sharma, et. al. 2007). Beginning in 1967, anecdotal 
reports of the use of thalidomide in cancer treatment began to 
be published. Some of the diseases treated were astrocytoma, 
multiple-myeloma, chronic lymphocytic leukemia, and malignant 
melanoma. New research is being done to investigate the mecha-
nism of action of this class of immunomodulatory drugs in various 
malignancies and in non-malignant conditions such as Alzheimer’s 
Disease and persistent erythema multiforme (He, et. al. 2013).
Methods
Articles and studies researched in this paper were obtained 
through the EBSCO and ProQuest databases with access pro-
vided by the Touro College Library. Additional research articles 
were obtained through the National Center for Biotechnology 
Information (NCBI) website and the Jackson Laboratory web-
site. Images and diagrams that are used throughout the paper 
were obtained from the research articles cited.
Chemical Analysis
Thalidomide is a racemic glutamic acid analogue also known as 
[+] alpha-[N-phthalidimo]-glutarimide. It consists of two linked 
rings: a glutamic ring and a phthalic ring. Because it contains a 
chiral carbon the molecule is unstable and can switch back and 
forth between two enantiomers which are mirror images of 
each other. This reaction takes place rapidly in water or body 
fluids. While only one state, the S-enantiomer is thought to be 
teratogenic, the safer state, the R-enantiomer, is not stable and 
cannot be preserved in the body.  (Bartlett, et. al. 2004)
Thalidomide has traditionally been synthesized by a multi-
step process which uses expensive ingredients and produces a 
very low yield. A recent research study by chemists at Stockton 
University in New Jersey reports on a new rapid synthesis of 
thalidomide and its analogs using easily obtained reagents which 
rapidly interact with the assistance of a microwave. It produces 
relatively high yields. The reaction of the corresponding anhy-
drides using DMAP (4-N, N- dimethylaminopyridine) as a base 
catalyst takes place in ten minutes at 150 degrees Celsius. The 
chemists developing this new method of production describe 
their innovation as a, “novel green one-pot synthetic technique.” 
(Benjamin, et. al. 2017)
Pharmacology
Thalidomide has an active half-life of 8 to 12 hours. It is bro-
ken down by hydrolysis in tissue fluids and metabolized by the 
liver using the cytochrome p450 system. Although it is absorbed 
slowly, it has a high oral bioavailability. The plasma concentration 
peaks after at least two hours. Little drug is bound to protein in 
the plasma. The average elimination half-life of both enantiomers 
is five hours. (Vargesson, et. al. 2015)
According the British Columbia Cancer Drug Manual ac-
cessed online, high fat meals increase the time to peak con-
centration. Thalidomide is distributed mostly in the internal 
organs such as the gastro-intestinal tract, liver and kidneys. It 
is found to cross the blood brain barrier and is also found in 
the ejaculate.
In 2004, a new derivative of thalidomide was introduced for 
treatment of multiple myeloma. Lenalidomide, under the trade 
name Revlimid is considerably more potent than thalidomide. 
It has an added amino group at position 4 of the phthaloyl 
ring and removal of a carbonyl group from the phthaloyl ring. 
Pomalidomide (3-aminothalidomide) was the second thalido-
mide analog to be used in treating multiple myeloma. It is even 
more potent than the analogs before it. A third thalidomide 
analog, Apremilast is now showing effectiveness as an oral treat-
ment for psoriasis and psoriatic arthritis. (Bartlett, et. al. 2004)
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Mechanism of Action: Innate immunity: Effects 
on Epidermal Regeneration, Soluble Mediators, 
and Natural Killer Cells
Studies of epidermal regeneration have shown that thalidomide 
increases human keratinocytes migration and propagation. 
Testing was done with a motility assay and thymidine incorpo-
ration assays to better understand how thalidomide promotes 
this proliferation. In addition, the chemokine IL-8 that promotes 
migration of neutrophils and keratinocytes significantly increas-
es with thalidomide treatment. Because of this, researchers have 
theorized that the mechanism with which thalidomide aids in 
wound healing is by promoting keratinocyte production and 
movement. This may be useful in explaining its ability to treat 
ulcerative diseases, such as Behcet’s (a rare disorder causing in-
flammation in blood vessels with symptoms that include mouth 
and genital sores, inflamed eyes, and rashes) and aphthous sto-
matitis (shallow sores inside the mouth or at the base of the 
gums that make it hard to eat or talk) (Paravar & Lee, 2008). 
The exact mechanism of thalidomide’s anti-inflammatory 
action via soluble immune mediators is still being investigated. 
However, researchers have linked thalidomide’s anti-inflamma-
tory action to its ability to speed up the degradation of messen-
ger RNA in blood cells. These effects have been analyzed in both 
human monocytes and mouse macrophages (Paravar, Lee, 2008). 
By reducing the half-life of the messenger RNA coding for 
TNF-alpha, (Tumor Necrosis Factor) it in turn reduces the 
blood serum level of TNF-alpha. TNF-alpha is a cell signaling pro-
tein (cytokine) involved in systemic inflammation. By reducing 
TNF-alpha, thalidomide is an effective treatment for inflamma-
tory diseases such as erythema nodosum leprosum (ENL) and 
lupus erythematosus (LE). Many studies have been performed 
that confirm this reduction of TNF-alpha. For example, 48-68% 
of patients with ENL have a reduction of TNF-alpha in the 
serum from their pretreatment levels. Tuberculosis patients also 
show reduced levels in in-vitro and in-vivo studies and patients 
gained a significant amount of weight while on the medication. 
HIV-1 patients also had reduced TNF-alpha levels while under 
treatment with thalidomide. A further confirmation comes from 
studies using rodent models of pancreatitis in which thalido-
mide was seen to have similar effects (He, et. al. 2013).
Another proposed mechanism of action involves thalido-
mide’s effects on Natural Killer (NK) cells which are vital in 
destroying tumor cells, intracellular pathogens, and cells in-
fected by viruses. Using in-vitro studies, thalidomide has been 
observed to enhance NK-cell-mediated lysis of cancerous cells. 
This was demonstrated in a study that co-cultured NK cells 
with the same patient’s cancerous cells. Additionally, thalidomide 
increases the secretion of NK cell activators such as IL-12 and 
specifically induces NK cell antitumor responses. In an in vivo 
study, the number of NK cells in a multiple myeloma patient 
were increased with thalidomide therapy. The results of these 
studies indicate that thalidomide’s ability to enhance NK-cells 
is the mechanism by which it aids in the treatment of multiple 
myeloma (Paravar, Lee, 2008). 
Adaptive immunity: B Cell Antibody Suppression, 
T Cell Stimulation
Thalidomide suppresses B cell antibody formation in studies 
primarily using New Zealand Black (NZB) and Murphy Roths 
Large (MRL) mice. These strains were chosen because they have 
a genetic predisposition to autoimmune disorders (The Jackson 
Laboratory Website, updated 2018). Thalidomide inhibits the 
usually increased production of splenic IgM in NZB mice and 
splenic and lymph node IgG1 in MRL mice. In clinical studies, 
leprosy patients receiving thalidomide and dapsone treatment 
had lower serum IgM levels than patients receiving dapsone 
alone. The combination of these studies suggests that thalido-
mide’s action may be based on its downregulatory effects on 
antibody production (Paravar & Lee, 2008). 
Thalidomide was shown to be able to co-stimulate T cells 
once they were already partially activated by the T cell receptor. 
Co-stimulation is an important mechanism for immune defense. 
A second signal is sent to naïve T cells which facilitates their ini-
tiation and further generation of an antigen-specific effector re-
sponse. The co-stimulatory effect of thalidomide can be used as 
an immunological adjuvant, that is, it can enhance the response 
to tumor antigens in cancer patients (Bartlett, et. al. 2004).
Reduction of Tumorigenesis: Apoptosis and 
Restriction of Tumor Growth, and Antiangiogenic 
Activity
Tumors grow and expand due to their ability to evade apopto-
sis. In studies, thalidomide has induced apoptosis (G1 growth 
arrest) in human cancerous cells. It has also been shown to 
decrease the expression of the apoptosis-suppressing protein 
Bcl-2 in blood and bone marrow of patients with multiple my-
eloma. Another mechanism proposed is thalidomide’s ability to 
induce monocyte apoptosis by involving the cytochrome c-de-
pendent pathway. (Cytochrome c is known for its role in the 
mitochondria as a key contributor in ATP synthesis. In our case, 
we are more interested in thalidomide’s stimulation of cyto-
chrome c’s other effect which is triggered when a cell receives 
an apoptotic stimulus. The cytochrome c is then released into 
the cytosol and triggers programmed cell death through apop-
tosis) (Paravar & Lee, 2008). 
In 1971, Dr. Judah Folkman of Harvard Medical School formu-
lated his hypothesis that tumor growth depends on angiogen-
esis, the formation of new blood cells in the malignant tissue. 
Thalidomide, as mentioned above, inhibits limb bud formation 
in the embryo. This led to the idea that the teratogenic and 
antiangiogenic actions may be related.
Dr. Folkman made the groundbreaking discovery that tumor 
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growth and angiogenesis were related when he was working on 
testing the efficacy of hemoglobin solutions as a substitute for 
blood transfusions. As a part of this study he injected isolated 
organs with mouse melanoma cells. He found that the tumors 
could not grow and spread in the isolated perfused organs, but 
when they transplanted these same tumor cells into mice, they 
were quickly vascularized and grew larger. After conducting 
more research trials to prove his hypothesis, Dr. Folkman pub-
lished an article in the New England Journal of Medicine that 
stated that tumor growth depends on angiogenesis and that in-
hibiting angiogenesis can be used to treat certain cancers. From 
1980 to 2005 Dr. Folkman’s lab worked on testing twelve angio-
genic inhibitors including interferon alpha, fumagillin, endostatin 
and, notably, thalidomide (Ribatti, 2008).
Angiogenesis, the development of new blood vessels, is vital to 
the growth and spreading of cancerous tumors. The cancer de-
grades basement membranes and extracellular matrix and brings 
endothelial cells towards an angiogenic stimulus. It also involves 
pericytes and smooth muscles cells as well. Various growth fac-
tors are also needed to form new blood vessels from preexisting 
micro vessels. These growth factors include vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF), and 
platelet-derived growth factor (PDGF) (Fialho, et. al. 2013).
One proposed mechanism for thalidomide’s antiangiogenic 
effect is its ability to inhibit VEGF and bFGF production, which 
thereby inhibits vessel growth. Studies using human endothelial 
cells showed that thalidomide inhibits VEFG secretion and cell 
migration and lowers the total number of capillaries. In studies 
using chicken embryonic chorioallantoic membrane (CAM) tha-
lidomide inhibited VEGF and bFGF induced vessel growth. In one 
trial done by the Department of Cellular and Molecular Biology 
and Pathogenic Agents of the University of Sao Paulo, twelve 
CAMs from chicken eggs were incubated with thalidomide im-
plants and analyzed after two days to review the percentage of 
vessel deterioration. The results showed significant regression 
of vessels in CAM that had thalidomide or thalidomide-loaded 
implants as compared to the negative control (NC) group and 
an implant not containing any drug (Fialho, et. al. 2013).
Another study proposed that thalidomide inhibits endothelial 
cell proliferation by inhibiting the binding of the SP-1 transcrip-
tion factor, which has many binding sites on the VEGF promoter. 
This protein usually binds to the VEGF promoter to initiate and 
activate the transcription of the gene directly. When its binding 
is inhibited, it causes less VEGF to be produced and therefore 
limits the cells’ growth (Yabu, et. al. 2005).
A third mechanism of action being researched is thalidomide’s 
ability to suppress the VEGF gene by downregulating the VEGF 
receptors Flk-1 and neuropilin-1. By reducing the productiv-
ity of the VEGF receptors, thalidomide lessens the effects of 
the vascular endothelial growth factor in general. This causes 
less signals for angiogenesis to be sent, so the body forms less 
vasculature. With a smaller supply of blood, the growing limbs 
do not receive enough oxygen and nutrients, and they subse-
quently do not grow properly and result in under developed or 
malformed limbs (Yabu, et. al. 2005).
 A study done using zebrafish embryos and Human Umbilical 
Vein Cells (HUVEC) showed promising results in this area. The 
thalidomide treated embryo was shorter in length than the con-
trol. In addition, the lumens of the dorsal artery and posterior 
cardinal vein were clearly seen (with hematoxylin and eosin 
staining) in the control but were so reduced in the embryo 
treated with thalidomide that they were barely visible (Yabu, 
et. al. 2005).
Teratogenesis
Over the past fifty years, many separate models for thalidomide 
embryopathy have been proposed, however a full understand-
ing of its mechanism of action is still incomplete. The proposed 
theories are not necessarily mutually exclusive. And it is possible 
that multiple mechanisms of action are each involved to some 
extent. Additional theories include nerve toxicity, inhibition of 
cell adhesion molecules and effects on chondrogenesis. 
One breakthrough discovery revealed that Cereblon (CRBN), 
a protein encoded by the CRBN gene, may be the primary tar-
get for binding by thalidomide. The authors found that thalid-
omide binds directly to CRBN, a substrate receptor for the 
CUL4A-DDB1 E3 ubiquitin ligase, a protein that employs an E2 
ubiquitin-conjugating enzyme that carries ubiquitin, recognizes a 
protein substrate, and assists the transfer of ubiquitin from the 
E2 to the protein substrate. The ubiquitin is used to tag specific 
proteins to be broken down by proteasomes. This binding in-
hibits the activity of the assembled E3 ubiquitin ligase complex 
so that it does not tag the specific proteins, and an unknown 
substrate is allowed to accumulate. This in turn effects the ex-
pression of the fibroblast growth factor eight (FGF8) and causes 
growth defects. Thus, the action of the E3 ubiquitin ligase com-
plex is necessary for limb outgrowth (particularly in zebrafish) 
and by disrupting this complex, thalidomide induces teratogenic 
effects. Consequently, they demonstrated that the deformities 
caused by thalidomide were directly mediated through stopping 
its inhibition of CRBN. In zebrafish and chickens, when they 
used an overexpression of a CRBN mutant that does not bind 
thalidomide, they did not notice the defects usually caused by 
this drug, proving that it is the binding of the drug to CRBN that 
is responsible for the embryopathy effect (Ito. et. al. 2010).
Following this discovery, CRBN was also shown to be cru-
cial for the mechanism of action of thalidomide’s anti-myeloma 
properties, as well as other immune-modulatory drugs (IMiDs). 
One of the downstream targets of CRBN was shown to be in-
terferon regulatory factor 4 (IRF4). This protein which regulates 
the transcription of interferons is essential for myeloma cell 
survival and is downregulated by IMiD therapy (Zhu, et. al. 2013).
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A recent series of experiments supported in part by the 
National Cancer Institute further confirmed the hypothesis 
that antiangiogenesis and teratogenesis are related. The re-
searches tested a variety of angiogenesis inhibitors, including 
thalidomide and its analog CPS49, using zebrafish and chicken 
embryo models. They focused on assessing the developmental 
defects and teratogenic effects that the drugs caused. They 
concluded that different classes of angiogenesis inhibitors, 
regardless of the molecular target or specific mechanism of 
action, are teratogenic to chicken embryos. This study also 
proved that using chicken embryos and zebrafish embryos is 
a valid way to screen new drugs for teratogenic effects before 
they are used in clinical trials on women of childbearing age 
(Beedie, et. al. 2016).
New Research in Treatments Using Thalidomide 
and Its Derivatives: Multiple Myeloma (MM)
Multiple Myeloma is a type of blood cancer that affects plasma 
cells. In multiple myeloma, malignant plasma cells amass in the 
bone marrow crowding out the normal plasma cells that help 
fight infection. This disease can damage the bones, immune sys-
tem, kidneys, and cause anemia. A randomized trial compared 
the costs and benefits of using a melphalan (chemotherapy) and 
prednisone (steroid) treatment in conjunction with thalidomide 
(MPT) as opposed to melphalan and prednisone (MP) alone. The 
testing was done on 135 elderly patients over the age of 65 with 
MM who were ineligible for stem-cell transplants. The results 
showed a significant increase in the median progression-free 
survival (PFS) of patients using a combination of drugs that in-
cluded thalidomide. PFS is the length of time during and after 
the treatment of a disease that a patient lives with the disease 
but it does not get worse. Also, the overall survival (OS) rate 
was 52 months as opposed to only 32 months for patients using 
only melphalan and prednisone.  The following graph compares 
the progression-free survival rate of patients using MPT versus 
MP treatment. The MPT group has a significantly higher PFS rate. 
The Y axis is the fraction of living patients who began in the 
study. Both the MPT and MP groups start at 1.00, meaning that 
100% of participants are alive. The X axis is the months of the 
treatment. The MPT group has a higher PFS rate during the forty 
months of the trial. The P value is 0.02, meaning the results are 
statistically significant (Sacchi, et. al. 2011).
One downside of adding thalidomide to the treatment reg-
iment is the adverse side-effects that were more frequent in 
patients using thalidomide, which will be discussed in more de-
tail in the “Adverse Effects of Thalidomide” section of this paper. 
Researchers observed a significant increase in neutropenia, 
deep venous thrombosis, infection, and peripheral neuropathy. 
The incidence of toxicity correlates with the drug dosage. The 
study concluded that while including thalidomide in the therapy 
showed an increase in activity against MM, it came with a sub-
stantial cost, which will be discussed later.
Trials have also been conducted using the second-generation 
thalidomide derivate, lenalidomide.  In a randomized, controlled 
clinical trial, lenalidomide therapy (in combination with dexa-
methasone, a corticosteroid, or with melphalan and prednisone) 
significantly improved PFS in patients with newly diagnosed MM 
who were not eligible for stem-cell transplants as compared to 
MP treatment alone. These improvements in progression-free 
survival were also reflected in patients’ health-related quality of 
life (McCormack, 2015). 
In general, the analog was found to have improved efficacy and 
increased tolerability as compared to thalidomide. Although the 
treatment regiments had similar efficacy results, lenalidomide was 
observed to have fewer toxic side-effects than its parent drug. The 
continuous use of lenalidomide did not have a negative impact on 
the drug’s tolerability. It also did not increase the cases of neutro-
penia as compared with shorter-term use of the drug. With new 
analogs, melphalan and prednisone plus a thalidomide-type drug 
could be considered the new standard of care for the treatment 
of patients with MM over age 65 years and for younger patients 
who are transplant-ineligible (McCormack, 2015).
Recent studies are working on understanding lenalidomide’s 
mechanism of action. They propose that it affects signal trans-
duction, also known as cell signaling, which leads to the sup-
pression of COX-2 but not COX-1. This can partly explain its 
selective efficacy on cells. Meaning, it is able to be more selective 
in the cells it targets so it can have a greater potency with less 
side effects. Even though the exact molecular targets of lena-
lidomide are not well known, its activity across a spectrum of 
conditions highlights the possibility of multiple target sites of 
action (Kotla, et. al. 2009).
Malignant Melanoma
Malignant melanoma is the most aggressive and life-threatening 
skin cancer. It develops in the melanocytes and has a very high 
Figure 1. Depiction of the downstream targets of thalidomide that 
may lead to its teratogenic properties (Zhu, et. al. 2013).
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tendency to spread to other parts of the body. Symptoms can 
include a new, unusual growth or a change in an existing mole. 
Brain metastases will develop in almost half of the patients with 
advanced melanoma and in 15-20% of these patients, the central 
nervous system is the first site of relapse. The overall survival rate 
is very short, only two to four months (Vestermark, et. al. 2008).
In one study, the antitumor activity and toxicity of thalidomide 
was evaluated in patients with phase II brain metastases related 
to metastatic melanoma. Thalidomide was administered orally 
to patients, with the dose increasing over a one-month period 
from 100 mg per day to 400 mg per day. Twenty-five men and 
eleven women with a median age of forty-eight years were en-
rolled in the study. The average survival rate for the study group 
was unchanged from historical data. Median PFS was 1.7 months 
and OS was 3.1 months. Although thalidomide showed limited 
activity against the metastatic melanoma in the central nervous 
system, minor effects on peripheral tumor manifestation were 
noted. This led researchers to conclude that thalidomide may 
one day be part of the treatment plan for patients with that 
form of metastasis in the future. Researchers also concluded 
that more investigation should be done using thalidomide in 
combination with Temozolomide, a cytotoxic chemotherapy 
drug (Vestermark, et. al. 2008).
Persistent Erythema Multiforme
Erythema multiforme is a common, usually self-limited disease 
which predominantly affects patients in their 20s and 30s. Its 
symptoms include target shaped lesions (circular red patches 
with central clearing) on the skin and mucous membranes. 
There are three clinical subgroups of erythema multiforme: 
classical, recurrent, and persistent erythema multiforme. The 
most severe form is the persistent erythema multiforme 
which can leave a patient stricken with continuous lesions. No 
potential cause has been found yet, so this subgroup is defined 
as idiopathic. 
Thalidomide can be effectively used as a treatment for this 
skin condition. It was initially introduced as a treatment for 
persistent erythema multiforme as early as the 1980’s because 
of its immunomodulatory and anti-inflammatory effects. The 
following case report in the recent literature illustrates its 
effectiveness. A fifteen-year-old boy in the Republic of China 
experienced a sudden onset of target-like lesions on his trunk 
and limbs. Although the wounds healed within two weeks, new 
eruptions continued to appear. After unsuccessful treatment 
attempts with oral corticosteroids and topical agents as well 
as the antiviral drug valaciclovir, thalidomide was prescribed 
to the patient. After two weeks of administering 100 mg per 
day, the lesions gradually healed, and no new ones developed. 
After two months of slowly reducing the dosage, there was no 
recurrence of disorder. The researchers noted that because of 
the risk of neuropathy associated with taking daily doses of this 
medication, clinical vigilance and regular neurological exams are 
advised (Chia-Wei, et. al. 2008).
Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus is an autoimmune disease, 
which affects multiple organ systems in the body. In this disease 
an individual’s own immune system attacks various cells causing a 
wide variety of symptoms. Typically, it causes extensive, disfiguring 
lesions. Although these lesions are not life threatening, they can 
be very itchy or painful. Many patients respond to standard treat-
ment methods such as sunscreen, topical corticosteroids, or oral 
antimalarial drugs. However, for cases in which these treatments 
did not prove useful, or if the CLE was severe, thalidomide can be 
an important therapeutic option (Sharma, et. al. 2007).
In a study done by the Department of Dermatology at the 
University Hospital of Leuven, Belgium, thirty patients received 
thalidomide treatment for refractory CLE over fifteen years 
(from February 1998 to August 2013.) Each of these patients 
had previously tried at least two different drug treatments 
with no success. All of them were required to follow vigorous 
contraceptive methods because of thalidomide’s known terato-
genic properties. Patients received an initial dose of 50 mg per 
day, which was increased to 100 mg if the CLE was extensive. 
Although six patients prematurely stopped treatment due to 
the negative side-effects, all patients who continued in the study 
experienced improvements within 1-9 weeks after beginning 
treatment. A high rate of relapse (73%) was observed in patients 
who stopped thalidomide treatment. In addition, five patients 
were not able to be weaned off the drug due to flare-ups of 
CLE when they attempted to taper off the doses. The research-
ers concluded that while thalidomide treatment for CLE does 
have strong efficacy, because of its considerable risk of polyneu-
ropathy, it should only be considered as a possible therapy for 
severe cases of CLE or for patients who have exhausted other 
treatment options without significant relief (Baret, et. al. 2015).
In another study done on twenty-five patients in India suffering 
from various inflammatory skin diseases, including discoid lupus 
erythematosus, thalidomide was found to be an effective treat-
ment. Of the seven patients with LE, four had excellent response, 
two had partial response and one discontinued treatment due 
to deep vein thrombosis (DVT). The authors recommended tha-
lidomide as an effective treatment but advised physicians to be 
watchful of thrombo-embolic events (Sharma, et. al. 2007).
Erythema Nodosum Leprosum (ENL)
When the author’s father, Stanley Newfield MD, was a young 
dermatology resident training at the United States Public Health 
Service Hospital in Staten Island, New York he was involved in 
diagnosing and treating many cases of leprosy, also known as 
Hansen’s disease. This research interest was perhaps especially 
appropriate since he is a kohen, the traditional caretaker for 
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people suffering from tzoras (leprosy) in the Torah. 
As a federal institution, his hospital was responsible for car-
ing for patients with transmissible infectious diseases. Leprosy 
patients were referred from a large area of the north-east-
ern United States for treatment. One of the complications of 
leprosy is the immune-system reaction known as Erythema 
Nodosum Leprosum. ENL is characterized by the presence of 
many inflammatory skin nodules and symptoms such as fever, 
arthritis, eye inflammation, neuritis, and swollen lymph nodes.  It 
was observed that many patients suffered from ENL, which was 
even more distressing to them than some of the other leprosy 
symptoms such as loss of sensation in the extremities and/or 
exaggerated skin folds on the face. 
Dr. Newfield explained that he was surprised, back in 1979, to 
find that the infamous drug, thalidomide, was the miraculously 
effective treatment for ENL. He was well-aware of the tera-
togenic effects of the drug which he learned about in detail in 
medical school. Now this same drug was resurrected for a new 
use, albeit with strong precautions to avoid administration to 
pregnant women. Due to his involvement in leprosy treatment, 
he was coauthor of a research report on the epidemiology of 
leprosy in New York City, which was published in the presti-
gious Journal of the American Medical Association.  
Many people have a fear of leprosy since it is transmissible 
through contact with an infected patient. However, this seems 
to require prolonged exposure, usually in a household setting. 
The research verified that very few leprosy patients acquire the 
disease in the continental United States, rather they brought 
the disease with them when they immigrated to this country. 
The average latent period from entering the United States until 
onset of symptoms was 4.8 years, with a range of 0 to 38 years 
(Levis, et. al. 1982).
Almost forty years have passed since thalidomide was first 
used for ENL treatment, and it remains the drug of choice for this 
condition, as evidenced by two current research reports originat-
ing from India, a country with a large number of leprosy patients. 
The first paper reports on eleven patients with ENL. Six of those 
patients had excellent response to thalidomide and five had to 
stop treatment prematurely due to side-effects (most commonly 
DVT but also rashes and tremors.) (Sharma, et. al. 2007) In the 
second study following one hundred patients diagnosed with 
ENL, the group of fifty patients treated with thalidomide had a 
faster and longer lasting clinical response than the control group 
of fifty patients treated with prednisolone, a strong steroid med-
ication. Patients on thalidomide also experienced fewer relapses 
of their cutaneous symptoms (Kaur, et. al. 2009).
Animal Models of Alzheimer’s Disease (AD)
Alzheimer’s Disease is a degenerative disease that destroys 
memory and other important mental functions. This is an in-
curable condition that afflicts an estimated 5.7 million people 
in the United States, mostly over the age of sixty-five. Research 
studies are currently being performed on a mouse model of AD. 
In one study, healthy mice were injected with streptozotocin 
(STZ), a chemical that causes AD-like cognitive deficits. In this 
study, one group of mice were pre-treated with thalidomide. 
Learning and memory behaviors were evaluated on the seven-
teenth, eighteenth and nineteenth days of the study using the 
Morris water maze test. In this test, a mouse is placed in the 
center of a circular pool and must find the hidden platform that 
allows it to escape. Mice that are not treated with the drug will 
improve their time to escape after doing the test multiple times. 
The SZT injections caused a significant decrease in the mice’s 
improvement in their performance on the test. In comparison, 
the learning and memory behaviors of the thalidomide treated 
mice were significantly better preserved and they were able to 
complete the tests with improved timing, although they were 
not as improved as the mice who did not receive any drugs. 
This positive result appears to be due to the anti-inflammatory 
effect of TNF-alpha inhibition (Elçioğlu, et. al. 2013). 
A second study used a strain of mice with the human 
APPswedish transgenic (APP23) mutation. This mutation is as-
sociated with Alzheimer’s Disease. These mutated mice show 
deficits in spatial memory which become severe with age.  (The 
Jackson Laboratory Website. 2018) This report showed that 
thalidomide treatment improved memory and learning ability 
in the mutated mice. The level of TNF-alpha in the thalidomide 
treated mice was decreased. This in turn reduced the amount of 
amyloid (A beta 1-42,) a harmful protein, which accumulated in 
their brain tissue. The control group mice treated with the inac-
tive vehicle had 750 units of harmful amyloid, while the thalido-
mide group had only approximately 100 units (He, et. al. 2013).
In mice brain tissue, the control group (treated with the vehi-
cle) developed a large number of harmful senile plaques but the 
thalidomide treated group showed very few.
Adverse Effects of Thalidomide
This section summarizes the adverse effects of thalidomide, some 
of which have also been mentioned previously. Thalidomide was 
withdrawn from widespread use shortly after the devastating 
effects on developing embryos was discovered. The drug came 
back into limited use for malignant and inflammatory diseases 
in non-pregnant women.  It can still have serious harmful effects: 
peripheral neuropathy (pain and tingling in the hands and feet), 
venous thrombosis (blood clots in the veins), skin rashes, consti-
pation, somnolence (excessive daytime sleepiness), weakness, and 
bradycardia (BC Cancer Drug Index. updated 2018).
Peripheral neuropathy is a common side effect that is associ-
ated with prolonged use of the drug, but there is no clear mech-
anism of action that explains its correlation with a cumulative 
dose. The risk for nerve damage is highest after 6 months or 
more of therapy. The symptoms are usually reversible when the 
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patient stops thalidomide treatment, although some patients do 
suffer long term nerve damage (Rajkumar, et. al. 2002).
Constipation caused by thalidomide can vary from mild to se-
vere. As many as 90% of patients can develop mild constipation. 
This effect is thought to be secondary to thalidomide’s action 
on the autonomic nerve endings in the gut. Severe constipation 
usually occurs in patients who are taking high doses of thalido-
mide. It is especially prevalent among patients who are already 
prone to developing constipation, such as those who lead an 
inactive lifestyle. Change of diet and exercise can help alleviate 
this side effect (Hall, 2003).
Deep vein thrombosis and pulmonary embolisms only occur 
in one to three percent of the patients receiving thalidomide 
as treatment for myeloma. There is not enough research done 
yet to determine whether the risk of DVT in these patients is 
higher than usual for patients receiving other types of treatment 
for this severe malignancy, due to the nature of the disease or 
the side effect of immobility that it can cause. Patients confined 
to bed rest tend to have higher rates of DVT. The risk is also 
elevated when patients receive thalidomide treatment in combi-
nation with dexamethasone or other chemotherapy drugs, have 
an inherited thrombotic predisposition, or are over the age of 
sixty-five (Hall, 2003).
A recent case report documents a thirty-eight-year-old fe-
male from Puerto Rico with a history of prenatal thalidomide 
exposure. She suffered from phocomelia, the dramatic birth 
defect in which the hands or feet are attached close to the 
trunk. An MRI scan revealed that the uterus and vagina were 
also absent. These internal anomalies have been less appreciated 
by physicians because they are not noticeable without special 
imaging, however they can cause serious symptoms such as pain 
and malignancy (Dotters-Katz, et. al. 2013).
The analog drug, lenalidomide, has not been found to be 
teratogenic in rabbits, a sensitive species used to detect birth 
defects. However, it may still have adverse effects such as mor-
billiform rashes (Huang, et. al. 2008). In a study done at Mount 
Sinai Medical Center in New York City, doctors found that 7.2% 
of the 806 patients receiving IMiD treatment developed rashes. 
In almost all cases, the rashes could be managed without hav-
ing to discontinue treatment. Thus, it appears that lenalidomide 
may lack some of the adverse effects of thalidomide, while still 
having superior immunomodulatory and antiangiogenic efficacy 
than its parent drug (Barley, et. al. 2016).
An additional analog, Pomalidomide, is now an approved 
drug for MM. A research study conducted in Aberdeen, United 
Kingdom analyzed its effect on zebrafish and chicken embryos. 
The tests showed no detectable teratogenic, antiangiogenic or 
neurotoxic effects. Despite having less side effects, it has more 
anti-inflammatory properties than either thalidomide or lenalid-
omide (Mahony, et. al. 2013).
Conclusion
The psalmist wrote, “The stone that the builders rejected became 
a cornerstone.” (Psalm 118:22) This report illustrates this concept 
as it pertains to the drug, thalidomide. This drug was universally 
banned due to its harmful side-effects. Years later it was found to 
have unique healing properties in several serious diseases.
It appears that the continued use and development of thalid-
omide treatments is justified. Although it can have many serious 
side effects, specifically crippling teratogenesis, it is often the 
last resort as treatment for patients suffering serious diseases. 
Care should be taken to prevent pregnant women from using 
this drug to avoid causing birth defects. Given the significance of 
these effects, the future of thalidomide is not in the drug itself 
but in the derivatives that are now being tested. Lenalidomide 
and pomalidomide are more effective and have less toxic effects. 
As scientists continue to discover their specific mechanisms of 
action they will be able to alter the drug to have even less ad-
verse effects and help more patients worldwide. The prognosis 
for PFS and OS for patients with MM and other forms of can-
cer will decrease even more and give the people suffering with 
these diseases hope for their future. With this new and exciting 
research thalidomide and its analogs have justly become import-
ant medical treatments. 
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Abstract
Due to the sensitivity of location, brain cancer is one of the most difficult and deadly known cancers. There are various forms of 
cancer in the brain with many shared characteristics as well as unique manifestations in each. While cancers originating in the 
central nervous system present in several ways, the most common forms are high grade gliomas generally, and glioblastoma or 
anaplastic astrocytomas specifically. With the advent of technology, researchers have been able to propose and refine extensive 
profiles of these relentless tumors, enabling greater and more successful treatment profiles to be developed. Where treatments 
used to consist primarily of chemotherapy and surgery, research has enabled the development of immunotherapy and gene 
therapy techniques as well as alternative treatments to take on the caustic disease.
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Introduction
The foremost distinction of brain tumors is between primary; 
those that originated within the brain itself, and secondary; those 
that developed beyond the blood brain barrier and migrated to 
the brain under metastatic conditions. Secondary tumors ac-
count for the majority of all brain cancers and approximately 
50% of these tumors metastasize from lung cancers (Gallego, 
2015). According to the 2014 World Cancer Report, patients 
diagnosed with glioblastomas were measured to have a median 
survival time of 12-15 months post diagnosis with fewer than 
5% of patients living beyond 3 years (Patchell, 2003).Under the 
World Health Organization’s grading protocol for central ner-
vous system (CNS) cancers, glioblastomas (GBM) are a grade 
IV glioma (Bleeker, et al., 2011). This is the most common form 
of primary brain tumor and the most fatal found in humans, 
accounting for 15% of all intracranial neoplasms (Bleeker, et al., 
2011; Young, et al., 2015). The average age at diagnosis is 64 years 
old and the approximate annual incidence of GBM per 100,000 
population is 3.19 cases, making an understanding of the dis-
ease and its treatment of paramount importance (Ostrom et 
al., 2017). GBMs develop rapidly de novo in astrocytes, star-
shaped neuroglial cells suspected to play a role in blood brain 
barrier maintenance and neurotransmitter management (Kolb 
& Whishaw, 2009). This swift development occurs without any 
previous primary or lower grade lesion development that may 
indicate or preclude the GBM onset, making early diagnosis and 
adequate treatment more difficult. 
Since 2005, the first-line standard of care has been estab-
lished as surgery followed by chemotherapy, most often with 
temozolomide (TMZ), and radiotherapy. Despite the established 
longevity of this standard, its efficacy is highly questionable and 
there is still recurrence in the majority of cases (Patchell, 2003). 
To complicate matters further, there is no second-line standard 
of care for glioblastomas and recurrence is consistently fatal 
(Roy, et al., 2015).
Discussion: Difficulties with Conventional 
Treatments
One of the significant factors contributing to the aggressive 
character of GBMs is their infiltrative nature. Astrocytes have 
extensive networks of processes forming from their cell bodies, 
creating an intricately branched structure extending through-
out the nervous system. Where some cancers merely invade 
their host tissue, the cells of grade IV astrocytomas penetrate 
their host with protrusions. These processes weave a complex 
margin with host tissue that blurs the border between invasive 
and host cells. This makes complete surgical resection nearly 
impossible as practitioners are unable to differentiate between, 
and separate, the healthy and malignant tissue. As a result, re-
currence is extremely high in GBMs and alternative treatments 
must often be considered post-surgery when complete resec-
tion is not achieved (Patchell, 2003). 
Beyond the inability to properly remove gliomas, the benefit 
of surgery is questionable. In a study of recurrent brain tumors, 
researchers found no significant benefit to a second resection, 
though a first resection did confer an increased overall survival 
(Suchorska et al., 2015). Nonetheless, the nature of the neurosur-
gical procedure lends itself to various complications. Along with 
the wound and postsurgical medical complications, brain surgery 
runs the risk of systemic and cortical injuries, damaging physical 
and mental health with the most common risk of neurological 
impairment (Jackson, et al., 2016). Research also found that the 
acquisition of motor and language deficits post-surgery is linked 
to decreased survival rates compared to patients without surgical 
brain damage (McGirt et al., 2009). The results of these studies 
indicate that the benefit of surgery is questionable.
Chemotherapy treatments generally follow the attempted re-
section procedures but have limited success due to the imperme-
ability of the blood brain barrier to foreign chemicals (Deeken & 
Loscher, 2007). TMZ is a common chemotherapy drug for gliomas 
and has demonstrated mild success against GBM and anaplastic 
astrocytoma but its overall effectiveness is slim and is accom-
panied by a cocktail of undesirable side effects (Friedman, et al, 
2000). The established first-line standard of care is precarious and 
insufficient. As a result, research has turned to alternative meth-
ods by which to treat and manage this deadly.
Genetic Analysis
In order to purposefully theorize and discuss possible solutions 
and treatments, GBM manifestation must first be understood. 
Occurring primarily in older patients, GBM progresses quickly 
and with low survival rates. A minority of cases have been seen in 
younger patients with a history of epilepsy connected to progres-
sive low-grade gliomas (Ostrom et al., 2015). To address the lack 
of understanding, research continues to look for commonalities 
in tumor onset. As genomic instability is an enabling characteristic 
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of cancer, efforts have been made in the field to source a prima-
ry effector with genetic basis. As of yet, there is only one con-
firmed molecular predictive factor for GBM - methylation of the 
O6-methylguanine-DNA methyltransferase (MGMT) promoter 
(Bleeker, et al, 2011). The relative dearth of information on the 
molecular basis for GBM requires additional research. 
Whole-genome single nucleotide polymorphism (SNP)-based 
array analysis of gene expression in GBM patients has indicated 
several genetic changes that shed some light on the nature of 
the illness. Notably, loss of heterozygosity frequently occurs on 
the 17p gene, which contains the tumor protein 53 (p53) (The 
Cancer Genome Atlas (TCGA), Research Network, 2008). Loss 
of heterozygosity refers to the deletion of a chromosome por-
tion with the corresponding homologous segment being dupli-
cated to compensate for the loss of gene neutrality (Bleeker, et 
al, 2011). The significance of this mutation is reflected in the loss 
of genetic code for p53.   p53 encodes a nuclear phosphopro-
tein involved in regulation of cell proliferation. In other words, 
wild type p53 is a tumor suppressor gene. Mutations in p53 not 
only cause loss of tumor suppression, they can activate p53 to 
an oncogene in a negatively dominant fashion implicating these 
mutations in a number of cancers (Finlay, et al., 1989). Further, 
loss of heterozygosity of chromosome 10q is associated with 
poor rates of survival and is the most common genetic alter-
ation found in primary and secondary GBM’s. This chromosome 
contains various tumor suppression codes, most notably the 
region containing ANXA7, an epidermal growth factor recep-
tor (EGFR) inhibitor, and deletions contribute to a proliferation 
of cell growth; a distinguishing behavior of cancerous tumors 
(Yadav et al., 2009). 
Additional research focuses on genetic amplifications associ-
ated with GBM. Specifically, amplification of the gene for EGFR 
on chromosome 7 has been shown to be a consistent charac-
teristic in glioblastomas (Finlay, et al, 1989; Bleeker, et al, 2011). 
Focal amplifications (amplifications containing a small concen-
tration of genes) correlate with overexpression or mutation 
of EGFR, leading to subsequent activation of the PI3K/AKT 
pathway, another indicator of poor prognosis (Beroukhim et al., 
2007; Phillips et al., 2006). General amplification of entire chro-
mosomes, specifically chromosome 7, has shown correlation 
with the activation of the Met axis, a codependent cycle with 
Hepatocyte Growth Factor (HGF) which furthers the occur-
rence of cell proliferation (The Cancer Genome Atlas (TCGA), 
Research Network, 2008). 
Another genetic component considers IDH1 mutations. 
The IDH1 gene codes for isocitrate dehydrogenase 1, a critical 
component of the citric acid cycle, catalyzing the conversion of 
isocitrate to α-ketoglutarate. Mutations of this gene have been 
discovered in 12% of glioblastomas (Watanabe, et al., 2008). 
Mutations of this enzyme do not appear to cause loss of func-
tion, rather, cancer-associated IDH1 mutations alter the reaction 
of the enzyme, enabling it to catalyze the NADPH-dependent 
reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). 
As many humans have a reduced capacity to dispose of 2HG 
in an efficient manner, overaccumulation of the metabolite has 
been implicated in the formation of malignant brain tumors 
(Dang et al., 2009). 2HG also has a penchant to activate NF-κB, 
a prominent protein complex that controls cytokine produc-
tion, cell survival, and DNA transcription, implicating it in many 
cancers, including various leukemias (Chen et al., 2016). 
Ultimately, the strongest evidence of a genetic aspect to GBM 
is that of the MGMT promoter. While TMZ treatment in general 
has shown some benefit, much of its effectiveness is diminished 
by this molecular occurrence. TMZ acts by modifying the O6-
position in guanines. This translates to DNA lesions leading to 
DNA cross-links preventing cell replication. MGMT can remove 
the alkyl groups and contribute to TMZ resistance but not 
when methylated. Because about 50% of patients exhibit MGMT 
methylation, the effectiveness of TMZ is considerably lessened 
in approximately half of all cases (Bleeker, et al., 2011). Research 
is being done particularly in this area to better understand the 
environment surrounding methylation and prospectively har-
nessing the power of methylation to increase TMZ effectiveness 
(Lee et al., 2018).
Additional aberrations in genetic behavior exist in GBM with 
varying degrees of frequency. With more tools becoming avail-
able, it is apparent that the picture of GBM is not clear and 
further genetic research is required. Nonetheless, these tools 
enable researchers to identify the most prevalent deviations 
from typical behavior. For example, many alterations occur 
within three primary pathways; the p53, RB, and PI3K/AKT 
pathways, and appear to occur in a mutually exclusive fashion 
(The Cancer Genome Atlas (TCGA), Research Network, 2008). 
This defines a narrower scope of application, hopefully resulting 
in the development of rational therapeutic techniques and drug 
design. These genomic approaches may ultimately contribute to 
more individualized therapies for greater patient longevity.
Immune Evasion and Immunotherapy
In addition to the complications involved with gene aberrations 
in malignant gliomas, the impressive rate at which GBMs evade 
natural immune response opens another point of study for 
prospective treatments. Avoidance of the immune system was 
added as a defining characteristic of cancer in 2011 and an ex-
amination of the natural immune response has helped develop 
vaccinations and treatments for various diseases (Hanahan & 
Weinberg, 2011). Nonetheless, the ability of tumors to dodge 
these receptors requires a better understanding, specifically in 
the brain. In line with original theories, the CNS is immuno-
logically privileged. Unfortunately, it is not quite as privileged 
as once suspected. While early theories assumed this privilege 
was a result of isolation of the brain by the blood brain barrier, 
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newer research refutes this. Peripheral immune cells do in fact 
cross the barrier, but CNS neurons and glia regulate immune 
responses in a different fashion than other cells (Carson, et 
al., 2006). Researchers have demonstrated this deviance from 
the standard immune system using experimental foreign grafts 
to rabbit brain. These grafts were rejected at a much slower 
rate than grafts to less unique locations (Medawar, 1948). An 
additional indication of CNS immune system inadequacy is the 
immune response of the brain in multiple sclerosis patients. The 
immune system of affected individuals appears to contribute 
directly to the proliferation of the disease rather than fighting it 
(Hemmer, et al., 2015). Despite these deficiencies, analysis sug-
gests proper manipulation of the immune system can assist in 
the fight against brain cancers, achieved through understanding 
the mechanism by which tumors evade it. 
ICT-107 is a multiple-antigen-pulsed dendritic cell vaccine 
containing multiple tumor-associated antigens (HER2, TRP-2, 
gp100, MAGE-1, IL13Rα2, and AIM-2) known to interact with 
glioma stem cells. These antigens may be ideal for vaccination 
as their introduction to the dendritic cell tumor environment 
stimulates T-cells to generate glioblastoma specific cytotoxicity 
(Huang et al., 2017). This immunotherapy was the first such trial 
to reflect significant results in terms of overall, progression-free 
survival in newly diagnosed GBM (McGranahan, et al., 2017). 
A phase III trial is awaiting additional funds to further investi-
gate the effectiveness of this vaccine (Phuphanich et al., 2012). 
Another vaccine in phase II trials is Gliovac. This vaccine utilizes 
autologous antigens from the patient subjects combined with 
allogeneic antigens (antigens with a dissimilar genetic makeup 
from that of the patient) derived from other GBM patients. 
Beyond using tumor lysate, the Gliovac vaccine is designed 
similarly to ICT-107 to encourage the development of cyto-
toxic T-cells to enhance the struggling immunological response 
(Schijns, Virgil E J C et al., 2015). Further studies examine the link 
between the CTLA-4 receptor, a constitutively active receptor 
on the Treg gene, and its downregulation of the immunologic 
response in active T cells (Leach, et al., 1996). By blocking CTLA-
4, researchers have seen considerable success with enhancing 
antitumor immunity, rejecting both artificially introduced and 
pre-established tumors. The rapid growth of immunothera-
peutic treatments stresses the importance of a more compre-
hensive understanding of the immune system and its reactions 
to foreign in vivo developments. More specific information on 
marker antibodies will go a long way in furthering treatments, 
not only for GBM but also for other immuno-evasive diseases.
Treatment with Infection
A seemingly counterproductive method of treatment has been 
considered to address incomplete resection of glioblastoma 
tumors. While the actual number of surgical site infections 
after malignant brain tumor resection is not well established, 
data indicates the rate to be about 3.4% (Uzuka et al., 2017). A 
speculative theory supported with anecdotal evidence present-
ed the idea that patients who developed postoperative bacterial 
infections and survived had a radically increased overall survival. 
A study reported four cases of patients with surgical site in-
fections living well beyond the expected range of survival for 
glioblastoma (Bowles, et al., 1999). This theory has been sub-
jected to several trials and though not statistically significant, re-
sults showed that many infected patients live longer on average 
though reverse logic may be cloud results. Infection may cor-
relate with increased life span because patients that live longer 
are more likely to develop an infection, not because infection 
lengthens survival (De Bonis et al., 2011).
Antiangiogenic Treatments
Antiangiogenic treatments have shown a lot of promise in can-
cers management and particularly in that of GBM as second-line 
treatments. The rationale for antiangiogenics is strong; as cancers 
are highly vascular, preventing the growth of blood vessels to sup-
ply the tumor should help deplete tumor resources and severely 
retard malignancy. Tumors are known to exploit the body’s nutri-
ent and oxygen supplies and require enhanced networks of blood 
and lymphatic vessels to facilitate this resource abuse (Nishida, 
et al., 2006). Vascular endothelial growth factor (VEGF) is a sig-
naling protein that stimulates the creation of blood vessels and 
has received increased attention as an indicator of oncogenesis 
(Pavlova & Thompson, 2016). To address this, researchers devel-
oped Bevacizumab, a monoclonal antibody that counters the 
effects of VEGF and has been approved for trials in the United 
States for some time. Dosed intravenously, Bevacizumab has been 
used independently as a monotherapy and in pairs or groups of 
antiangiogenics for a multi therapeutic approach in various cancer 
types. In early trials, a statistically significant number of patients 
demonstrated an improvement in overall survival, but random-
ized phase III trials have been unable to demonstrate an apprecia-
ble improvement in overall survival required to move this form of 
therapy forward (Bleeker, et al., 2011).
Retroviral Delivery
A promising treatment technique addresses issues with alterna-
tive treatments. Retroviral replicating viruses (RRVs), are a novel 
way of treatment delivery and contain a wide variety of unique 
characteristics that allow for highly specific gene transfer in an 
efficient manner. Pharmaceutical companies are combining many 
of the above therapies into a single, comprehensive treatment 
method for recurrent high-grade gliomas with the goal of ex-
tending these concepts to further treatments. 
Retroviruses are positive-sense RNA viruses. These obligate 
parasites cannot reproduce or complete their life cycle without 
a host cell. Once within a host, these viruses use the enzyme 
reverse transcriptase to produce DNA from the viral RNA 
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sequences. This DNA strand is then incorporated into the host 
cell genome with an integrase enzyme. By transferring it’s ge-
netic data into the host, the virus ensures it will be reproduced 
when the host reproduces. The applications of these viruses 
can allow scientists to produce desired proteins and genetic 
products for treatment purposes. These viruses confer many 
advantages to the treatment of cancers and in particular, of 
glioblastoma. One such benefit of RRVs is the selective accep-
tance within cells. It has previously been established that tumors 
exhibit a distinct loss of immunity and that a central aspect of 
cancer development is the evasion of the immune system. Cell 
populations naturally assess tissue to prevent proliferative, un-
controlled growth, and cancers evolve to avoid the anti-tumor 
response. This evolution evades immune checkpoints and reg-
ulators but also enables immunoediting, the process by which 
cancers read, react, and adapt to immune processes. By disabling 
the anti-tumor response, cancer cells can replicate continuously 
unchecked (Butt, et al., 2004). The lack of immunity that per-
mits cancers to exist also creates an opportunity for medical 
intervention. RRVs are generally recognized by healthy cells and 
dealt with accordingly by the normal immune system, but the 
reduced defense mechanism of cancer cells allows the RRV to 
incorporate genetic components into the cancer gene pool. This 
selective acceptance safeguards healthy tissue while priming 
cancer cells. Another key feature of RRVs is the ability to spread 
non-lytically and without an exceptional inflammatory response. 
Gene products are not produced until the virus is activated 
and this avoids an inflammatory response from the innate im-
mune system (which is not heavily compromised). Coupled 
with a nonlytic retroviral infection, this delivery system enables 
researchers to target specifically cancerous or immunocompro-
mised cells (Logg, et al., 2012).
The Tocagen therapy relies on an engineered retrovirus known 
as Toca 511 (vocimagene amiretrorepvec) for delivery. Toca 511 
is a murine leukemia virus that infects dividing cells, preferentially 
integrating into cells that are immune-deficient — in this case 
GBM cells. In addition, the retrovirus has no trouble crossing the 
blood brain barrier, an issue that arises with other treatments. 
The virus contains the genetic code for an altered cytosine 
deaminase (CD), a protein enzyme that catalyzes the reaction 
converting cytosine residues to uracil (Ostertag et al., 2011). In 
trials, after several cycles of RRV treatment, researchers found 
a high concentration of CD present in tumor cells, but none or 
insignificant levels expressed in quiescent cells. The retrovirus 
delivery method efficiently targets tumor cells and integrates its 
genetic contents into the DNA of the host cell without affecting 
the genetic integrity of healthy cells in the body.
While the success of the genetic transfer is significant, the 
expression of optimized CD within tumor cells is of little conse-
quence. Further action is required to have an impact on cancer-
ous cells. 5-fluorocytosine (5-FC) is subsequently administered 
as a prodrug, a drug in an inactive form. Despite widespread up-
take of 5-FC by the majority of cell types, this inactivity prevents 
any notable response from quiescent or typical cells. However, 
in the Toca-511 pretreated tumor cells, 5-FC is converted by 
CD to 5-fluorouracil (5-FU), a potent antineoplastic cancer 
drug used as the drug of choice for colorectal, esophageal, gas-
tric, and many other cancers. While the precise mechanism of 
5-FU is unknown, it is suspected to interfere with DNA syn-
thesis, protein synthesis, and RNA processing (Pinedo & Peters, 
1988). Collectively, these contribute to an incompatible state 
for the tumor cell leading to apoptosis and subsequent removal 
by the immune system. Furthermore, 5-FU has also been shown 
to destroy myeloid-derived suppressor cells. These cells help 
evade the immune system and elimination of these suppressor 
cells allows the patient’s natural immunity to assist in tumor 
destruction (Cloughesy et al., 2016). An additional advantage 
of the engineered 5-FU produced in Toca-511 allows the active 
drug to diffuse through the cell membrane, giving the potential 
to have therapeutic effects reaching beyond the cytosol of the 
parent cell (Hemmer, et al., 2015). There is strong evidence to 
suggest this phenomenon, called the bystander effect, occurred 
in preliminary trials and it resulted in an improved overall sur-
vival rate as well as an improved recurrence free outcome. The 
Tocagen drugs are undergoing clinical trials but the progress 
they signify in science is considerable and opens the door to a 
proliferation of improved treatment techniques.
Multi-Therapy
The multi hit model of cancer, also known as the Knudson hy-
pothesis, is the theory originally proposed in 1953 hypothesizing 
a stepwise component to oncogenesis. The theory suggests that 
cancer onset is not the result of a single mutation, rather the 
outcome of many mutations, creating conditions for the perfect 
storm that is cancer (Nordling, 1953). Knudson’s hypothesis 
has greater validity after “Hallmarks of Cancer” was published 
by Weinberg and Hanahan (Hanahan & Weinberg, 2000). The 
hallmarks reiterate the idea that cancer is multi-faceted and 
more complex than a single aberration in physiology and de-
velopment. The theory gives rise to an alternate approach to 
treatments; if the disease is multifaceted, then so must be the 
treatment plan. Various treatment proposals utilize this theo-
ry for multi-hit therapy. Some antiangiogenic treatments are 
being applied in conjunction with others for a comprehensive 
approach. Several attempts have been made, or are now in trials, 
that couple effective treatments like that of TMZ with newer 
medications to enhance their effectiveness. In concurrence with 
TMZ, patients have been tested with a wide variety of phar-
maceutical cocktails, including gefitinib and erlotinib, a pair of 
EGFR inhibitors (Bleeker, et al., 2011). Patients have also been 
treated with radiotherapy and Gliadel wafers. These wafers 
are intracranial implants containing carmustine, a nitrosourea 
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alkylating agent, and give a steady treatment of chemotherapy 
to their host after being inserted into the brain (van den Bent 
et al., 2008). Direct insertion prevents the need to circumvent 
the blood brain barrier and offers a continuous administration 
of the drug for the duration of the treatment. As a nitrosourea, 
carmustine alkylates DNA strands, preventing normal gene 
expression in cancer cells and dampening tumor development. 
Further, contrary to previous research, resistance to a single al-
kylating agent does not predict resistance to alternate alkylating 
agents, allowing for a multi-agent approach to prevent cancer 
gene expression (Schabel, 1976). 
The development of chimeric antigen receptor T-cell therapy 
(CAR-T) builds on the success of above-mentioned treatments 
such as retroviral genetic manipulation and immune system 
enhancement. This technique utilizes engineered T-cells to rec-
ognize specific markers in cancer cells and induce apoptosis. 
One lab at the Memorial Sloan Kettering Cancer Center fo-
cused on B cell acute lymphoblastic leukemia and is examin-
ing options to extend this therapy to gliomas. In the leukemia 
study, patients with relapsed B cell acute lymphoblastic leuke-
mia had T-cells isolated from plasma and treated with a vector. 
The vector programmed T-cells to produce chimeric antigen 
receptor, a receptor that can be engineered to enable the T 
cells to recognize specific proteins found in cancers (CD19 in 
this case) (Brentjens et al., 2013). One particular advantage of 
CAR-T therapy is the use of the patient’s own immune cells. 
Using autologous material decreases the incidence of rejection 
or other complications that frequently occur with the intro-
duction of foreign cells (Almasbak, et al., 2016). CAR-T therapy 
has demonstrated high rates of success with above an 88% long 
term survival rate and is being evaluated for expansion to a 
greater variety of cancers, including high- and low-grade glioma 
(Wilkins, Keeler, & Flotte, 2017).
The range of ideas employed with multi-hit therapies and 
techniques takes advantage of the advances made in genetic 
and molecular research. Introducing therapies that make use 
of immunotherapy and genetic recombination, or that address 
multiple facets of angiogenesis are particularly useful in tackling 
the multidimensional aspects of cancer. Combination treat-
ments allow scientists to develop a more comprehensive blend 
that can address the particular deficiencies associated with each 
individual medication and enable an extensive treatment plan 
for the greatest chances of survival.
Conclusion
Glioblastoma multiforme is a high-grade malignancy with a poor 
prognosis. While additional preventative research is required to 
improve diagnostic methods and screening, management meth-
ods are under rapid development to improve not only survival 
but also quality of life. A greater focus on intermolecular func-
tioning within GBM helps provide a better understanding of how 
to effectively diagnose and recognize the cancer. Additionally, 
such information allows the introduction of periodic screening 
in higher risk individuals as determined by these advances. By 
analyzing intermolecular pathways such as kinase receptors and 
genetic modifications, researchers can develop steps or proce-
dures to counter the cancer. This basic research extends itself 
heavily to the applied sector and allows for the creation of ther-
apies and treatments that respond to the characteristics and ac-
tions unique to this disease and the complexities of its location. 
Many treatments have already been proposed in an attempt 
to contain the rapid tumor proliferation associated with glio-
blastomas. With the knowledge gained from the success and 
failures of these treatments, adjusted multi-therapy approaches 
and novel replacement techniques have been developed. From 
genetics and immunological studies to bacterial and retroviral 
infections, these alternatives offer increased variability and pos-
sibility for patients. Despite the grim prognosis that typically 
accompanies the diagnosis of GBM, there is the potential for the 
cancer to no longer be as debilitating as it currently is or once 
was. Particularly through immunotherapy and gene therapy, as 
well as the use of antiangiogenics and nitrosourea alkylating 
agents, GBM can soon be combatted beyond the standard of 
surgical resection and chemotherapy.
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Neuraxial analgesia is one of the most popular and effective forms of pain relief for labor and childbirth used by more than 50% 
of women in North America. Despite the standard use of the procedure, there is much that is still inconclusive about the side 
effects on mother and baby. Current studies show it has an impact on some outcomes and seemingly no effect on others.  While 
the extent of the impact is still unclear, there are some adverse side effects of neuraxial analgesia, which include instrumental 
deliveries, respiratory distress and lower Apgar scores. Further research is required to conclude how and to what extent neuraxial 
analgesia impacts mother and baby.
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Introduction  
Labor and childbirth are known to be extremely painful expe-
riences. Over the years there have been multiple methods de-
veloped which provide pain relief. Neuraxial analgesia, known 
colloquially as ‘epidural’, is one of the most popular forms of pain 
relief and is used by 50-70% of women in North America. It be-
came a standard form of labor analgesia during the 1970s (Silva 
and Halpern 2010).
When neuraxial analgesia is administered, a small amount of 
anesthetic is inserted into the epidural space of the spine to 
prevent pain signals from traveling from the spine to the brain 
(Schrock and Harraway-Smith 2012). The drugs used most often 
in North America are bupivacaine and ropivacaine (Silva and 
Halpern 2010). There are few forms of epidurals used. For the 
epidural procedure, a catheter is inserted directly into the epi-
dural space of the spine and the patient receives a continuous 
flow or multiple injections of local anesthetic. Spinal anesthesia 
refers to local anesthesia inserted into the subarachnoid space 
and one injection is usually sufficient. Combined spinal-epidural 
analgesia includes an initial spinal intrathecal injection as well as 
an epidural catheter for additional drugs. Neuraxial analgesia is an 
umbrella term which includes all three methods:  epidural, spinal 
and combined spinal-epidural.
This text includes all three types of neuraxial analgesia used 
in labor. When using the term ‘epidural’, it refers to any of the 
three forms.
During labor and delivery, the primary concern is the safety 
and health of the mother and neonate.
Despite the longevity and standardized use of the procedure, 
there is much that is still unknown about the side effects of epi-
dural analgesia and its impact on labor progress and maternal 
and neonatal outcomes. This text aims to explore if there are any 
adverse effects of epidural on the process of labor and delivery 
and on the health of the mother and neonate.
Methods
Original studies and scientific papers found through TouroLib 
access to databases such as PubMed, Proquest, and EBSCO 
were used fir this review. Google scholar was also used. Many of 
the studies are retrospective since readily available data greatly 
increases the population sample size. To ensure the research in-
cluded pertains to current techniques, most studies used were 
published within the last ten years.
Oxytocin Augmentation
There are several ways in which epidural may have an effect on 
the mother during labor. Epidural has been linked to increased 
need for oxytocin augmentation during labor and delivery. 
Oxytocin is a hormone secreted by the pituitary gland. During 
labor, it stimulates uterine contractions and dilates the cervix. 
Oxytocin is continually secreted during labor through a positive 
feedback loop. Contractions push the fetal head towards the cer-
vix which stimulates additional oxytocin to be produced. If labor 
does not progress at a proper rate, synthetic oxytocin can be 
administered intravenously to strengthen the contractions. This 
process helps progress the labor, however, it increases the risk 
of multiple adverse outcomes for the neonate (Bell et al. 2014).
A retrospective case-control study was done using clinical re-
cords of all mothers admitted to Riga hospital between January 
1, 2013, and December 31, 2013. Infants included in the study 
were singleton pregnancies, at least 37 weeks of gestation, in 
cephalic position and vaginally delivered.
Epidural analgesia was given on demand, and the birth had 
to occur more than one hour after the epidural analgesia was 
used.  Eight hundred and thirty-two women were included in 
the study, 304 who received epidural and 528 in the control 
group. Women who had epidural analgesia had higher rates of 
augmentation of their first stage of labor with oxytocin than 
women who did not receive epidural analgesia (Krievina et al. 
2015). These findings are consistent with a study which also 
found increased oxytocin use in women receiving epidural anal-
gesia (Decca et al. 2004).
Another study of  160 women, 80 receiving epidural analgesia 
and 80 in the control group found no difference in the percent-
age of patients who received oxytocin, but the maximum rate of 
oxytocin infusion was significantly higher in the epidural group, 
compared to the control group [P=.001] (Mousa et al. 2012).
These studies have exhibited an increase in the relationship 
between epidural and the need for synthetic oxytocin adminis-
tration, which increases the risks for complications during labor 
and delivery.
Length of Second Stage Labor
Epidural has also been studied in association with its effect on the 
second stage of labor. The second stage of labor is also known 
as the pushing stage. Prolonged second stage labor has been 
associated with adverse effects on neonatal outcome, including 
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an increased relative risk of birth-asphyxia related complications 
and increased chances of NICU admission (Sandstrom et al. 
2017).  The longer the second stage of labor, the lower the infants 
one-minute Apgar score was and the higher the incidences of as-
phyxia. Prolonged second stage labor also has adverse effects on 
the mother. Li et al., discovered that the longer the second stage 
of labor progressed, the higher the incidences of cesarean section 
and postpartum hemorrhaging (Li et al. 2011). A study conducted 
across Washington state found that in nulliparous women, there 
was a two-fold increase in the median duration of second stage 
labor in women who received epidural analgesia when compared 
to those who did not.  It also recorded a two-hour increase in 
second stage labor in the 95th percentile for women who re-
ceived epidural analgesia (Souter et al. 2018).
A similar retrospective analysis was performed on all live, 
singleton, full term, vaginal deliveries in a university hospital 
between the years 2012-2014. Exclusion criteria included oper-
ative deliveries due to fetal distress, major fetal anomalies and 
chromosomal abnormalities The inclusion criteria were met by 
15,499 deliveries.  In this sample, women delivering with epidur-
al analgesia were associated with an additional 82 minutes of 
second stage labor in the 95th percentile for both nulliparous 
and multiparous women. The study examined the effects of epi-
dural analgesia on both nulliparous and multiparous women, and 
within each of those groups, there were women who received 
oxytocin augmentation were compared to those who did not. 
There was a significant effect found in all four groups.  This study 
found epidural analgesia to be overall associated with over a 
one-hour increase in second stage labor (Shmueli et al. 2016).
A retrospective cohort study done on all live, singleton births 
in the University of California, San Francisco between 1976 and 
2008 studied the effects of epidural on labor length. The study 
excluded pregnancy complications and cesarean sections that 
took place during the first stage of labor. The study included 
42,268 women, where 49.9% had received epidural analgesia 
and 50.1% did not.  Statistical analysis showed that women in 
the 95th percentile of the second stage of labor who received 
epidural analgesia had an average difference of more than two 
hours in duration of second stage labor when compared to 
women who did not receive an epidural. This number was sta-
tistically significant in both nulliparous and multiparous women 
(Cheng et al. 2014).
Instrumental or Operative Vaginal Delivery
Epidural has also been studied in its association with the need 
for instrumental or operative vaginal delivery. Instrumental or 
operative vaginal delivery is when forceps or vacuum extraction 
is used to extract the fetus from the vagina. This has been asso-
ciated with adverse neonatal outcomes.
One study conducted on 2052 women in San Diego studied 
the risk of instrumental vaginal deliveries and cesarean sections 
in nulliparous and multiparous women when epidural analge-
sia is administered during the first stage of labor.  The study 
excluded multiple births, inducements and preterm births. In 
nulliparous women, the relative risk of operative vaginal delivery 
was 2.5 when compared to women without an epidural. For 
multiparous women, the crude relative risk was 11.5 for opera-
tive deliveries (Nguyen et al. 2010).
A retrospective study on 350 female patients who received 
epidural analgesia and 1400 controls showed that vacuum ex-
traction and cesarean sections were more frequently performed 
in the epidural group than the control group [p<0.001]. The epi-
dural analgesia slowed down the progress of labor, which led to 
an increased rate of instrumental deliveries. The instrumental 
delivery appeared to affect the neonatal outcome more than 
the epidural analgesia itself (Hasegawa et al 2013).
A study conducted on 100 neonates born with epidural anal-
gesia and 100 without had results consistent with other studies 
regarding epidurals and instrumental deliveries. Instrumental 
delivery, which included both forceps and vacuum extraction, 
had taken place during 13 births, 11 of which were from the epi-
dural group [p<.010], making this a statistically significant study 
(Shrestha et al. 2014).
Krievina et al. 2015, whose population size was 832, discov-
ered no difference between epidural analgesia groups and the 
non-epidural groups in regards to the use of vacuum extraction. 
The study recorded vacuum extraction only used in first-time 
mothers (Krievina et al. 2015).
While not indisputably conclusive, there is evidence in the 
research of a correlation between epidural analgesia and an in-
creased need for instrumental deliveries.
Cesarean Section
A few studies noted the association between epidural analge-
sia and increased rate or risk of cesarean sections. Nguyen et 
al., (2010) conducted a study showing that administration of 
epidural analgesia during the first stage of labor increased cesar-
ean section rates (Nguyen et al. 2010). Hasegawa et al., (2013) 
also recorded that cesarean sections were more frequently 
performed on the group of women receiving epidural analgesia 
than the control group [p<.001] (Hasegawa et al., 2013). Mousa 
et al. and Decca et al. both recorded no increased cesarean 
section rates (Mousa et al. 2012) (Decca et al. 2004). The results 
of the studies disagreed but both Nguyen et al. and Hasegawa 
et al. studies consisted of significantly larger populations than 
either Mousa et al. or Decca et al.
Maternal Fever
Epidural is known to increase maternal temperature. Maternal 
temperature during labor and delivery is associated with effects 
on the neonate. Intrapartum fever is related to infectious and 
noninfectious etiology.  It is a well-known risk factor for adverse 
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neonatal outcomes including neonatal sepsis, seizures, asphyxia 
and mortality (Petrova et al. 2001). It is also known to effect 
obstetric outcomes; intrapartum fever significantly increases 
the rates of cesarean sections and operative vaginal deliveries 
(Lieberman et al. 1999). Whether increased fever related to epi-
dural has the same adverse effects as other intrapartum fever is 
a question that has been studied.
One study was performed to investigate the relationship 
between combined-spinal epidural and increased maternal in-
trapartum temperature. Seventy women were included in the 
study, 35 receiving combined spinal-epidural anesthesia and 35 
who did not receive any pharmacological form of pain relief. At 
the start of the study, the median temperature of the women 
was the same in both groups; after the first hour, there was an 
increase of intrapartum maternal temperature in the women 
receiving epidural analgesia. The difference in temperature be-
tween the two groups remained until the sixth hour and on-
ward, where no statistically significant difference was found. 
Five of the 35 women receiving combined-spinal epidural 
developed intrapartum fever while no fever was found in the 
group receiving non-pharmacological pain relief (P=0.027). 
However, there were no statistically significant differences in 
neonatal outcome. None of the infants born to mothers who 
had intrapartum fever developed neonatal sepsis, required anti-
biotic treatment, nor were they evaluated for neonatal infection. 
This study showed that combined-spinal epidural had an impact 
on intrapartum maternal temperature and can cause fever. It 
does not, however, have any adverse effects on neonatal or ma-
ternal outcome (de Orange et al. 2011).
A statewide study was conducted in Colorado on the association 
between epidural analgesia, maternal fever and neonatal antibiotics. 
Antibiotic administration to neonates who are at risk of infection 
is essential in preventing neonatal sepsis. However, unnecessary ex-
posure to antibiotics is associated with significant risks. 
There was no difference found between epidural and non-epi-
dural groups in the administration of antibiotics to newborns 
born to mothers with fever.  Women who received epidural an-
algesia were 5.4 times more likely to develop intrapartum fever. 
However, the infants had antibiotics administered equally in all 
cases of fever, regardless of what the cause was. This indicates 
that infants born to mothers who received epidural analgesia 
are more at risk of receiving unnecessary antibiotic treatment 
(White et al. 2017). While epidural-related fever did not seem 
to have a physiological effect on the neonate, the fever did lead 
to unnecessary antibiotic exposure. 
Apgar Scores
One of the first assessments performed on a neonate is the 
Apgar score. The Apgar scoring system is a rapid method of as-
sessing the clinical status of a newborn at one and five minutes 
of age. The Apgar score comprises of five components: 1. Color 
2. Heart rate 3. Reflexes 4. Muscle tone and 5. Respiration. Each 
component is given a score of 0,1, or 2. This is an accepted and 
standard method for reporting the status of an infant immedi-
ately after birth. While the Apgar score cannot be used to pre-
dict outcomes or diagnose alone, it is a useful tool in assessing 
the newborn. Because this is the standard test performed on 
all infants born in Western countries, it is simple data to collect 
and study and is one of the foremost things to examine when 
determining a baby’s status (acog.org). Since most studies are 
conducted retroactively and all infants are scored on the Apgar 
system, it is an easy and commonly studied component.
A study was conducted in Spain on all full-term infants ex-
cluding inductions, elective cesarean sections and major preg-
nancy complications. The mean Apgar scores at one and five 
minutes were slightly but statistically significantly lower in 
the group of infants exposed to epidural analgesia [p=0.001] 
(Herrera-Gomez, 2015).
A different study conducted by Krievina et al.  had a similar 
infant population, however with only singleton infants includ-
ed. There was no statistically significant difference in the Apgar 
scores of infants whose mothers received epidural analgesia and 
those whose mothers did not. In this case, the birth had to be 
at least one hour after the epidural analgesia was administered. 
Although the outcome was different than in the previous study, 
the population size was much smaller in this study than in the 
study conducted by Herrera-Gomez (Krievina et al. 2015).
Another study recorded the Apgar scores were significantly 
lower in neonates who were delivered via vacuum extraction 
when compared to those delivered via spontaneous vaginal 
delivery and cesarean sections, regardless of whether the moth-
er had an epidural or not. However, this study also found that 
epidural analgesia significantly increased the incidences of oper-
ative delivery. This leads to an indirect association between epi-
dural analgesia and lower Apgar scores (Hasegawa et al. 2013).
Respiratory Distress
One of the variables that is observed when a child is born is the 
respiratory state of the newborn. A case-control study discusses 
the effects that epidural analgesia can have on the respiratory 
state of newborns in the immediate neonatal period.  The case 
consisted of newborns who had gone into respiratory distress. 
The control group was comprised of site matched neonates of 
similar gestational age who did not go into respiratory distress. 
Infants included were late preterm or term. Exclusion criteria for 
this case group were major congenital malformations associated 
with newborn respiratory distress, culture-proven sepsis with-
in 72 hours of birth or elective cesarean sections. Two hundred 
and six infants and 206 matched controls were included in the 
study. Seventy percent of infants who experienced respiratory 
distress had mothers who were exposed to epidural analgesia. In 
the control group 63% of infants had mothers who were exposed 
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to epidural analgesia. After statistical adjustments, the difference 
between the two groups was statistically significant [P=.04]. This 
study shows an association between epidural use and subsequent 
respiratory distress in the infant (Kumar et al. 2014).
A study conducted in Spain with 2399 infants studied the as-
sociation between epidural analgesia and need for resuscitation. 
From the infants born to mothers who used epidural analgesiac, 
resuscitation was required in 28.7% versus 17.6% in the infants 
whose mothers did not have epidural analgesia [p=.001]. This 
study shows a correlation between epidural analgesia and the 
risk of resuscitation in newborns (Hererra-Gomez 2015).
Breastfeeding
The benefits of breastfeeding both on infant and mother have 
been well documented. In infants, breastfeeding is associated 
with reduced incidences of respiratory and gastrointestinal 
tract infections. Breastfeeding is also shown to reduce the long-
term risk of diseases, obesity and diabetes. Maternal benefits 
include reduced bleeding after delivery, more rapid involution of 
the uterus and lower risks of future diseases (Eidelman 2012).
A study was conducted on the relationship between epidural 
analgesia during labor and onset of lactation in healthy women. 
Those included in the study were all singleton, full-term, vaginal 
deliveries and pregnancies that had no other pathological condi-
tions. Women who experienced complications during labor were 
excluded. Only healthy babies with Apgar scores of greater than 
eight and those that did not require intensive care were included. 
All the women who participated in the study intended to breast-
feed.  There were 209 women who received epidural analgesia 
and 157 who did not. There was a five and twenty day follow up 
with the mother.  There was no difference found in the onset of 
lactation between the two groups.  Onset of lactation was deter-
mined as the time between birth and the peak intensity of the 
three major symptoms of lactation: breast tension, heat, and pain. 
At 20 days postpartum, more mothers who received epidural an-
algesia were formula feeding their babies than the mothers who 
did not receive epidural analgesia (Mauri et al. 2015).
Conflicting results were obtained in a retrospective study 
conducted by Herrera-Gomez et al. 2015 on all full-term infants 
born in San Juan de la Cruz Hospital between March 2010 and 
March 2013. Exclusion criteria included induced labors, elective 
cesarean sections and high-risk pregnancy factors. The study in-
cluded 2399 infants. One of the variables studied was the onset 
of early breastfeeding, which was defined as within the first two 
hours of birth. Early breastfeeding onset was observed in 82.4% 
of infants in the epidural group and in 91.1% of infants in the 
non-epidural group, a significant difference with the odds ratio 
(OR) factor of 1.96 (Herrera-Gomez et al. 2015).
A study by Dozier et al. (2013) which observed the relation-
ship between epidural analgesia and breastfeeding cessation, 
found similar results to Mauri et al. 2015. This study included 
722 full term, singleton vaginal deliveries in which the moth-
er-initiated breastfeeding. A significant crude relationship was 
found between epidural analgesia and breastfeeding cessation 
within 30 days [p<.01]. It was also found that the overall in-
teraction between epidural analgesia and intravenous oxytocin 
negatively affected breastfeeding (Dozier et al. 2013).
Another study conducted on 100 women who received epi-
dural analgesia and 100 women who did not. Exclusion criteria 
were cesarean sections, preterms, low birth weight and other 
complications. The timing of the initiation of breastfeeding was di-
vided into three groups: within six hours of birth, six to 24 hours 
postpartum and after 24 hours. In the epidural and non-epidural 
group, 96 and 98 infants in each group respectively had started 
breastfeeding within six hours. Only one in each group estab-
lished breastfeeding between six to twenty-four hours. Two new-
borns in the epidural group and one in the non-epidural group 
started breastfeeding after 24 hours. The P value was .06 not a 
statistically significant value (Shrestha et al. 2014).
Most studies show no significant difference in the onset of lac-
tation between mothers who had epidurals and those who did 
not. Women who did not have epidurals were more likely to be 
breastfeeding for a longer period. However epidural analgesia was 
not the primary factor in predicting the duration of breastfeeding.
Conclusion
The research discussed in this paper covered a variety of topics 
such as oxytocin, length of labor, increased need for instrumen-
tal-assisted deliveries, Apgar scores and breastfeeding. There are, 
however, many other areas of impact that have not been covered, 
such as hypertension, NICU admission and urine passage. The 
exact impact that epidural analgesia has on maternal and neonatal 
outcomes is not conclusive. However, studies show that neuraxial 
analgesia is associated with increased risk of some maternal and 
neonatal outcomes such as instrumental deliveries, respiratory 
distress and lower Apgar scores, while having less of an effect on 
variables such as breastfeeding. Due to the considerable number 
of variables that determine maternal and neonatal health, it is 
difficult to identify which outcomes are due solely to epidural 
analgesia. Most of the research focuses on whether neuraxial 
analgesia causes side effects, but there is less research on the rea-
sons why it does. Perhaps if the mechanism could be better un-
derstood, then more may be understood as to who is at greater 
risk for experiencing side effects and clinicians can  then have the 
possibility  and tools to better treat and educate mothers to be.
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Parkinson’s disease is the second most common neurodegenerative disease that negatively affects many American lives. It is 
characterized by the degeneration of dopamine-secreting neurons in the Substantia Nigra Pars Compacta (SNpc). Individuals 
with Parkinson’s Disease lack motor coordination and experience severe motor impairments. Unfortunately, there is currently 
no treatment method available that can successfully cure the disease. In fact, all of the mainstream available treatments only 
eliminate some PD symptoms, and they cause many negative side effects. Although nontraditional, exercise is a side effect free 
treatment method that can potentially slow the progression of the disease and alleviate some symptoms.  This paper first gives a 
comprehensive overview of the pathology and current treatments of Parkinson’s disease.  Then this paper reviews the benefits of 
exercise therapy for PD patients and the potential biological mechanisms that drive the success of exercise therapy.
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Introduction
Although not as prevalent as Alzheimers, Parkinsons disease(PD) 
is the second most common age-related neurodegenerative dis-
order (Paillard, et. al. 2015, Maiti, et. al. 2017). It occurs in about 
1-2% of the population over 65 and has been found to occur 
even less in younger populations (Maiti, et. al. 2017). Thus, age 
is considered to be one of the most prevalent risk factors for 
the development of the disease. Although Parkinson’s disease 
does affect multiple parts of the brain, it is mainly character-
ized as a neurodegenerative disease that causes the degradation 
of dopaminergic neurons located in the Substantia Nigra Pars 
Compacta (SNpc) (Maiti, et. al.  2017, et. al.  2013). In a healthy 
person, the axons of these neurons extend to the Striatum 
where they help relay inhibitory signals by secreting dopamine 
which in return causes the basal ganglia to send inhibitory sig-
nals to Globus Pallidus and thalamus. These inhibitory signals 
help regulate movement by preventing the thalamus from over 
stimulating the motor cortex and causing impairment of motor 
coordination (Maiti, et. al.  2017). Due to the degradation of 
SNpc neurons, patients with Parkinson’s disease have a signifi-
cant decrease of dopamine secretion in the Striatum and as a 
result they experience significant motor impairments (Petzinger, 
et. al. 2013, Maiti, et. al.  2017). 
Symptoms
PD is a neurodegenerative disorder that slowly worsens over 
time, thus, individuals with Parkinson disease experience a wider 
array of symptoms as the disease progresses. It takes around 15 to 
20 years for PD symptoms to progress and it is estimated that the 
first visible symptom is seen only once 80% of the SNcp neurons 
have died out. Due to the progressive nature of the disease, early 
symptoms are subtle and often unidentifiable (Sveinbjornsdottir, 
2016, Maiti, et. al.  2017). At first, most individuals will experience 
twitching in their arm, leg, jaw, lips or chin (Maiti, et. al. 2017). 
This symptom is called a resting tremor and is observed in the 
early stages of the disease in about 70% of PD patients (Maiti, et. 
al. 2017) (Moustafa, et al., 2016). It is most commonly found in 
the arms and the legs, and it usually starts off only on one side 
of the body. Gradually, this tremor develops bilaterally affecting 
both sides of the body (Maiti, Manna, & Dunbar, 2017). The second 
most common symptom is rigidity or stiffness of the muscles and 
joints (Maiti, et. al. 2017) (Moustafa, et al., 2016). This side effect 
causes individuals with PD to feel week and have severe cramping 
pain (Maiti, et. al. 2017). Individuals with PD also lose their ability 
to move quickly and experience a symptom called bradykinesia 
(Moustafa, et al., 2016, Maiti, et. al. 2017). Bradykinesia is char-
acterized by loss of automatic movements, slow handwriting, 
decreased eye blinking, lower speech volume, difficulty initiating 
movement and difficulty in stopping continuous movements. In 
addition, PD patients also experience balance and coordination 
problems and will often fall. All of the above symptoms are con-
sidered to be primary symptoms of Parkinson’s Disease and are 
essential for the diagnoses of the disease (Sveinbjornsdottir, 2016, 
Maiti, et. al.  2017). 
In addition to the above symptoms ,some secondary symptoms 
may develop. These include continued changes in speech including 
the slurring of words, the repetition of words and excessively 
slow or abnormally fast speech. Urination and defecation become 
exceedingly hard due to the slow movement of smooth mus-
cle in the digestive tract. Swallowing and chewing food becomes 
very difficult because of the bodies inability to perform peristalsis 
properly.  In addition, PD patients often have a hard time staying 
asleep at night due to “insomnia, Rem sleep behavior disorder, 
sleep apnea, sleep attacks and restless leg syndrome (Maiti, et. al. 
2017).” Some people with PD also experience depression, mood 
problems, anxiety, cognitive dysfunction, apathy and Dementia 
(Chauduri & Schapira, 2009) (Maiti, et. al. 2017). 
Mechanisms of Parkinson’s Disease
Parkinson’s Disease can manifest due to external factors or as a 
result of inherited genetic mutations. Most cases of PD are con-
sidered to be non-genetic forms of PD, that result from envi-
ronmental stimuli (Maiti, Manna, & Dunbar, 2017).  Both genetic 
forms and sporadic forms of PD follow similar mechanisms of 
neuronal degeneration.  Three of the most probable pathways 
of neuronal degeneration are death through mitochondrial 
dysfunction, A-synuclein aggregation, malfunctioning chaperone 
proteins and Autophagy lysosomal pathway damage.  
Mitochondrial dysfunction can be caused by both genetic and 
environmental factors. Some environmental factors that cause 
PD include pesticides, herbicides, fungicides, and insecticides. 
Consequently, farmers and individuals who live in rural areas 
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are considered to be more susceptible to PD due to direct ex-
posure to these substances through the air and drinking water. 
Other environmental factors that cause PD included bacterial 
toxins, viruses and illegal street drugs such as synthetic forms 
of heroin and rotenone. These environmental factors “inhib-
it complex one activity and cause dysfunction in the electron 
transport chain which causes oxidative stress (Maiti, et.al. 2017, 
p. 12).”  Gene mutations of the DJ-1 and Pink 1 genes also cause 
mitochondrial dysfunction that can result in oxidative stress by 
inhibiting the formation of mitochondrial protective proteins. 
Once initiated by either environmental or genetic factors, oxi-
dative stress causes the phosphorylation of tau proteins which 
eventually aggregate to form Lewy Bodies. These Lewy bodies 
accumulate in the cell making it exceedingly hard for the cell to 
complete basic tasks needed for neuronal function . Lewy bod-
ies also make pores in the cell membrane resulting in “neuro-
nal death via oxidative stress, energy failure, excitotoxicity, and 
neuronal inflammation. Eventually, the infected neurons begin to 
die due to their inability to perform tasks essential for survival”. 
In addition to oxidative stress, mitochondrial dysfunction can 
also directly lead to energy failure. Energy failure refers to the 
cells inability to produce the chemical energy needed for cell 
survival. Energy failure causes the degeneration and death of 
dopaminergic neurons (Maiti, Manna, & Dunbar, 2017). 
Mutations in the a-synuclein gene cause an alternative mech-
anism of neuronal degeneration. This mutation leads to the 
creation of misfolded α-synuclein proteins that eventually ag-
gregate and develop into Lewy Bodies .   Lewy bodies block up 
the cell making it close to impossible for basic cell functions to 
be completed. In addition, the Lewy bodies can make holes in 
the cell membrane which cause cell death by initiating, oxida-
tive stress, energy failure, excitotoxicity, and neuroinflammation 
(Maiti, et. al. 2017).  Thus, the α-synuclein gene mutation directly 
affects neuronal cell death. 
Mutations of the parkin and UCHL1 genes can lead to the 
death of SNpc neurons by causing the destruction of ubiqui-
tin-proteasome system(UPS) and molecular chaperones (Maiti, 
Manna, & Dunbar, 2017). The UPS actively brakes down short 
polypeptides into intracellular plasma membrane proteins, and 
it also helps with degeneration of “misfolded or damaged pro-
teins in the cytosol, nucleus or endoplasmic reticulum (Maitiet. 
Al. 2017, p. 9).”  Chaperone proteins play an important role in 
ensuring that proteins are folded properly. Damage to these 
two systems lead to the accumulation of misfolded proteins and 
to the impairment of the Autophagy Lysosomal pathway(ALP). 
The ALP helps degrade large protein debris that cannot be de-
graded by the UPS. When the UPS, chaperone proteins and ALP 
fail to complete their respective jobs, misfolded proteins begin 
to aggregate in the cell and form Lewy bodies (Maiti, Manna, & 
Dunbar, 2017). The Lewy bodies go on to disrupt cell function 
leading to the degeneration SNpc neurons. 
The Spread of the Disease
Many researchers believe that once Parkinson’s disease is initiat-
ed, Lewy body infected neurons transmit the disease to adjacent 
uninfected neurons (Maiti, Manna, & Dunbar, 2017). This method 
of proliferation is known as the prion hypothesis. Interestingly, 
many studies have found that α-synuclein begins to aggregate 
in the enteroendocrine cells of the gastrointestinal tract and 
then spreads to the brain via prion infection. Although this may 
be the method of proliferation used in some cases of PD, it is 
definitely not used in all PD cases since Lewy bodies are not 
necessary for initiation of PD (Maiti, et. al. 2017). 
Inflammation may also be responsible for the spread of 
Parkinson’s disease (Zhang, et al., 2011) (Phania, et. al. 2012). 
Neuronal inflammation occurs due to head trauma or the de-
velopment of pathogenic disease such as PD. Inflammation in the 
PD brain is characterized by activated microglia cells, astrocyte 
cells and imported T-cells that crossed the blood-brain barrier 
(Cebrián & Sulzer, 2017). In the case of Parkinson’s disease, the 
immune response is unbalanced, and instead of eliminating the 
disease it aids in the progression of the disease.  
Microglia cells are activated as a result of α-synuclein accu-
mulation (Cebrián & Sulzer, 2017). Once activated they act as 
phagocytic cells and participate in the removal of toxins and 
dead neurons (Vivekanantham, et al., 2015). They also produce 
“a plethora of pro-inflammatory mediators including prosta-
glandins, cytokines, chemokines, complement, proteinases, ROSs 
and RNSs (Vivekanantham, et al., 2015).” These substances ini-
tiate cell death by directly causing oxidative stress. In addition, 
microglia phagocytose extracellular neuromelanin that was re-
leased by dying neurons (Cebrián & Sulzer, 2017). During this 
process cytokines and hydrogen peroxide are released and cell 
death via oxidative stress is initiated (Zhang, et al., 2011).  
Astrocytes are supposed to help regulate the immune re-
sponse by protecting neurons from oxidative stress. In theory 
this would allow the microglia cells to participate in the immune 
responses without initiating neuronal cell death. However, be-
cause Parkinson’s disease affects a part of the brain that has 
almost no astrocytes, this regulatory system fails to occur. In 
addition, many of the astrocytes present in the PD brain contain 
α-synuclein aggregations and release harmful substances such 
as cytokines, chemokines, and IFN-T (Cebrián & Sulzer, 2017). 
Thus, although astrocytes have the potential to be neuroprotec-
tive in Parkinson’s disease, they are neurodestructive. 
In addition to the damage that both astrocytes and microglia 
cells cause independently, they also work together to proliferate 
the disease by increasing the permeability of the blood-brain 
barrier. They accomplish this task by releasing cytokines which 
actively increase the permeability of the blood-brain barrier. This 
allows CD4 T cells and CD8 T cells to enter the central nervous 
system easily. Once the T cells reach the SNcp, they are acti-
vated by microglia cells that present antigens on their surfaces 
34
Ilana Tokarsky
using MHC II molecules and MHC I molecules (Kannarkat, Boss, 
& Tansey, 2013). This activation causes the release of more cy-
tokines which leads to cytotoxicity and further activation of 
microglia cells (Kannarkat, et. al. 2013, Federoff, 2014). Thus, 
infiltrating T cells aid in the progression of Parkinson’s disease 
(Phania, et. al. 2012). 
Treatment
Traditional treatment for Parkinson’s disease is limited to medi-
cations, surgeries, stem cell implantation and gene therapies that 
are only effective in eliminating side effects and cannot cure 
the disease. Most of these treatment methods have a multitude 
of side effects and only work for a limited amount of time or 
on a small population of Parkinson’s patients.  Various tratmen-
toptions and their success in treating PD are reviewed below 
with a particular focus on their success in treating PD and their 
adverse side effects.
Medications
Levodopa, a precursor form of dopamine, is perhaps the most 
common PD medication (Connolly & Lang, 2014)  because it 
can cross the blood-brain barrier where it is converted to do-
pamine.  By increasing dopamine levels in the brain, this medi-
cation successfully reduces resting tremors (Maiti, et. al. 2017). 
Unfortunately, Levodopa has also been found to cause vomit-
ing, nausea, restlessness, drowsiness, low blood pressure, sud-
den onset of sleep and impulsive control disorders (Connolly 
& Lang, 2014) (Maiti, et. al. 2017). Additionally, chronic use of 
levodopa results in dyskinesia and motor fluctuations (Smith, et. 
al. 2012).  Levodopa also has been found to quickly lose its effec-
tiveness because it is converted immediately upon arrival into 
the central nervous system and by the time it reaches the target 
area enzymes have already started breaking it down (Maiti, et. 
al.  2017).  Thus, to increase the potency of levodopa, many do-
pamine agonists are administered in combination with levodopa. 
Monoamine oxidase-B (MAO-B) inhibitors such as selegiline 
and rasagiline are examples of dopamine agonists that are used 
in combination with levodopa (Maiti, et. al. 2017). MAO-B is an 
enzyme that participates in the breakdown of dopamine (Kay 
et. al. 2013). MAO-B inhibitors help prevent the breakdown of 
dopamine and increase the potency of levodopa (Smith, et. al. 
2012) (Maiti, et. al.  2017). Although these medications have been 
successful in prolonging the effects of levodopa, they also cause 
a multitude of negative side effects. Which include, “Dizziness, 
dry mouth, insomnia, muscle pain, rash, nausea, constipation, 
severe headache, tachycardia, arrhythmia, hallucinations, chorea, 
or difficulty in breathing (Maiti, Manna, & Dunbar, 2017, p. 19).” 
Another commonly used dopamine agonist is Catechol-O- 
methyltransferase (COMT) inhibitors (Maiti, Manna, & Dunbar, 
2017). These drugs prevent the breakdown of dopamine and 
increase the efficiency of levodopa (Smith, Wichmann, Factor, & 
DeLong, 2012) (Maiti, Manna, & Dunbar, 2017). Entacapone and 
tolcapone are two examples of commonly used COMT inhibitors 
(Smith, Wichmann, Factor, & DeLong, 2012). Along with increasing 
the lifespan of dopamine these drugs cause hepatotoxic, nausea, 
orthostatic hypotension, urine discoloration, dizziness and mito-
chondrial dysfunction (Maiti, Manna, & Dunbar, 2017).
Dopamine agonists such as pramipexole and ropinirole are 
examples of drugs that are used instead of levodopa to treat the 
early stages of Parkinson’s disease. They help alleviate Parkinson’s 
symptoms by increasing dopamine levels in the brain. These drugs 
are not as effective as levodopa, and they cause similar side effects 
as levodopa. Some of the side effects commonly observed while 
administering these drugs are hallucinations, low blood pressure, 
nausea, dizziness, drowsiness, dry mouth, swollen legs and feeling 
faint upon standing (Maiti, et. al.  2017). 
Anticholinergic drugs are also used to treat Parkinson’s dis-
ease. These drugs inhibit the release of acetylcholine, which 
is overproduced in the brains of Parkinson’s patients due to 
diminished dopamine inhibitory signaling (Maiti, et. al.  2017). 
They are successful in alleviating tremor and rigidity in about 
50% of patients (Smith, et. al.  2012) (Maiti, et. al. 2017). Their 
adverse side effects include memory loss, confusion, hallucina-
tions, constipation, urination problems, dry mouth, dry eyes and 
blurred vision (Smith, et. al. 2012). Due to the limited population 
that can be helped with anticholinergic drugs and the adverse 
side effects of these drugs they are less commonly used for the 
treatment of PD. 
Surgical Treatments
Deep brain stimulation(DBS) surgery is a common surgery used 
to treat the advanced stages of Parkinson’s disease. This surgery 
is only performed once all the medications mentioned above 
begin to lose their potency (Smith, et. al. 2012). Additionally, this 
surgery can only be performed on individuals who had success 
in using levodopa and show no signs of dementia or psychiatric 
abnormalities (Smith, et. al. 2012) (Okun, 2012). During DBS 
surgery electrodes are implanted into GPi and STN of the brain 
(Okun, 2012) (Maiti, et. al. 2017). These electrodes are attached 
to two batteries that are implanted in the chest directly under 
the color bone (Maiti, et. al. 2017).  Electrical signals are then 
generated by the implanted batteries and sent to the electrodes 
in the brain where they stimulate inactive neurons (Okun, 2012) 
(Maiti, et. al. 2017). Once implanted this device is controlled by 
an external handheld device (Maiti, et. al.  2017). DBS has been 
shown to successfully eliminate many motor abnormalities in-
cluding motor fluctuations. Additionally, because DBS eliminates 
the need for levodopa it successfully reduces dyskinesia and 
dystonia (Smith, et. al. 2012) (Maiti, et. al.  2017).  Unfortunately, 
DBS entails a surgery that can cause stroke, hemorrhage, infec-
tion, speech issues and balance problems (Okun, 2012) (Maiti, 
et. al.  2017) (Smith, et. al. 2012).  DBS has also been found to 
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increase depression, mania and suicide risk (Okun, 2012). Thus, 
although DBS can be helpful in treating PD, it may also cause 
adverse symptoms that can lead to death. 
Another two surgeries which are used to treat Parkinson’s 
disease are pallidotomy and thalamotomy. Pallidotomy is a sur-
gery in which a part of the globus pallidus is destroyed . As a 
result of this destruction, “the synaptic connections with thal-
amus or striatum are altered in a way which decreases tremor, 
rigidity, bradykinesia and posture abnormalities in PD patients 
(Maiti, et. al. 2017, p. 21).” Thalamotomy is the destruction of the 
thalamus, which disrupts the connection between the basal gan-
glia and the motor cortex. This procedure restores neurotrans-
mitter balance and reduces tremor . However, thalamotomy is 
unsuccessful in alleviating other symptoms such as bradykinesia, 
rigidity, and dyskinesias (Maiti, et. al. 2017).  
Stem Cell Implantation
Stem cell implantation therapy involves the implantation of 
human fetal-derived dopaminergic tissues into the striatum. 
Implantation of these tissues into the brain results in higher 
levels of dopamine, which indicates that these stem cells mature 
properly and are able to create synapses. When porcine-derived 
dopamine-producing cells are used moderate improvements in 
symptom control are observed. However, when allogenic human 
fetal ventral mesencephalic cells are used much greater symp-
tom relief is observed (Maiti, et. al. 2017). “These cells survive 
and make appropriate synaptic connections, while increasing DA 
levels within the host cells (Maiti, et. al.  2017, p. 22).”  Although 
stem cell implantation seems promising, it causes many safety is-
sues including unchecked proliferation and tumor development 
(Smith, et. al. 2012). Thus, more research is needed to develop 
this treatment technique and increase its safety.
Gene Therapy
Although most cases of Parkinson’s disease are sporadic, there 
are some genetic forms of the disease. Scientists are now start-
ing to develop gene therapy techniques that can cure the genet-
ic forms of PD. Some of the techniques that are being tested are 
viral vector-mediated gene delivery, AADC-TH -GCH therapy,  
RNA interference-based therapy and CRISR-Cas-9 gene editing 
system. Most of these therapies have been successful in animal 
models, and some have also been used to treat humans success-
fully. However, most of these therapies must be tested further 
in order to ensure their safety (Maiti, Manna, & Dunbar, 2017).
Exercise as a Treatment Method for PD
There is no treatment method for Parkinson’s disease that is 
symptom-free. In fact, all of the treatments available for PD are 
not successful at curing the disease, and when used they gener-
ate adverse side effects. Thus, Patients diagnosed with Parkinson’s 
disease often feel helpless and experience depression because 
until recently, their diagnosis meant awaiting and experiencing the 
impending uncontrollable loss of movement until death. 
However, in the past two decades, athletic programs such as 
Boxing, Tai Chi, dancing, treadmill training and forced bicycling 
have begun to bring hope to Parkinson’s patients. These programs 
are designed in a way that teaches Parkinson’s patients physical 
skills that helps stop the progression of the disease and even al-
lows some individuals to regain full range of movement. Studies 
have proven the success of these programs, but there is no sig-
nificant scientific work that can explain how exercise alleviates 
Parkinson’s symptoms on a biological level. In the past couple of 
years, scientists have turned their attention to discovering the un-
derlying biological mechanism that allows the above exercise pro-
grams to be so successful in treating Parkinson’s disease. Based 
on the current scientific research the most probable mechanisms 
are that exercise promotes neuroplasticity and neuroprotection. 
The Two Main Components that make an 
Exercise Program Successful
Most of the Successful exercise programs incorporate goal 
based learning and aerobic exercise. The inclusion of these two 
components helps promote neuroplasticity, which is defined as, 
 A process by which the brain encodes experiences and learns 
new behaviors… the modification of existing neural networks 
by addition or modification of synapses in response to chang-
es in behavior or environment, which can encompass exercise. 
Neuroplasticity includes a wide range of structural and phys-
iological mechanisms including synaptogenesis, neurogenesis, 
neuronal sprouting, and potentiation of synaptic strength, all of 
which can lead to the strengthening, repair, or formation of neu-
ronal circuitry (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013).
Goal-based learning refers to the incorporation of tasks that 
are aimed at improving specific skills that are impaired in PD. 
Intensity, specificity, complexity, repetition, and difficulty are all 
important aspects of goal-based exercise that help drive. Goal-
based exercise also stimulates cognitive engagement of the 
prefrontal cognitive circuits. These circuits are involved in early 
motor movement and the development of automaticity. Thus, 
activation of prefrontal circuits helps patients with Parkinson’s 
disease relearn skills that were previously automatic. Aerobic 
exercises are similar to goal-based exercise in the fact that 
it too promotes cognitive engagement and neuroplasticity. 
“Aerobic exercise is defined as vigorous and sustained physical 
activity that leads to increased cardiopulmonary function result-
ing in improved oxygen consumption (maximum oxygen uptake) 
and blood flow to the brain (Petzinger, et. al. 2013, p. 719).” By 
increasing blood flow to the brain, aerobic exercise stimulates 
neuroplasticity and improves cognitive prefrontal cortex func-
tion. When goal based and aerobic exercise are combined their 
effects are compounded, and significant changes in neuroplasti-
city are observed (Petzinger, et. al. 2013). 
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The Successful Programs and how they Incorporate 
Goal Based Learning and Aerobic Exercise
“Tai Chi, as a mind-body exercise, consists of a series of dance-
like movements linked in a continuous sequence, flowing slowly 
and smoothly from one movement to another that emphasizes 
weight transfer and movement of the body.” (Yan Yang, 2015, 
p. 2) It has been shown to improve dynamic postural control, 
balance, gait, and quality of life (Petzinger, et. al. 2013, Yan Yang, 
2015). In one study, scientists observed improved stride length, 
stability and maximum excursion in patients who had partici-
pated in tai chi classes twice a week for 24 weeks (Petzinger, 
Fisher, McEwen, Beeler, & Walsh, 2013). Tai chi incorporates cog-
nitive engagement by practicing combinations of movements 
and control of an individual’s center of gravity (Yan Yang, 2015). 
However, it does not include intense aerobic exercise, and it 
is not clear if this lowers its success rate compared to other 
exercise debilitation programs.  
Dance is an aerobic form of exercise that has also shown 
promise as a potential treatment for Parkinson’s Disease. 
Dance enhances motor learning by making people pay atten-
tion to music and rhythm (Blandy, Beevers, Kerry, & Morris, 
2015) (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013). In 
addition, partner dancing further stimulates cognitive engage-
ment by teaching people partner coordination (Petzinger, Fisher, 
McEwen, Beeler, & Walsh, 2013). By incorporating both cog-
nitive and aerobic exercise, dance has been found to improve 
gait, motor impairment and balance (Blandy, Beevers, Kerry, & 
Morris, 2015).  
Boxing therapy has become a very popular form of exer-
cise therapy for PD in the past couple of years. In 2006 The 
Rocksteady boxing foundation located in Indiana opened the 
first noncontact boxing program for PD Patients. Since then, 
Rocksteady boxing programs have been established across the 
United States. Boxing therapy takes a whole-body approach by 
including dynamic balance activities and multi-directional reach-
ing and stepping. These programs also include jump rope and 
framework activities that help improve people’s ability to initi-
ate movement (Combs, et al., 2011). Boxing helps improve bal-
ance, gait, parkinsonian symptoms and quality of life (Combs, et 
al., 2011) (Petzinger, et. al. 2013).  Scientists have reported that 
the benefits of boxing last for a long time even if patients stop 
participating in as many classes as they originally did. The boxing 
programs included aerobic exercise and goal-based exercise 
by incorporating fast-paced multi-directional body movement 
(Combs, et al., 2011). Thus, boxing is one of the most promising 
forms of exercise therapy available for PD patients. 
Cycling training is another popular form of exercise rehabili-
tation. Both forced cycling and voluntary cycling programs have 
been found to help improve PD symptoms (Nadeau, et al., 2017). 
In forced cycling PD patients are placed on an electric bike and 
forced to pedal at a speed that is above their comfort level 
(Ridgel, et. al.  2009). This system helps recruit cognitive involve-
ment and has been shown to improve neuroplasticity in the 
human brain. In addition, forced cycling helps improve tremor 
and bradykinesia. Voluntary cycling has been shown to improve 
cardiovascular capacity, executive function, motor learning and 
walking speed (Nadeau, et al., 2017). Both voluntary and forced 
cycling are promising treatment options for Parkinson’s Disease, 
and scientist still have not determined which form of cycling is 
more successful.
Treadmill training, when used to treat mild to moderate PD, 
helps improve, “velocity, postural stability, gait rhythmicity and 
joint excursion (Petzinger, Fisher, McEwen, Beeler, & Walsh, 
2013, p. 717).” Some studies have reported treadmill training to 
be completely infective at treating Parkinson’s disease. This in-
consistency may be a result of improper feedback during work-
outs, which is supposed to promote cognitive engagement and 
enhance motor learning (Petzinger, et. al. 2013). Thus, treadmill 
training is a prime example of an exercise program that must 
include both goal based and aerobic exercise in order to be 
effective.
Neuroprotection
Neuroprotection is the driving force behind the neuroplastic 
effects that both goal based and aerobic exercise exert on the 
PD brain. Exercise provides neuroprotection by increasing do-
pamine release and dopamine receptor expression, decreasing 
dopamine clearance from the synaptic terminals, stimulating the 
release of neuroprotective factors and initiating an anti-inflam-
matory response. 
Exercise therapy promotes the release of dopamine, decreas-
es dopamine clearance from the synaptic cleft and facilitates the 
binding of dopamine to D2 receptors in the dorsal striatum. 
Exercise has been found to increase dopamine synthesis and re-
lease in both human and mice models (Horak & King, 2009). One 
theory for how this is accomplished is that exercise increases 
tyrosine hydroxylase (TH) levels in the PD brain. TH is an en-
zyme that increases dopamine levels by converting L-tyrosine 
to L-dopa (a precursor form of dopamine) (Morgan, Corrigan, 
& Baune, 2015). TH has also been found to decrease aggregat-
ed a-synuclein proteins, which play a primary role in neuronal 
death in PD (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013). 
In addition, exercise decreases DAT levels, which participates in 
the degradation of dopamine in the synaptic clefts. This increas-
es the dopamine available to bind to dopamine receptors. D2 
receptors in the Putman are activated with intensive exercise 
and are available to bind to dopamine (Jakowec, Wang, et. al. 
2016). D2 receptors play an important role in cortical-striatal 
glutamatergic modulation and are essential for motor learning 
(Jakowec, et. al. 2016) (Petzinger, et al., 2015).  
Exercise plays a role in modulating the inflammatory response 
in the Parkinson’s diseased brain. It is well known that exercise 
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reduces inflammation and oxidative stress (Shu, et al., 2014). 
One of the ways that physical activity reduces inflammation is 
by increasing anti-inflammatory cytokine interleukin 10. Exercise 
also increases interleukin 6 which usually acts as an inflammato-
ry substance, but in the case of exercise, its effects are anti-in-
flammatory. Interleukin 6 accomplishes its job by eliciting, “an 
anti-inflammatory response that includes increased expression of 
several factors including interleukin 10 and interleukin 1 receptor 
antagonists, and inhibition of factors such as tumor necrosis fac-
tor alpha (Petzingeret, et. al.  2013, p. 722).” In addition, exercise 
reduces the proliferation of astrocytes and microglia cells which 
secrete harmful inflammatory cytokines. Physical activity also may 
drive the conversion of activated microglia cells from M1 myeloid 
cells which secret harmful cytokines to M2 myeloid cells which 
helpful secret cytokines (Jakowec, et. al. 2016). This may mean that 
exercise not only reduces inflammation but also stimulates the 
development of a positive immune response.  
Exercise also increases the secretion of neuronal protec-
tive factors, which include brain-derived neurotrophic factor 
(BDNF), Galia cell-derived neurotrophic factor (GDNF) and hy-
poxia-inducible factor 1 alpha (HIF-1α). Both BDNF and GDNF 
promote neuronal growth, prevent neuronal death and help 
the neurons function properly (Paillard, Ronlland, & Barreto, 
2015) (Morgan, Corrigan, & Baune, 2015). BDNF, in particular, 
is activated by aerobic exercise and has been found to reduce 
rigidity and muscle stiffness (Morgan, Corrigan, & Baune, 2015) 
(Jakowec, Wang, Holschneider, Beeler, & Petzinger, 2016). Skilled 
based exercise increases cortical-striatal function, which results 
in an increased demand for oxygen. The lack of oxygen activates 
transcription factor HIF-1α. This transcription factor increases 
neuronal health by regulating genes that control, “Metabolism, 
mitochondrial integrity … and signaling cascade pathways in-
volved in nitric oxide synthase and glutamine synaptogenesis 
(Jakowec, Wang, Holschneider, Beeler, & Petzinger, 2016, p. 41).” 
Thus, both aerobic and skill-based exercise help increase the 
release of neuroprotective factors.
Conclusion
Parkinson’s Disease is the second most common neurodegen-
erative disease, and its prevalence is expected to double by 2040 
(Ridgel, et. al. 2015). There is no cure for Parkinson’s Disease. All 
the available mainstream treatments cause adverse side effects 
and are only successful at eliminating a small number of symp-
toms. However, alternative therapies such as exercise have been 
found to reduce targeted symptoms, without causing negative 
side effects. Unfortunately, exercise therapy although growing in 
popularity is not being used by most primary doctors to treat 
Parkinson’s Disease. Educating affected individuals and medical 
practitioners on the benefits of exercise programs can poten-
tially help improve the lives of many individuals. Why should 
medications that cause a plethora of side effects be prescribed 
when we can use exercise programs instead? Why tell patients 
that there is no hope in sight for them, when in fact exercise 
can potentially stop the progression of Parkinson’s disease and 
in some cases eliminate all Parkinson’s disease symptoms. It 
is time for medical professionals to change their outlook on 
Parkinson’s Disease, instead of relaying a message of helpless-
ness they should relay a message of hope.
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Objective: To determine the significance of various types of dietary fat in the progression of atherosclerosis leading to heart disease.
Methods: Study inclusion criteria constituted relevance to the discussion topic and peer reviewed literature. Age of the published 
material was taken into account as well, with greater preference being given to more recent research as the topic of nutrition and 
its relation to chronic disease remains an emerging science. 
Results: This research review found an overall significant relationship between the type (monounsaturated, polyunsaturated, sat-
urated and trans-fat) of dietary fat intake and the incidence of cardiovascular disease. While earlier research identified an 
increased risk of cardiovascular disease to be associated with an overall increased intake of dietary fat, newer studies recognized 
the increased risk to be associated more specifically with saturated and trans fatty acids. Substitution of other dietary fats in 
place of saturated fat in the diet also plays a role in cardiovascular disease. The studies reviewed here found a protective effect 
of polyunsaturated fatty acids when replacing saturated fat in the diet. On the other hand, replacing saturated fats with carbo-
hydrates has no evidence of improved cardiovascular health. Studies looking at the implications of substituting saturated fat with 
monounsaturated fats remain inconclusive at this time.  Aside from dietary fat intake, the progression of atherosclerosis leading to 
cardiovascular disease can be caused by oxidative stress such as in the case of hyperglycemia and diabetes. 
Conclusions: As health care costs continue to rise in this country, preventive medicine plays an increasingly important role in the 
prevention and treatment of chronic disease. Research shows that decreasing the percentage of saturated fats in the diet and sub-
stituting these with healthier polyunsaturated fats, as well as minimizing oxidative stress in the body can decrease the incidence 
of cardiovascular disease, a leading cause of death in the United States. 
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Introduction
In February of 1980 the United States Department of Agriculture 
and Department of Health and Human Services jointly pub-
lished the first set of Dietary Guidelines for Americans. During 
this time, health scientists were beginning to focus on the link 
between macronutrient intake and a correlated risk for chronic 
diseases. In these original guidelines, Americans were encour-
aged to keep their total fat intake levels below thirty percent of 
their diet, have less than ten percent of dietary fat come from 
saturated fat, and maintain a cholesterol intake that was under 
300 mg per day (Canty, 2018).
The guidelines have been updated every five years since and 
have evolved based on accumulating scientific evidence, popu-
lation patterns in health status, food consumption, and physical 
activity. The 2015 Dietary Guidelines have a stronger emphasis 
on healthy eating patterns and regular physical activity. However, 
there has been minimal change in the recommendations for fat 
intake for almost 40 years since the first set of guidelines. In 
2015, the Dietary Guidelines for Americans recommended that 
fat be 20-35% of the diet with less than 10% coming from sat-
urated fat and minimizing trans fats as much as possible. While 
the 2015 guidelines did not address cholesterol, the recommen-
dations from 2010 remain the same as well (<300 mg/day) (U.S. 
Dept. of Health and Human Services, 2015). 
Controlling fat intake has consistently been recommended to 
improve health for Americans with a specific focus on limiting 
saturated fat in the diet. However, heart disease, a form of car-
diovascular disease, remains to be the leading cause of death 
for both men and women worldwide. Stroke, a complication of 
cardiovascular disease is the fifth leading cause of death in the 
Unites States. Dietary fat intake is a major modifiable risk factor 
in the development and progression of cardiovascular disease. 
(Center for Disease Control, 2017).
Methods
Studies reviewed in this paper were selected from journal data-
bases, library catalogs, and Health and Nutrition Science profes-
sional websites. Papers were gathered from PubMed, CINAHL, 
Medline, and similar scientific search engines using advanced 
search phrases “PUFA,” “MUFA,” “dietary fat intake,” “trans-fat,” 
“oxidative stress” and “CVD”.
The writer considered over 36 papers and over 20 papers 
were included in the final research review. Study inclusion crite-
ria consisted of relevance to the discussion topic and peer-re-
viewed literature.  Age of the published material was taken into 
account as well, with greater preference being given to more 
recent research as the topic of nutrition and its relation to 
chronic disease remains an emerging science.
To improve the writer and reader’s understanding of the rela-
tion between dietary fat intake and disease, noted textbooks in 
advanced biochemistry topics were referenced and included in 
the discussion section of this paper. 
Discussion
Fat is an essential macronutrient required by the body. In 1927, 
the effects of fat deficiency on growth and development in-
spired researchers Evans and Burrs to dub fat “vitamin F”. Two 
years later, in 1929, Evans and Burrs found that a fat-free diet in 
weanling rats produced impaired growth, scaly skin, tail necro-
sis, increased mortality, and impaired fertility (Ross, et. al, 2014). 
These symptoms were reversed when provided with linoleic or 
linolenic acid and the term “essential fatty acids” was coined. 
Almost thirty years later, in 1958, Essential Fatty Acid Deficiency 
(EFAD) was first demonstrated in humans, when infants fed a 
milk-based diet lacking essential fatty acids (EFA) showed severe 
skin symptoms alleviated by the addition of linoleic acid. Total 
Parenteral Nutrition Support, lacking fat-soluble vitamins, was 
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also shown to produce EFAD in a 6-year-old girl maintained on 
total parenteral nutrition for five months (Burr, 1981).
We require fat and fat-soluble vitamins for energy reserves, 
cell signaling, synthesis of hormones, and their structural role in 
cell membranes (Canty, 2018). The average intake of fat in this 
country has remained relatively consistent since the 1990s. 
The average American consumes 33% of his calories from fat 
and 10% from saturated fat. There were significant changes over 
the years in the consumption of monounsaturated fat (MUFA) 
(14.6% to 13%, p = 0.03) and polyunsaturated fat (PUFA) (6.9%-
8.0%, p = <0.001) as well as the ratio of PUFAs to saturated fat 
(7.1%-8.1%, p = < 0.001) (fig. 1) (Vadiveloo, at. al. 2013).
Atherosclerosis is the narrowing of the arterial wall caused 
by a buildup of plaque. As the endothelial layer on the artery 
wall weakens, it becomes susceptible to plaque accumulation by 
a high concentration of Low-Density Lipoprotein (LDL) -cho-
lesterol in the blood. As the plaque begins to build, monocytes 
and macrophages are attracted to the site of the plaque con-
tributing to stenosis (Narrowing of the artery lumen). The layer 
of smooth muscle in the artery begins to grow a fibrous cap 
over the plaque. As the plaque continues to develop, this cap can 
rupture and form a blood clot that may cause a heart attack or a 
stroke (Escott-Stump, 2015, Mahan and Raymond, 2017). 
Types of Fats
As part of the Strong Heart Study, researchers examined the 
association between dietary fat intake and coronary heart dis-
ease in 2,938 Indian American adults ages 45-79 for an average 
of 7 years. Over 400 participants experienced Coronary Heart 
Disease (CHD) during this time, including 138 fatalities. The re-
searchers divided participants into two age group categories, 
47-59 years and 60-79 years. Across both age groups, individuals 
who developed CHD were more likely male, hypertensive and 
with lower High-Density LipoProteins (HDL) levels and higher 
serum triglycerides. Amongst the older group, those that devel-
oped CHD had higher LDL levels as well. Amongst the younger 
group, an increasing rate of mortality due to CHD was seen 
with greater quartiles of total fat intake, specifically saturated 
and monounsaturated fat (Lee, et. Al. 1990). This study suggests 
that abnormal lipoprotein levels (low HDL, high LDL) are asso-
ciated with an increased morbidity in adults. Additionally, total 
fat, rather than a specific type of fat, is associated with increased 
mortality from CHD.
The Seven Countries Study (Keys, et. al. 1984) investigated the 
intake of various fatty acids as well as dietary cholesterol in rela-
tion to serum cholesterol and 25-year mortality from coronary 
heart disease. The study was carried out from 1956-1964 and 
constituted 16 cohorts across seven countries to include over 
12,000 men between the ages of 40-59 years. Dietary intake data 
was collected and standardized by one dietitian. In 1960 total 
lipids were measured (at that time there was no instrument avail-
able to measure trans-fat, omega-3 or omega-6 fatty acids). Data 
was collected and reported for saturated, monounsaturated and 
polyunsaturated fats. Later, in 1987, total lipids were isolated and 
cis and trans fats, as well as omega-3 fatty acids, were identified. 
The individual saturated fatty acids, namely lauric acid and myris-
tic acid, were significantly related to cholesterol levels (p < 0.001). 
Moreover, the researchers identified a strong positive relation-
ship between the intake of saturated fats and death rates from 
CHD (p <0.001) (fig. 2). It is worthwhile to note that a 25-year 
lapse in time from the collection of data to the analysis may have 
impacted the researchers’ findings.
More recent studies support these findings as well, indicating 
that the source of dietary fat influences heart disease. A 20 year 
follow up of the Nurses’ Health Study looked at the associ-
ation specific types of dietary fat intake as they relate to the 
risk of coronary heart disease. The study consisted of 78,778 
US women who were without CVD or diabetes at the initi-
ation of the study in 1980. At the follow up, 1,766 incidences 
of CHD were reported, 525 of which were fatal. Researchers 
found that intake of polyunsaturated fats was inversely associ-
ated with CHD (P = 0.004) (fig. 3). The results were substantial 
amongst women with an overweight BMI (>35 kg/m2). Trans-fat 
intake was associated with an increased risk of developing CHD 
(P=0.01), particularly in women under 65 years of age (Colditz, 
Hankinson, 2005).
Figure 1: Trends in dietary fat consumption (NHANES)
Source: Canty, D. Advanced Nutrition: Protein, Fats and Carbohydrates. 
Spring 2018.
Figure 2: Correlations Between Fat Intakes (E%) and Serum 
Cholesterol and 25y CHD Death Rate 
Source: Canty, D. Advanced Nutrition: Protein, Fats and 
Carbohydrates. Spring 2018.
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These findings are consistent with a 2006 cross-sectional 
study of 1,123 adults between the ages of 20 and 98 explaining 
the possible connection between the inverse relationships. The 
researchers looked at the relationship between fasting plasma 
polyunsaturated fatty acid (PUFA) levels and markers of inflam-
mation. They found a statistically significant, negative correlation 
between the intake of PUFAs, specifically omega-3 and omega-6 
fatty acids and plasma levels of pro-inflammatory markers (IL-6, 
TNF, IL-10, CRP). This study suggests that the anti-inflammatory 
properties of polyunsaturated fatty acids are associated with 
lowering plasma levels of pro-inflammatory markers that play a 
role in the progression of atherosclerosis (Ferruci, et. Al. 2006)
Replacing Saturated Fat in the Diet
Current guidelines from the HHS and USDA recommend <10% 
of calories come from saturated fat and the American Heart 
Association recommends no more than 5-6% of intake should 
come from saturated fat to decrease LDL cholesterol. However, 
there are fewer studies and recommendations discussing what the 
recommended replacement for saturated fat in the diet should be. 
A meta-analysis of eight randomized control trials that includ-
ed over 1,000 incidences of CHD amongst 13,614 participants, 
found that increased PUFA intake in place of saturated fat in 
the diet reduced CHD events by 19% (Mozaffarian, et. Al. 2010). 
More specifically, each 5% increase in PUFA consumption re-
duced the risk of CHD by 10%. The analysis suggests that these 
improvements in the incidence of CHD were likely the effect 
that PUFAs had on lowering LDL in the blood. The short-term 
studies part of this identified a 5% energy intake from PUFAs 
that replaced a 5% energy intake from saturated fat lowered 
LDL cholesterol by 10 mg/dl while having no significant impact 
on HDL cholesterol. This intake of PUFAs in place of saturat-
ed fats lowered the total cholesterol to HDL ratio by 0.16. 
Conversely, no change in the total cholesterol to HDL ratio 
was found when saturated fat in the diet was replaced with 
carbohydrates. The observational studies identified a 44% de-
crease in CHD risk associated with each unit decrease of total 
cholesterol to HDL ratio.
It is important to note that these studies measured the effects 
of replacing saturated fatty acids with PUFAs in the diet and 
therefore cannot ascertain whether the benefits were relat-
ed to the decrease in saturated fatty acids or the increase in 
dietary PUFAs.  It can be concluded that replacing saturated 
fats with PUFAs in the diet likely decreases the incidence of 
CHD while replacing saturated fat with carbohydrates does not. 
Consequently, it may be concluded that the effects of replacing 
saturated fat in the diet with monounsaturated fat are mixed. 
Future studies looking at the implication of replacing saturated 
fat with proteins and/or MUFAs would be beneficial.
Animal vs. Plant Fats
Emerging research looked at monounsaturated fatty acids to 
identify if the source of MUFAs had a relationship to its im-
pact on heart disease. Researchers used data from the Nurses’ 
Health Study that included 63,000 women and data from the 
Health Professionals Follow-Up study that included 30,000 men. 
Both of these studies utilized food frequency questionnaires ad-
ministered every four years to evaluate participants’ diets.
When analyzed, participants with a higher intake of MUFAs 
from plant sources showed a 16% lower risk of death (from any 
cause) compared with those that had a lower intake. In contrast, 
participants with a higher intake of MUFAs coming from animal 
protein exhibited a 21% increase in risk of death related to any 
cause. Replacing dietary MUFAs from animal sources for the 
equivalent per gram in plant sources may lower the risk for 
death by heart disease or any cause of death between 24% and 
26% (Roeder, 2018).
Similar findings have been reported for with saturated fat. It is 
thought that plant sources of saturated fat may,  in fact, play less 
of a role in the morbidity and mortality from coronary heart 
disease than animal sources. These findings can be explained 
by a recent study looking at the structural implications of fatty 
acids. An animal source of saturated fatty acids is located mainly 
at the sn-2 position of the glycerol backbone as shown in figure 
5 and affects the metabolism, functionality, and physiological ef-
fects of the saturated fatty acids (fig. 4) (Nettelton, et. al. 2017).
The Multi-Ethnic Study of Atherosclerosis aimed to determine 
the association between SFA intake from varying food service 
and in the incidence of CVD. The study included 5,209 par-
ticipants between the ages of 45–84 that were followed for a 
Figure 3: Fat intake and CHD risk in women; Nurse’s Health Study 
20y Follow-up 












Figure 4: Implications of Structure and Position of Saturated 
Fatty Acids Source: Nettleton, 2017.
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decade from 2000. Diet was assessed using a food frequency 
questionnaire and over 300 cases of CVD were assessed during 
follow up valuations.
After adjusting for confounding factors, researchers conclud-
ed that a higher intake of saturated fat from dairy sources was 
associated with a lower risk of CVD (95% CI for + 5 grams per 
day and 5% of energy intake from dairy sources of saturated fat). 
In contrast, meat saturated fat was associated with an increased 
risk of developing CVD with the same increase in grams per day 
and % energy intake (fig. 5). 
Substituting 2% of energy intake from meat sources of satu-
rated fat with dairy sources of saturated fat was associated with 
a 25% decreased risk of CVD (Otto, et. al. 2012). This particular 
study found no association between CVD and intake of plant 
or butter saturated fats, however, intakes recorded in the Food 
Frequency Questionnaires were narrow. 
Processed Fat: Trans Fat
Since in 2006, food manufacturers have been required to list 
trans-fat on all food labels. Trans fats (trans unsaturated fatty 
acids) are artificially produced solid fats. Liquid vegetable oils are 
heated with catalysts in a process called hydrogenation, which 
breaks double bonds in unsaturated fats and adds hydrogens, 
thereby solidifying the fat, making it a solid at room temperature. 
The current dietary guidelines for healthy Americans recom-
mend keeping trans-fat intake “as low as possible” (< 10% of 
total calories). These recommendations are based on studies 
that have found that trans fats increase LDL-cholesterol levels 
in the blood while decreasing healthy levels of HDL-cholesterol. 
One early study demonstrated this by providing 34 adult women 
and 25 adult men with three diets that each study subject fol-
lowed for three consecutive weeks. All three diets were mixed, 
natural diets and identical in nutrient consumption except for 
10% of energy intake coming from oleic acid (a monounsat-
urated fat with one cis bond), trans isomers of oleic acid, or 
saturated fatty acids. LDL cholesterol was significantly higher 
on the trans fatty acid diet compared to the other two diets (P 
<0.0001) with no significant differences found between men and 
women (Mensink, Katan, 1990).
A significant relationship has been reported between dietary 
trans-fat and coronary heart disease. Dietary data was stud-
ied from participants in the Nurses’ Health Study and intake of 
trans fat was calculated using the questionnaires completed by 
more than 80,000 female participants, all of whom were with-
out diagnosed cardiovascular disease at the time. Over the 8 
year follow up period, 431 cases of new CHD were diagnosed. 
Adjusting for age and total caloric intake, the intake of trans 
fat was directly related to increased risk of CHD (P = 0.001). 
Margarines, cookies, cakes and refined white bread were each 
significantly associated with an increased risk of developing 
CHD, with a stronger association found for the participants 
who stated consistent margarine intake for the last 10 years 
(Willett, 1993). 
More recently, the DASH diet (Dietary Approach to Stop 
Hypertension) has been found to reduce the risk of cardiovas-
cular disease in women. The DASH diet focuses on consuming 
adequate servings of fruits and vegetables, lean proteins and 
limiting intake of saturated and trans fatty acids (2 a day where 
a serving is 1 teaspoon of margarine). A study followed more 
than 88,000 women between the ages of 34 and 59 years. Food 
frequency questionnaires were collected 7 times between 1980 
and 2004. Over 2,000 cases of nonfatal myocardial infarction, 
over 3,000 strokes and 976 women died of CHD over the 24-
year follow-up period. After adjusting for confounding factors, 
increased DASH scores were associated with decreased risk of 
acquiring some form of CVD (P <0.01) (Fung, et. al. 2018).
Do PUFAs Have any Faults in Relation to Disease?
Lipid peroxidation is the oxidative deterioration of lipids pos-
sessing double bonds by interaction with a reactive oxygen spe-
cies (ROS). Given their higher content of double bonds, PUFAs 
are more susceptible to oxidation than SFAs and even MUFAs. 
Antioxidants, such as vitamin E and vitamin C, in our diets and 
in our bodies, serve to detoxify the oxidative damage caused by 
ROS. In a healthy individual, the generation of reactive oxygen 
species is in normal balance with antioxidant activity. However, 
increasing amounts of oxidative damage and/or decreasing 
amounts of antioxidants leads to oxidative stress in which ele-
vated levels of ROSs can lead to oxidative damaging of proteins, 
carbohydrates and DNA molecules. 
Oxidative stress has been linked to disease states such as ath-
erosclerosis and certain cancers. The question remains whether 
the disease state causes the increased lipid peroxidation and 
oxidative stress or if the oxidative damage leads to the disease 
state (Ross, et. al, 2014).
Coconut Oil: Celebrity Status Threatened
The American Heart Association published a 2018 Presidential 
Figure 5: Dietary Source of Saturated Fat May Affect CVD Risk
Source: Canty, D. Advanced Nutrition: Protein, Fats and 
Carbohydrates. Spring 2018.
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Advisory that had much of the health community involved in a 
conversation regarding saturated fats and their role in oxidative 
damage and chronic disease. The AHA’s advisory mentioned a 
New York Times piece highlighting a recent health survey in the 
United States which found that 73% of Americans classified coco-
nut oil as a “health food” compared to 37% of nutritionists. The 
AHA contributes the positive perception of coconut oil in its 
relation to health promotion and disease prevention to a result 
of good marketing by the coconut oil industry (Sacks, et. al. 2017).
Statistics from the USDA reveal that coconut oil consumption 
increased from 2013 to 2014 by 9.55% and then dropped in 
2014 and 2015 to 6.23% and 13.47% respectively. This informa-
tion sheds some light on the increased promotion of coconut 
oil as a health food by the coconut oil industry and the belief 
of Americans, that it is a health food.  However, coconut oil’s 
nutrition profile did not change during this time. It remains to 
be 82% saturated fat, and like all densely saturated fats, plays a 
role in cardiovascular disease.
A recent review looked at seven interventional studies com-
paring coconut oil with unsaturated fats in the diet and their 
individual influences on lipid profiles of study participants. All 
seven trials resulted in higher total cholesterol for those receiv-
ing coconut oil intervention, all of which were statistically signif-
icant. Six out of the seven studies found a statistically significant 
increase of LDL cholesterol for the intervention group.  HDL 
levels were statistically significantly raised in five studies for 
those receiving the coconut oil intervention (Eyres, et. al. 2016). 
The AHA warns consumers that the HDL improvements seen 
with diet or drug treatment cannot be directly linked to changes 
in CVD occurrences and therefore encourages Americans to 
look at the LDL changes as effected by various fats alone in 
regard to their role in CVD (Sacks, et. al. 2017). 
Atherosclerosis: Other Players
As the walls of the arteries get thicker, narrowing the lumen 
due to plaque buildup, patients with atherosclerosis experience 
worsening symptoms of CVD, including hypertension (Nelms 
et. al 2016) . During the initial stages of plaque buildup, the en-
dothelial cells of the luminal lining, which provide the barrier 
between the lumen and the vascular wall, may experience dys-
function and contribute to increased plaque and blood pressure. 
Certain stimuli can trigger the dysfunction of the endothelial 
cells, deeming these stimuli proatherogenic. Diabetes and oxida-
tive stress are amongst the major players that contribute to the 
eventual loss of functionality of the endothelial cells, along with 
dyslipidemia, abnormally elevated cholesterol or fats (lipids) in 
the blood (Chistiakov, et. al. 2015).
Glucosamine, often used in the management of osteoarthritis, 
has anti-inflammatory effects by contributing to a redox state in 
an oxidative environment. In an attempt to take advantage of its 
properties, glucosamine supplements consisting of 300 mg were 
given to 20 individuals daily for 30 days and arteriosclerosis and 
CVD were compared to 19 controls. Flow-mediated vasodila-
tion was monitored in all participants at the start and for the 
duration of the four-week trial.  At the end of four weeks, pa-
rameters such as blood pressure, blood glucose, and lipid levels 
were measured. No significant changes were found in these clin-
ical markers prior to or following the study between the two 
groups. However, glucosamine supplementation significantly 
improved flow-mediated vasodilation (P = 0.02) highlighting the 
role that oxidative stress independently plays in atherosclerosis 
and cardiovascular disease (Katoh, et. al. 2017).
This is similar to what is seen in the strong correlation be-
tween diabetes, specifically type 2, and incidence of CVD. The 
American Heart Association considers diabetes to be one of 
the seven top causes of cardiovascular disease. More than 68% 
of people over the age of 65 with diabetes will die from a form 
of heart disease. Adults with diabetes are twice to four times as 
likely to die of heart disease than adults of the same age without 
diabetes (American Heart Association, 2018). 
Oxidative stress has been shown to contribute to athero-
sclerotic buildup in animal models. Elevated blood glucose in 
type 2 diabetic patients allows for glucose persisting in the 
bloodstream to become damaged, increases the amount and 
rate at which reactive oxygen species (ROS) accumulate. ROS 
are potent oxidants that, without adequate antioxidant activity, 
can proliferate and cause oxidative damage in individuals leading 
to the dysfunction and apoptosis of endothelial cells, worsening 
atherosclerosis and hypertension leading to worsening cardio-
vascular complications (Jay, et. al. 2006). 
A double-blinded crossover study looked at the role that 
antioxidants could play in lowering levels of ROS and oxidative 
stress and mortality risk due to CVD in diabetes over the age 
of 55.  Exclusion criteria included uncontrolled hypertension 
and history of a myocardial infarction and/or stroke within the 
last month. Participants were randomized to receive either 
a vitamin E (a potent Anti-oxidant) supplement or a placebo 
pill. At the end of eight weeks, researchers measured forearm 
blood flow and found that vitamin E supplementation signifi-
cantly improved blood flow (P <0.01), demonstrating improved 
cardiovascular profiles in diabetic patients receiving antioxidant 
supplementation (Alshiek, et. al. 2017).
Implications
The Lifestyle Heart Trial suggests a correlation between a life-
style change in patients with atherosclerosis and regression in 
their artery lesions. Forty-one participants with atherosclerosis 
were randomized to an experimental group (n=22) and control 
group (n=19). Angiographies were conducted at baseline and 
again at a one-year follow-up. During the year the experimental 
group was given a low-fat, vegetarian diet with less than 10% 
of calories coming from fat and a ratio of PUFAs to saturated 
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fat  of less than 1. The experimental group was also required 
to participate in aerobic exercise and attend weekly support 
group meetings. Following one year, blood serum was collected 
and analyzed from all 22 participants. The results showed an 
average percentage diameter stenosis decrease from 16.9% to 
16.5% amongst the experimental group. The control group who 
continued with their usual diet and lifestyle showed stenosis 
progression from 15.5% to 18.5%. The average percentage re-
gression in the diameter stenosis of the control group was 82% 
(18 out of 22). In the experimental group, total cholesterol was 
lowered by 24.3% and LDL concentration by 37.4%. This study 
shows that a lifestyle change in patients with coronary heart 
disease can lead to significant regression in arterial stenosis 
(Ornish, et. al. 1990). Changes in lipid profiles and angina pecto-
ris are displayed in the tables (ref., tables 1 and 2).
Conclusions and Recommendations
The Dietary Guidelines for Americans published every five years 
is a set of evidence-based guidelines to promote healthy nutri-
tion habits and prevent nutrition-related disease in the American 
population.  These guidelines are constantly evolving based on the 
latest research findings and available science. Despite its regular 
updates, the DGA has remained relatively consistent in its rec-
ommendation for the dietary consumption of fats. 
Recent National Health and Nutrition Examination Survey 
data shows Americans are consuming 33% of their calories in the 
form of fat. This paper reviewed the literature on types of fats and 
their individual relationship to the progression of cardiovascular 
disease, the cause for one-third of all deaths in this country. 
Indeed, the type of fat a person is consuming impacts his or 
her risk of cardiovascular disease. Higher amounts of saturated 
fat in the diet have been found to be associated with increased 




















































Weight (kg) 91.1 (15.5) 80.4 (22.8) 81.0 (11.4) 81.8 (25.0)
Table 1: Changes in Risk Factors Source: Ornish, D. 1990









Frequency 5-10 (14-1) 2-35 (3-77) 0.45 (0.76) 6-24 (12-9)
Duration (min) 2-73 (4-69) 3-47 (7-95) 1-58 (4-48) 6-97 (14-5)
Severity 2-3 (1-6) 1-8 (1-1) 1-7 (1-2) 2-5 (1-2)
Table 2: Changes in Angina Pectoris Source: Ornish, D. 1990
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risk of CVD. Replacing saturated fat with carbohydrates has 
not been found to improve lipid profiles or CVD risk factor 
biomarkers. On the other hand, replacing saturated fat with 
unsaturated fats, specifically PUFAs, have been associated with 
lowering an individual’s risk of developing CVD. The data on 
MUFAs remains inconclusive at this time. 
The research suggests that health care professionals should 
encourage their patients and clients, especially those at risk for 
cardiovascular disease, to consume a diet lower in saturated 
fat and to mindfully replace those items with wholesome, real 
foods, and fats higher in PUFA content while remaining wary 
of processed carbohydrates. As part of a healthy diet, consum-
ers should also consume adequate foods high in antioxidants 
to provide a buffer for the potentially oxidizing effect of a diet 
higher in PUFAs. 
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Osteoporosis and Degenerative Disc Disease can cause a loss of height in the spine. This paper focuses on the mechanisms that 
cause age-related loss of height and its effects. Possible relationships between receptor activator nuclear factor kappa-B ligand 
(RANKL) and estrogen with osteoporosis are discussed, as well as possible genetic causes. Exercise may prevent osteoporosis. 
Osteoporosis may cause a loss of height, vertebral fracture, a decrease in maximum lung capacity, and hip fracture. Degenerative 
disc disease may cause shortening of the spine. Disc height loss can result in a reduction in the range of motion and stiffness 
at the affected spinal segments. Degenerative disc disease may cause a small increase in vertebral height which can lead to 
complications in treatments. 
What Are the Mechanisms and Effects of  
Age-Related Shortening of the Spine?
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Introduction
As early as the age of 30, people may begin to become shorter. 
Studies show that from the age of 40, people begin to lose about 
half an inch per decade. Some health risks associated with loss of 
height are spinal fracture, back pain, hip fracture (Hannan et al., 
2012), and a decrease in lung capacity (Krege et al., 2015). Total 
health care costs in the United States of osteoporotic hip fractures 
is estimated at 18 billion dollars annually (Hannan et al., 2012). 
There are three main reasons why people become shorter 
as they age, and they are all related to the spine. One reason is 
osteoporosis, a decrease in bone density. As the skeleton loses 
density, it compresses, making the body shorter. Osteoporosis 
is the most common bone disease, affecting 200 million people 
worldwide, and leading to over 9 million fractures annually (Yu 
& Wang, 2016). Giving the aging population, the predicted annual 
healthcare costs of an osteoporotic compression fracture in the 
USA alone is 25.3 billion dollars. Loss of water in the interverte-
bral discs due to aging also accounts for shortening of the spine. 
The discs become compressed, because of the weight placed on 
them by the upper body, resulting in a loss of height (Jarman et 
al., 2015). Another possible cause for shrinking is the abnormal 
bending of the spine. However, the body isn’t really shortening, 
rather bending, and just giving the appearance of loss of height. 
Flattening of the arch of the foot may also give a person the 
appearance of a shorter stature; however, most of a person’s 
height loss can be attributed to changes in the lumbar spine 
(Videman et al., 2014).  This paper discusses the possible causes 
and effects of osteoporosis and degenerative disc disease, and 
how they result in a loss of height.
Methods
Data was found by using ProQuest and PubMed databases 
through Touro college’s online library. Keywords used were loss 
of height, osteoporosis, and degenerative disc disease.
Physiology of Osteoporosis
Bone is 30% collagen fibers and 70% non-organic minerals such 
as calcium. Osteoblasts are cells that make bone. Osteoclasts 
break down the bone and resorb the minerals into the blood, 
but osteoblasts keep making new bone to counter the loss; 
this is known as bone remodeling. Osteoporosis is a condi-
tion where osteolysis overshadows osteogenesis (Yu & Wang, 
2016). Osteoporosis can begin at the age of 30, but it is most 
pronounced in older people, especially in postmenopausal 
women because estrogen suppresses the receptor activator 
of nuclear factor kappa-B ligand (RANKL), a molecule that 
promotes osteoclast differentiation and formation (Eghbali-
Fatourechi et al., 2003). Estrogen also increases the expression 
of osteoprotegerin (OPG), which functions as a decoy receptor 
for RANKL (Hofbauer et al., 1999). During menopause, when 
there is a decrease in estrogen, there is an increase in RANKL 
and decrease in OPG, resulting in increased osteoclast activity, 
and a net loss of bone.
Studies show that men also experience bone loss due to a 
decrease in estradiol concentrations (Falahati-Nini et al., 2000). 
However, in both men and women, a decrease in growth hor-
mone secretion due to aging is also responsible for a decrease 
in bone formation (Drake et al., 2015).
Trabecular bone loss begins in the third decade of life while 
cortical loss typically begins in the sixth decade of life (Drake 
et al., 2015). Trabecular loss, which occurs before gonadal sex 
steroid deficiency, may be caused by secondary osteoporosis. 
Secondary osteoporosis is bone loss caused by factors other 
than aging or postmenopausal status. Glucocorticoid excess 
can cause decreased production of osteoblast precursors and 
increased apoptosis of mature osteoblasts. Primary hyperthy-
roidism causes cortical bone loss. Vitamin D deficiency causes 
demineralization of bone and is associated with lower bone 
density. Type 1 diabetes mellitus causes osteoporosis because of 
an inability to reach peak bone mass (Emkey & Epstein, 2014). 
There are many other causes of secondary osteoporosis, but 
this paper focuses on age-related causes.
Since both genders experience trabecular bone loss with 
aging, age-related factors other than sex steroid deficiency may 
be involved. Cytokines accumulate due to aging factors, including 
menopause, and make the bone marrow prone to inflammation 
(Yu & Wang, 2016). Inflammation activates transcription factor 
nuclear factor kB, which causes osteoclast differentiation and 
inhibits osteoblasts (Chang et al., 2009). Also, oxidative stress, 
characterized by the presence of too many reactive free radi-
cals in the body, increases with age. Oxidative stress activates 
nuclear factor-kB which in turn causes bone loss (Khosla et al., 
2011). It is unclear if osteoporosis causes further inflammation 
in the bone marrow which would then activate more nuclear 
factor-kB, exacerbating the osteoporosis (Yu & Wang, 2016). 
Osteoporosis may indirectly cause further bone loss. 
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Osteoblasts and adipocytes both come from a mesenchymal 
stem cell. In osteoporosis, since osteoblasts production is in-
hibited, there are more adipocytes forming instead. Adipocytes 
secrete the hormone leptin which has been found in mice to 
promote adipogenesis and inhibit osteogenesis (Yue et al., 2016). 
Osteoporosis is also caused by gene expression. Histone 
Demethylases KDM4B and KDM6B remove gene silencing his-
tones from the osteogenic master regulator gene (Ye et al., 2012). 
Mice that had KDM6B knocked out had impaired osteogenesis 
(Zhang et al., 2015). Aged mice and female mice that had their 
ovaries removed had elevated levels of the osteogenic gene si-
lencing histones, suggesting an epigenetic link between aging and 
low estrogen levels with impaired osteogenesis (Ye, et al., 2012). 
Studies of astronauts have shown that they lose bone from 
bones that are normally weight bearing, such as the femur and 
tibia. Astronauts returning to Earth have extensive bone resorp-
tion, which shows that osteoclasts were breaking down the 
bone (Shigematsu et al., 1997). Normal bone density was not 
restored after reambulation (Vico et al., 2000). Prolonged bed 
rest is also associated with decreased bone density in weight 
bearing. Interestingly, a study of 24 bedridden women showed 
that high load resistive exercise had no significant impact on 
bone loss, although it did prevent muscle atrophy (Beller et al., 
2011). These studies show that the force of gravity is necessary 
for maintaining normal rates in bone remodeling, and a lack of 
this force may result in osteoporosis. 
Predisposing risks for osteoporosis occur during childhood 
and adolescence because maximizing peak bone mass is import-
ant for its prevention. However, exercise during maturation can 
mitigate the effects of osteoporosis. Weight-bearing exercises 
are found to be effective in generating bone anabolism (Santos 
et al., 2017). Exercise may be a form of prevention, but once os-
teoporosis develops, exercise may lead to osteoporotic fracture 
due to the stress put on the weak bones. 
Osteoporotic Vertebral Fracture and Height Loss
The decrease in bone density caused by osteoporosis can cause 
vertebral fractures. Vertebral fractures can be measured using 
the spinal deformity index (SDI). Using the SDI, a mild com-
pression fracture (20-25% compression) in a vertebra is given 
a value of one, moderate fractures (25-40% compression) are 
two units, a severe fracture (more than 40% compression) is 
given a value of 3 (fig. 1). The SDI is the sum of the units of each 
vertebra from T4 to L4. Height loss was calculated by subtract-
ing the current height from the arm span. The arm span length 
was considered the person’s peak height. In a study of women 
aged 70 years and older with osteoporosis and a history of at 
least one moderate or severe vertebral fracture, for each unit 
increase in SDI, height decreased by about 0.5 cm (Krege et 
al., 2015). Osteoporosis causes a loss of bone in the vertebrae, 
resulting originally in a decrease in density of the vertebrae. 
The weight placed on the spine may then cause the vertebrae 
to compress, increasing the bone density of the vertebrae (the 
density may be elevated due to compression; however, there is 
a decrease in bone mass and height). Therefore, height loss is a 
marker for vertebral fractures.
Osteoporosis and Lung Capacity
SDI is also negatively correlated with pulmonary function. For 
each unit increase in SDI, forced inspiratory vital capacity, which 
is the maximum volume of air inhaled, decreased by 1.62% and 
inspiratory time, the time it takes for the maximum volume of 
air to be inhaled, decreased by 2.39% (Krege, et al., 2015).  There 
was no significant correlation between the flow rate, which is a 


















SDI = 1 + 2 + 1 + 1 = 5
Fig. 1. Spinal deformity index is the sum of fracture grades for T4 
to L4 vertebrae. In the example shown, the patient has three mild 
and one moderate vertebral fracture, for an SDI of 5. SDI, spinal 
deformity index. Modified from Krege et al., 2015
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and the SDI. This result indicates that vertebral fracture is linked 
with restrictive, not obstructive, lung disease. Restrictive lung dis-
ease occurs when the lungs aren’t compliant, and they become 
stiff, limiting the lungs’ expansion, and causing a volume decrease. 
An obstructive disease does not affect the lung volume; rather it 
causes a decrease in flow due to the resistance of the obstruc-
tion. Therefore, since people with vertebral fractures experience 
a decrease in lung capacity but not in flow rate, osteoporosis 
can be classified as a restrictive lung disease. The reduction in 
inspiratory time is caused by a decreased lung volume, so there 
isn’t as much air going into the lungs, and therefore it requires 
less time for inhalation. Perhaps the decrease in inspiratory vital 
capacity is due to a loss of volume in the thoracic cavity because 
of compression of the spine. This decrease in volume may limit 
the compliance of the lungs. No evidence was found that would 
suggest an effect of height loss on the heart. 
Other studies were performed using expiratory mea-
surements. One study found that for each thoracic vertebral 
fracture forced vital capacity declined 9% (Leech et al., 1990). 
Others suggested that there is no relationship between ver-
tebral fractures and pulmonary function. However, the analysis 
performed by Krege et. al. is unique in its use of SDI to quantify 
the vertebral fracture. Another possible reason for different re-
sults found in the studies is because the other studies used ex-
piratory measurements while Krege et al. used inspiratory mea-
surements. Also, the measurement done by Leech et. al. was only 
considering thoracic fractures while the study done by Krege et 
al. considered both thoracic and lumbar segments. A limitation 
to the Krege et al. study is that it combined both thoracic and 
lumbar segments rather than assessing them separately.
Osteoporotic Hip Fracture
Height loss is also associated with osteoporotic hip fracture, 
defined as incident fractures of the proximal femur occurring 
either after age 50 or in postmenopausal women. A study that 
followed 3081 adults over 50 years revealed a positive correla-
tion between height loss and risk of hip fracture. For this study, 
hip fracture was defined as a first-time fracture occurring in the 
absence of overwhelming trauma. The study recorded height 
loss of male and female participants over 24 years. Most partic-
ipants were middle-aged during these 24 years. The study also 
considered recent height loss, height loss occurring during the 
two years prior to the hip fracture, as a possible correlation to 
the risk of hip fracture. Most participants were elderly during 
the two years of their recent height loss.
The study used Cox proportional hazards regression (HR) to 
calculate hazard ratios and 95% confidence intervals for height 
loss and risk of hip fracture. For each inch of height loss oc-
curring during the 24 years, the HR was 1.4 in men and 1.04 
in women. These results show that height loss was significantly 
associated with hip fracture in men but not in women. Men with 
long-term height loss of two inches or more had about twice 
the risk of fracture than men with less height loss. Recent height 
loss occurring two years prior to hip fracture increased the risk 
of hip fracture by 54% for men and 21% for women. Recent 
height loss was more of an indicator of fracture risk compared 
to long-term height loss most probably because recent height 
loss occurred during elderly ages while long-term height loss 
occurred during the participants’ middle-aged years.
That study proved a relationship between height loss and hip 
fracture; however, height loss can be caused by many factors, 
postural changes, osteoporosis, disc degeneration, and kyphosis 
which may contribute to fracture risk. No information was given 
about posture for the participants, which is a limitation of the 
study. The exact cause is unknown, but height loss is an indica-
tor of an increased risk of hip fracture. Another limitation of 
the study is that participants were all from one town and were 
primarily Caucasian (Hannan, et al., 2012).
Physiology of Degenerative Disc Disease
The intervertebral disc has a hard-outer portion called the an-
nulus fibrosus and a gelatinous inner portion called the nucleus 
pulposus. The annulus fibrosis can further be divided into 2 por-
tions. The outer zone is made of type 1 collagen fibers and the 
inner zone is comprised of type 2 collagen fibers. The nucleus 
pulposus is 85% water. The intervertebral discs act as a water 
cushion and distribute pressure uniformly over the endplates 
of the vertebrae. While a person is in an upright position, the 
weight placed on the intervertebral discs causes the discs to 
lose water. The water escapes to blood vessels in the bone mar-
row space in the endplate of the vertebrae. These blood vessels 
are also responsible for giving the intervertebral discs nutri-
tion. When the pressure on the intervertebral discs decreases, 
like when a person lays down or in a zero-gravity environment, 
fluid reenters the intervertebral disc. The difference in height 
between a person in a vertical and horizontal position can be 
1% of his height (Schuenke et al., 2011). 
As people age, they may get what is known as degenerative 
disc disease. However, there are those who view degenerative 
disc disease different than normal disc ageing, maintaining that 
degenerative disc disease is “an accelerated ageing process in-
cluding structural failure”, while there are those who use the 
two terms synonymously (Galbusera et al., 2014). In this paper, 
degenerative disc disease refers to disc degeneration associated 
with normal ageing. 
 Over time, the annulus fibrosus weakens and loses elasticity. 
Also, proteoglycans, water retaining molecules, diminish within 
the degenerating discs. With the decrease in water, the discs 
lose their ability to resist compression and torque. The discs 
shrink because of the weight placed on them, and less water is 
present to counter this force (Jarman et al., 2015). This com-
pression of the intervertebral discs results in a decrease in a 
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person’s overall height. Studies show that a decrease in estrogen 
can cause disc degeneration (Lou & Chen, 2014).  
Disc Height Loss
A study of 37 men and 33 women, with an average age of 48 
showed that degenerative disc disease is positively correlated 
with disc height loss. The 70 participants were asymptomatic 
for back pain to exclude pathologic degeneration. Additionally, 
participants were not diagnosed with osteoporosis and didn’t 
have any spinal fractures. T2-weighted MR images were used 
to determine if the patient had degenerative disc disease. T2-
weighted MRI signals water content; therefore, an MR image 
showing a white disc indicated a healthy disc that contained 
water, while images of a dark disc indicated degenerative disc 
disease since the dark color in the image indicated that the disc 
lacked water. Another indicator of degenerative disc disease is 
an absence of the differentiation of the nucleus pulposus and the 
annulus fibrosis. The study used MR imaging of the lumbar spine 
to assess the height and shape of the intervertebral discs. The 
height of the disc was measured as the mean of the anterior 
and posterior disc height. Disc convexity was calculated as the 
ratio of the central disc height and the mean of the anterior and 
posterior height. 
The study showed that disc degeneration resulted in a de-
crease in disc height. Also, the lower intervertebral discs were 
shorter than discs higher in the spine (for example, the disc 
between L2 and L3 was shorter than the disc between L1 and 
L2), most probably because the greater weight placed on the 
lower discs cause them to be more compressed. Degenerative 
effects on disc height were found to be more pronounced with 
increasing age. Weight, overall height, and gender did not cor-
relate with disc height. Discs were found to be less convex in 
the presence of disc degeneration. Also, the lower level discs 
were less convex. One drawback of this study is that partici-
pants didn’t have osteoporosis, so the effects of degenerative 
disc disease together with osteoporosis can’t be determined 
(Pfirrmann et al., 2006). 
Height Changes in Intervertebral Discs  
and Vertebrae
Another study was done using 232 monozygotic twin men. The 
fact that they are twins is not relevant to the findings of this study. 
Intervertebral disc and lumbar vertebrae heights were measured 
from MRIs and compared with the measurements of one group 
after five years and the remainder after 16 years. After five years, 
the vertebrae did not significantly increase in height. However, 
after 15 years, the vertebrae significantly increased by an average 
of 3.1% which was an average of 0.8 mm. The lower vertebrae 
increased in height more than the upper vertebrae did. The disc 
heights had a mean decrease of 3.45% or 0.4 mm after five years 
and an average decrease of 10% or 1.2 mm after 15 years. Disc 
height loss was greater than the height increase of the vertebrae, 
resulting in a net loss of height. The axial disc areas significantly 
increased by 4.7% over 5 years and 14.2% over 15 years.  Disc 
volume was calculated by multiplying the mean disc height by the 
axial disc area. Over 5 years, the disc volume did not significantly 
change, but after 15 years, the volume significantly increased by 
2.3% in the discs between L2 and L4, and significantly increased 
by 3.7% in the discs between L4 and S1.
This study shows that disc shortening is associated with an 
increase in vertebral height. A 1 mm decrease in the height of 
either the superior or inferior discs was associated with an 
increase of .09 mm in vertebral height. The effects of the supe-
rior and inferior discs are additive. Age was not a confounder 
on the relationship between the discs and the vertebrae. Since 
the vertebrae increase as the discs decrease, the lumbar spine 
only minimally decreases. The reason for this vertebra-disc re-
lationship may be because the increased tension between the 
vertebra and annulus fibrosus causes ossification to strengthen 
the connection between the disc and the vertebra. This reason 
would help explain why vertebral height increases occur more 
at the anterior and posterior sections of the endplates, because 
it attaches to the annulus. Another possible explanation for the 
relationship between disc height and vertebral height is that 
endplate lesions can expose the vertebrae to disc substances, 
which may lead to inflammation and bone growth on the end-
plate. Support to this hypothesis is that studies have found an 
association between disc degeneration and lesions of the bony 
endplate. 
Over the 15-year study, the lumbar spine decreased by an 
average of 1.4% or 2.0 mm. The mean decrease in total height of 
participants was 3 mm. Most of the overall height loss experi-
enced by participants of this study occurred in the lumbar spine 
(Videman et al., 2014).
Degenerative Disc Disease and Spinal Flexibility
Intervertebral disc height loss may result in a decrease in the 
range of motion and stiffness of the affected spinal segment. It is 
unclear however if disc height loss is the cause, or possibly due 
to damages of annular tissue or ligaments. One possible way to 
restore spinal flexibility is to inject a hydrogel to compensate 
for the loss of height of the discs (Balkovec et al., 2016).  
A possible concern with simply using a hydrogel to add height 
to the discs is that sometimes the surrounding vertebra increas-
es in size as was found in the Videman et al. study, so there may 
no longer be sufficient space for a larger disc in the spine. 
Conclusion
Osteoporosis may cause a loss of height, vertebral fracture, a de-
crease in lung capacity, and hip fracture. Osteoporosis is caused 
by activation of RANKL and a reduction in osteoprotegerin. 
Histone demethylase KDM4B is also linked to osteoporosis. A 
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decrease in Estrogen can cause osteoporosis. Weight-bearing 
exercise may reduce the progression of osteoporosis. 
Degenerative disc disease may cause shortening of the spine. 
Discs lower in the spine experience a greater loss of height, pre-
sumably because the greater weight placed on them causes them 
to condense more. Disc height loss may result in a decrease in 
the range of motion and stiffness of the affected spinal segments.
Further studies should be done to determine the effects of 
the enlargement of the vertebral bodies in response to degen-
erative disc disease. Using a hydrogel to restore height in the in-
tervertebral discs may not be a sufficient method of treatment 
since the intervertebral space may be partially occupied by 
newly formed vertebral bone. Also, further studies are needed 
to examine if degenerative disc disease can cause an increase in 
bone density of the lumbar spine. Bone density scans are taken 
of the lumbar spine to diagnose a patient with osteoporosis, but 
if degenerative disc disease is increasing the bone density, then 
the diagnosis may be incorrect. The bone density measurements 
would appear to be within normal limits even though the patent 
may have osteoporosis.
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Abstract
Xenotransplantation is a breakthrough medicinal technology that is an attempt to change the lives of millions of people.  The 
problems in the current organ transplant system risk the lives of patients each and every day.  Intense waiting periods and 
extremely costly procedures exemplify the stress and pressure that these patients face as an attempt to save their own lives. 
Xenotransplantation is the idea of growing human organs in a different species, using incredible stem-cell and CRISPR technology. 
This can introduce an answer to some of the issues in the current transplant system.  Many technical and ethical issues are 
becoming relevant with the introduction of this new medical phenomenon.  If these barriers can be overcome, xenotransplantation 
can offer a quicker, cheaper, and more effective option for patients in need of an organ transplant. 
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Introduction
Thousands of sick patients are in desperate need of an organ 
transplant, often having their entire lives depending on this one 
vital procedure. Before they can undergo treatment, a proper 
organ donor must be found, and the process is harder than 
ever imagined. Numerous factors affect the long waiting time, a 
period that can frequently become over a year. The main slow-
down is the simple shortage of organs ready for transplant. In 
response to the overwhelming need for organ donations, new 
medical research is being explored as an attempt to alleviate the 
high demand. Xenotransplantation poses as a possible solution 
to this problem and has the capabilities to be very helpful in the 
medical world; releasing the great amount of stress and anxiety 
involved in the classic organ transplant system that is now in 
place. However, this new medical process introduces new bio-
medical and ethical issues. Scientists and doctors are currently 
exploring the possibilities of this new technology, weighing the 
costs against the benefits; an important attempt to improve the 
medical world of organ transplantation.
History of Organ Transplants
The concept of organ transfer in a procedural sense has been 
around for centuries, in-fact cases of organ transplantation dates 
back to ancient times. There is even written proof and docu-
mentation from archeological records that suggest that organ 
and tissue transplantation is thousands of years old. However, 
modern-day organ transplantation is a relatively new medical 
phenomenon that has saved the lives of millions of people from 
end-stage organ failure. 
In the early 1900’s, Dr. Alexis Carrel experimented with kid-
ney transplantations in cats, becoming the first surgeon to ex-
plore vascular surgery (Howard et.al., 2012).  Carrel’journey to 
organ transplantations started with success in vascular surgery 
and suturing of vessels. These experiments also advanced the 
knowledge of organ preservation, showing that human tissue 
could be stored in either saline solution, the patient’s serum, 
or defibrinated blood, until it is needed. Carrel then went on 
to organ transplantations, experimenting with kidney transplan-
tations between dogs, and from dogs to cats. He realized that 
the animals only lived with the transplant for a short period 
of time and he knew that there was some sort of rejection 
going on in the host’s body. Alexis Carrel made extraordinary 
advancements in the medical exploration of organ transplants 
and created the possibility for more research in this area 
(Rothwell, 2011). In 1923, Dr. Harold Neuhof wrote a book 
called The Transplantation of Tissues, which revealed the work 
of many different tissue transplants including skin, cornea, mus-
cle, pancreas and nerve tissue (Howard et.al., 2012).
Soon after, the first human kidney transplant was recorded 
using a kidney from a donor that had died six hours prior. The 
blood type of the donor was type B and the recipient was type 
O, which prevented the kidney from functioning, leading to the 
patient’s death. However, this may not have been the only cause 
for the disfunction of the kidney as other trials have also been 
proven unsuccessful. In 1953, a kidney transplant was done from 
mother to son which only lasted three weeks before the re-
cipient rejected the donor organ. In the beginning years of the 
1950’s, Dr. David Hume performed almost ten kidney transplan-
tations which are now considered the first of their kind in the 
modern era of transplantation. However, none of the recipients 
had a long-term survival after their kidney transplant. 
These and other trials revealed that such organ transplants 
would not be possible without immunosuppressant drugs. With 
this development, organ transplant became a real option for 
patients with organ failure. Dr. Joseph Murray performed the 
first successful kidney transplant in 1962, leading into many 
other victorious cases around the world. The ‘60’s were very 
progressive years for this specific research and medication, as 
the first lung and heart transplants were also done during this 
time (Howard et. al., 2012). 
Problems With the Current Organ Transplant 
System
As immunosuppressant drugs allowed organ transplantation to 
start becoming a viable option for victims of organ failure, the 
need for transplantable organs became overwhelming. In the past, 
kidneys from living donors were being used, but this supply is lim-
ited and not nearly enough to provide for all in need. Even with 
deceased donors for transplants, the available donor organs, un-
fortunately, do not cover the demand (United Network for Organ 
Sharing, Data, 2018). 
Although most technical problems involved in the process have 
been solved, organ transplantation is not seen as a long-term cure 
for patients as there are still biological issues and financial problems. 
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The biggest and most complicated problem is the patient’s 
rejection of the new organ. When a patient undergoes an organ 
transplant surgery, the body’s immune system becomes stim-
ulated against the “foreign” organ and tries to kill it. Patients 
are usually given strong medication to suppress their entire 
immune system, but that can become counterproductive as the 
patient is now vulnerable to other diseases. Different drugs, 
such as Cyclosporin, have been approved to control much of 
the rejection, but transplantations can still have those dangerous 
effects (MTF Biologics, 2017). Although they have been shown 
to improve symptoms, these drugs can have many negative side 
effects including tremors and seizures. 
Another problem is the long waiting period that patients wait 
in order to receive a proper match for donation. There are sim-
ply not enough donors to fill the demands, causing many victims 
to die in the ‘waiting room’. Although the shortage of organs is 
the main cause for the waiting time, the length that the patient 
waits can vary, depending on a number of factors. The blood or 
tissue type, the size of the organ, and the medical urgency of the 
situation are some factors that will fluctuate the waiting time. In 
any case, the patient almost always needs to wait for a proper 
donor before proceeding with the transplant. This is not practical 
in many cases when the organ transplant is extremely urgent. On 
average, twenty people die every day while waiting for an organ 
donor (United Network for Organ Sharing, Data, 2018). 
Also, organ transplants are extremely costly and many people 
simply cannot afford such medical procedures. Kidney trans-
plants cost over four hundred thousand dollars, and a heart 
transplant goes up to over one million (Rapp & Vandermey, 
2017). This cost does not even include the health maintenance 
of such a procedure, nor the cost of immunosuppressant drugs 
that cost as much as ten thousand dollars per year, for life 
(Gordon, et. al. 2008). 
Methodology of Xenotransplantation
Looking for a solution to this unmet medical need, re-
searchers have come up with a new method known as 
Xenotransplantation, which is the process of “grafting or trans-
planting organs or tissues between members of different spe-
cies.”  Xenotransplantation is using stem-cell and CRISPR tech-
nology to grow human organs in a host of a different species. 
This idea comes from chimerism, the ability to create a “living 
thing that is composed of cells from two or more organisms” 
(Dunlap, 2017). The basic procedure is to use the pig as a host 
by cutting out the HOX genes that code for growing certain 
organs and the genes that code for porcine microorganisms 
from their genome. HOX genes are the sequence of genes in 
the genome that directs the body organization in an embryo 
(KhanAcademy, Khanacademy.org, 2018).  Using CRISPR-Cas9 
technology, described below, genetic engineers can knock out 
the genes in the pig that code for the development of specific 
organs, and replace them with specialized human stem cells that 
will grow human organs instead. The hypothesis is that infusing 
differentiated human stem-cells into this embryo will result in 
the pig growing a human organ instead of its own.
CRISPR-Cas9 Technology
CRISPR-Cas9 stands for Clustered Regularly Interspaced Short 
Palindromic Repeats, and is breakthrough technology in genome 
editing. CRISPR is a special region in DNA that is characterized 
by having repeated nucleotides and spacers. This unique DNA 
region was first recognized in bacterial genomes and has since 
been adapted in the laboratory as the CRISPR Cas9 complex 
(Vidyasagar, 2018). Cas9 is a protein that acts as the molec-
ular scissors that can cut the DNA in a double-strand break. 
When combined with a guide RNA (sgRNA), it forms the Cas9 
Complex. The Cas9 first binds to a sequence in the genome 
and the guide RNA unwinds the double helix. The guide RNA 
is precisely designed to match up with the specific strand of 
DNA that needs to be edited. Then, the Cas9, with the help of 
its nuclease domains, cuts the DNA, creating a double-strand 
break in the double-helix. The DNA tries to repair itself but the 
reparations are usually flawed which inevitably shuts off that 
particular gene.  This is why CRISPR is “a great tool for knocking 
out specific genes” (NatureVideoChannel, 2017). 
Stem-Cell Research
Another biomedical technique is somatic cell nuclear transfer, 
known as SCNT, or cloning. Conceptually, the nucleus from a 
somatic (body) cell replaces the nucleus in a fertilized oocyte of 
another individual. This hybrid blastocyst is capable of generating 
a stem cell line” (Columbia.edu, 2018). The created stem cells 
will be identical to the donor and have many uses in the medical 
field. One such example would be to use these cloned cells to 
create human organs in pigs a step in the xenotransplantation 
process. The idea is to fuse the stem cells from the patient into 
a porcine embryo, hoping that the pig will grow human organs 
that can then be used as the transplant for the intended patient. 
In a few short months, the patient could potentially be on his/
her way to a complete recovery. This will only be a possibility, 
however, if the barriers of Xenotransplantation are overcome. 
Brief History of Xenotransplantation
Aside from cross-species blood transfusions, which were 
around since the 17th century, skin grafts are considered the 
first attempted trial in xenotransplantation. Skin grafts from an-
imals to human patients were performed as early as the 19th 
century. Frog skin was the most popular species to was the 
most frequent source of the donor material to the skin grafts. 
Different attempts at xenotransplantation were tested, mostly 
using primates as the donor animal. Out of thirteen trials, only 
one kidney transplant from a chimpanzee to a human patient 
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was successful with the patient living for an entire nine months 
before dying as a result of rejection of the kidney.  In 1964, 
the first heart xenograft from a chimpanzee to a human was 
performed. The patient died within two hours of the operation. 
Later, in 1992, a doctor named Starzl performed a baboon to 
human liver transplant, with the patient surviving for seventy 
days. Along with the numerous failures, some of the early xeno-
transplants resulted in temporary patient survival. But, in gener-
al, the organs were rejected in an even more serious case than 
with a same-species transplant. The rejections of this kind are 
so severe that immunosuppressive drugs are not strong enough 
to stop the rejective response to the xenografts (Cooper, 2015)
The Advantages of Porcine Xenotransplantation
Recently, the focus has been on the use of organs from the pig 
and hog family, porcine, as they are comparable to human or-
gans in size, anatomy and physiology, compared to other species 
(Niu, Wei, & Lin, 2017). Pigs, compared to other species such as 
baboons, would be a valuable candidate for organ xenotrans-
plantation. Pigs can be bred in large herds and with a relatively 
short maternity period, making them a more available option. In 
addition, they are not a costly animal to breed (Cooper, 2015). 
The advantages of xenotransplantation from pigs would be 
enormous, starting with the obvious increase in availability of 
organs for transplantation. Right now, there is a shortage of 
human organs for transplants, but using organs from another 
species will solve this problem, it will also make immediate 
transplant surgery possible for patients with an urgent situation. 
In addition, organs that are retrieved from human cadavers have 
already experienced the trauma of brain death which may lead 
to other issues later on. With animal donor organs, the organs 
will be removed from a healthy pig that is under anesthesia, 
avoiding the problem altogether. Another important solution 
that xenotransplantation brings is the decrease of the risk of 
a pathogen being transferred from the donor to the patient. 
Diseases such as the West Nile Virus and rabies have been 
passed through organ transplant surgery resulting in a number 
of deaths. The pigs intended to be used for xenotransplantation 
are being raised in the best conditions and are being supervised 
closely which reduces the likelihood of any illness to be trans-
ferred from donor to patient (Cooper, 2015).
Zoonoses and Porcine Endogenous Retrovirus 
(PERV)
CRISPR-Cas9 can be used in xenotransplantation research by 
knocking out specific genes in the pig that cause rejection when 
transplanted into human patients. Zoonoses are diseases that 
are transferred between humans and animals, caused by bac-
teria, parasites, and viruses. These diseases pose the major bar-
rier preventing xenotransplantation from becoming proto-call 
in the medical world. The potential transfer of porcine related 
infections into the human genome is a major risk of xeno-
transplantation. The pig herds intended to be used for medical 
reasons have been raised under the most sanitary conditions 
and have been screened for most pathogens and viruses that 
can possibly harm the recipient. However, porcine endogenous 
retroviruses that lie in the porcine genome have the capability 
to hurt human health. PERV are viral elements in the porcine 
genome, and being that they are innately a part of the DNA, the 
retroviruses cannot be eliminated by means of selective breed-
ing or drugs. PERVs have the ability to recombine with other 
genetic elements of the recipient’s genome. Similar to pigs, hu-
mans have their own set of endogenous retroviruses, known as 
human endogenous retroviruses, or HERVs. If the PERV were to 
come in contact with the human endogenous retroviruses, the 
former genes can recombine and disturb the human genome. 
Naturally, the HERVs are attempted to be halted by some sort 
of stop codons or deletions, but some bypass the stop codons 
and actually “play an important role in human physiology as well 
as in pathogenesis” (Machnik, et al., 2014).
Studies of HERVs have concluded that class I of HERVS group 
together with γ- and ε-retroviruses, and during a xenotrans-
plantation it is these genes that can recombine with PERVs that 
also belong to the γ-retroviral group (Machnik, et al., 2014). 
Studies have recently confirmed that two out of three PERV 
types, namely PERV-A and B, have been seen to replicate in 
human cells during in-vitro research, meaning in a clinical setting. 
To date, no PERV infection of human cells have been document-
ed in-vivo, but the possibility of this occurring needs to be taken 
into real account as new pathogens can be created at the point 
of interaction, and these new pathogens can cause unpredict-
able damage (Prabha & Verghese, 2012).
Recent discoveries, however, have shown major advancements 
in this area. Scientists have used CRISPR technology to success-
fully cut out sixty-two PERV sequences from a porcine genome. 
The nuclei of these cells were then transferred into enucleated 
pig oocytes by somatic cell nuclear transfer, and then implanted 
into surrogate female pigs. The results were astonishing with 
thirty-seven piglets being born, all with inactivated PERVs in the 
genome. This research greatly expands the possibilities in the 
realm of xenotransplantation, although other issues are yet to 
be resolved (Denner, 2017).
The Issue of Rejection
With all the prementioned advantages, there are still barriers 
preventing pig organ xenotransplantation from becoming the 
standard medical procedure. Scientifically speaking, the biggest 
barrier to overcome is the problem of rejection; the patient’s 
natural response to an alien in the body. Firstly, within seconds 
or minutes of the transplant, the possibility of hyperacute 
rejection can happen. This type of rejection occurred when 
pig organs were transplanted into nonhuman primates. The 
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preformed antibodies of the receiver attached themselves to 
the pig’s vascular endothelium and as protocol reaction to a 
pathogen, the cascade system was initiated. This caused the en-
dothelial cells to convert into procoagulant phenotypical cells, 
resulting in hyperacute rejection. Attempts have been made to 
prevent this by depleting the antipig antigens, or the comple-
ment system from the recipient’s serum, however, there are 
still other forms of rejection that may occur.  Acute humoral 
xenograft rejection may occur during the first few days after the 
transplant, and cellular rejection can become a problem even 
weeks after the operation. This rejection is acute-cell mediat-
ed, meaning that different cells in the patient’s body recognize 
the foreign organ as unfamiliar and begins to attack it. The cells 
involved are usually the natural killer cells, macrophages, and 
cytotoxic T cells. It is believed that even immunosuppressant 
drugs cannot prevent this rejection from being triggered. If the 
recipient is able to survive with the graft for a longer period of 
time, chronic rejection may occur. The exact cause of this type 
of rejection is not completely understood. However, the main 
point regarding all types of rejections is that the antibodies or 
killer-cells in the recipient attack the donated graft, resulting in 
a slow, but ultimately fatal destruction of that organ (Esker & 
Cooper, 2010). The information regarding the rejection or ac-
ceptance of a pig organ in a human patient is extremely limited, 
as only a few procedures have been tested so far. The scientists 
and doctors cannot study this further until a patient survives 
the procedure for a longer time (McLean & Williamson, 2004). 
Rejection of the organ can occur in any transplant, regardless 
of whether the graft is from the same species or not. The differ-
ence is that in a xenotransplant rejection, the immunosuppres-
sant drugs are not strong enough nor sophisticated enough to 
significantly extend the patients survival time. 
Potential Solution for Xenograft Reject
Genetic Engineering of the pigs is the newest and most success-
ful method to date to prevent or mitigate the rejection of the 
organ graft. One major advancement is the creation of a genet-
ically engineered pig that expresses a human complement-reg-
ulatory protein. This protein is found in the pig’s vascular endo-
thelial cells and protects the tissue of this donated organ from 
being attacked by the pre-formed antibodies during hyperacute 
rejection (Bloom, Moulton, McCoy, Chapman, & Patterson, 
1999). Genetic engineers have also produced pigs which have 
had the gene for α1,3-galactosyltransferase removed. The gene 
for α1,3-galactosyltransferase codes for the production of the 
enzyme that adds Galα1,3Gal oligosaccharides to different basic 
glycoproteins and glycolipids in pigs. In general, Gal is a major 
target for the human antibodies, as it is seen as a major invader. 
The removal of this gene, and therefore the halt of the Gal pro-
duction in the pigs, has significantly reduced the hyperacute re-
jections that usually occur during the pig to nonhuman primate 
xenograft trials (Esker & Cooper, 2010). 
The results of this research have been positive; the length of 
survival time increasing by the use of the genetically engineered 
pig organs. A pig heart of this type lasted for 3-6 months, kidneys 
for close to three months, and livers for days. The extension 
of the survival period is proof of the success of the genetic 
research (Esker & Cooper, 2010).
There are also genetic solutions being studied that will disable 
the natural killer cells and the macrophages from attacking the 
xenograft, although they have yet to be tested in pig to non-
human-primate transplant. Genetic engineers are working on 
producing pigs that are HLA-E or HLA-G transgenic as these 
immunoregulatory molecules are expected to stop natural kill-
er cell cytotoxicity (Esker & Cooper, 2010). 
The Issue of Coagulation Dysregulation
Another barrier that has arisen during the xenotransplanta-
tion trials is the development of thrombotic coagulopathy and 
consumptive coagulopathy, different types of coagulation dys-
regulation. Coagulation dysregulation is irregular blood clotting 
in areas of the circulatory system. The xenograft recipient will 
usually develop one of these, or possibly both, which poses a big 
limitation to the survival time of the graft. In heart transplants 
from genetically modified pigs to baboons, thrombotic coagu-
lopathy is the predominant symptom, while in the kidney graft, 
the baboon developed consumptive coagulopathy. It is thought 
that physiological differences between pigs and primates are the 
causes for these problems, although the exact reason for the 
coagulation dysregulation development remains unclear. It is 
known, however, that activated endothelial cells of the donated 
organ are the cause for inflammation and coagulation in the 
recipient. Ischemia, or inflammation, is inevitable in most types 
of organ transplants, but various types of intertwined factors 
can be the cause of graft endothelial cell activation (Cowan, 
Robson, & d’Apice, 2011). One proposition suggests that the 
endothelial cells activated by either the antibodies or the start 
of the complement, increase the activity of TF, tissue factor. 
The introduction of the TF into the portal vein activates the 
instant blood-mediated inflammatory reaction, known as IBMIR. 
Characteristics of IBMIR are platelet binding, complement acti-
vation, and thrombosis (Esker & Cooper, 2010). 
Ethical Problems With Xenotransplantation
In addition to the biological barriers of Xenotransplantation, 
problems regarding ethical and moral topics come into question 
when researching the possibilities for the future. Transplantation 
in general has a public risk associated with the administration of 
immunosuppressant drugs. These drugs are known to lower the 
patient’s ability to fight off infections, and therefore increase the 
risk of contamination. For the patient, the risks involved need 
to be weighed by their own physician; however there are public 
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concerns involved as well. The new genetic engineering, plus the 
previously used immunosuppressant drugs, have the potential to 
“open the way for the emergence of new viral mosaics into the 
general population” (Anderson, 2006). 
The opposing side of the ethical debate brings up valid points 
as well. With thousands of people in desperate need of organ 
donations, is it ethically fair to deprive them of the possible solu-
tion that can potentially save so many lives? The introduction of 
xenotransplantation can greatly reduce the waiting period for an 
organ donation, and additionally provide the patient with a long-
term graft. The immunosuppressant drugs have saved so many 
people from death; is it morally okay to ban them on the slight 
chance that they can cause an infection outbreak? These ques-
tions are some of the many that have come up in discussion over 
the last couple of years, as the medical world is coming closer to 
introducing this new phenomenon to regular medical protocol.  
Another ethical problem involved in xenotransplantation is 
the issue of personal privacy and confidentiality. This question 
arises due to the necessity of monitoring of the patient after 
an organ transplant, going as far as to institute a lifetime sur-
veillance of the patient. This surveillance has become a part of 
the system as an attempt to prevent pathogenic diseases from 
spreading through organ transplant surgery. As previously dis-
cussed, the pathogenic risks involved in xenotransplantation are 
very great and have caused medical outbreaks in the past. In 
fact, in the year 2000, a hepatitis C breakout was reported due 
to an infected donor that was mistaken to be healthy. Since 
then, tremendous precautions have been taken while looking 
for organ donors, as the transfer of pathogens through trans-
plants can lead to numerous fatalities. Opponents of the mon-
itoring system believe that this provision is an invasion of the 
patients’ privacy, as well as the privacy of their family and friends. 
Here lies the question whether or not the invasion of privacy 
is considered to be ethical for the safety of the patien and the 
“problem of maintaining ethical standards in situations such as 
this is vexing” (Anderson, 2006). 
The only possible way to effectively protect society from infec-
tious diseases via xenotransplantation is if the national and inter-
national powers decide on a logical system, keeping the ethical 
debates in mind. The World Health Organization has previously 
come together to discuss this exact topic, although no agreement 
was yet to be decided.  To date, the only guidelines put in place 
are those of the Food and Drug Administration’s Recombinant 
DNA Advisory Council. The RAC approved gene recombination 
studies to be done at Harvard and MIT, advancing the medical 
research of this field. The RAC’s permission was granted with 
the consent of the citizens of Massachusetts, justifying the ethical 
questions involved in such research (Anderson, 2006). 
The American Society of Transplant Physicians voice their 
concern of infectious diseases being spread internationally. They 
feel that United States regulations are not strong enough in 
comparison to the severity of the risk involved. It is presently 
legal for patients in need of an organ donation to receive or-
gans from live donors living in impoverished countries, where 
infections are known to be rampant. For example, there is a 
website named Liver4you.org which arranges liver donations 
from people in the Philippine Islands. Bringing these diseases 
across to the United States through the organ transplant poses 
as a major threat to the wellbeing of society (Anderson, 2006). 
Often, doctors and surgeons are also researchers of new 
xenotransplantation medication, which poses additional ethical 
questions regarding the split between their medical responsi-
bilities and their personal studies. The physicians can frequently 
be confronted with “the well-being of the patient in direct op-
position to the advancement of academic medicine” (Anderson, 
2006). An example of what might result from such a situation 
is a doctor convincing a patient to participate in a clinical trial 
that he/she would otherwise not join. An infamous case of this 
sort, known as the Baby Fae case, took place in 1984 when a 
young child was used in a medical trial of a xenotransplantation 
using a baboon heart. The parents were encouraged by optimis-
tic doctors who hoped to provide the baby with “immediate 
and long-term survival” but she only survived for four weeks 
following the graft. Medical researchers have become cautious 
getting involved in xenotransplantation studies in fear of this 
sort of issue cropping up, in addition to the history of medical 
science misconduct (Anderson, 2006). 
Additionally, with the introduction of stem cells into the pig 
embryo, the possibility of creating a pig with human elements 
presents an ethical issue. The ethical debate discusses the pos-
sibility of human gametes to be created and an embryo to be 
formed as an interspecies chimera. Although it is agreed upon 
that the embryo would not be able to develop, the mere cre-
ation of it poses as an ethical question. Also, the differentiation 
of human stem cells needs to be studied in depth as the ques-
tion arises of what is stopping the stem cells from entering the 
pig’s brain, or other areas, which will blur the margin of what is 
considered human and what is considered animal? Is it morally 
permissible to perform a procedure that can potentially give a 
pig, human, high-level brain functions? These ideas are unlikely 
in the scheme of things, but pose concerns in the biomedical 
world nonetheless (Masaski & Nakauchi, 2017). 
Conclusion
Scientific researchers are constantly trying to better the med-
ical world; looking for solutions and applying their incredible 
knowledge to helping humanity.  The biomedical field is ex-
ploring the possibilities of genetic engineering combined with 
stem-cell research, hoping for xenotransplantation to one day 
become a standard medical procedure for patients with organ 
failure. When it comes to genetic engineering, the possibilities 
are endless; however, xenotransplantation has many barriers to 
58
Chana Erlbaum
overcome before it can become the standard medical proce-
dure. However, the latest research may explore the best course 
of action regarding this dynamic research. Researchers have 
proposed for xenografts to be used for patients in the waiting 
period that are waiting for an organ donor. This way, although 
xenotransplantation is not yet a final solution, it will at least 
minimize the number of deaths of patients, and the health risks 
for waiting for a proper transplant.  This change in proto-call 
has the tremendous potential to save millions of lives, giving the 
patient the ability to live the few months until they can receive 
a proper transplant. Researchers are only beginning to uncover 
the technology’s tremendous potential and long-term survival 
of xenografts may be a few years away. Even so, it is possible that 
for now, temporary xenotransplantation can be the life-saving 
procedure that patients are hoping for (Servick, 2017). 
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Abstract
In the last half a century, researchers and scientists discovered the application of somatic cell nuclear transfer (SCNT) to clone 
mammalian embryos to produce a line of pluripotent stem cells for medical and laboratory use.  This is a breakthrough technology 
that is applied to stem cell research, regenerative medicine, and cloning.  Somatic cells are non-germ cells that are differentiated 
but provide the nuclei that are transferred to enucleated oocytes. The replacement of the nuclei results in a developing embryo 
that contains the genetic information of the donated nucleus, which can either be transplanted into a surrogate mother to 
produce a genetically similar offspring or grow in-vitro to extract embryonic stem cells (ESC). This process has made it possible 
for the cloning of numerous mammalian species, such as pigs, cattle, mice, and, recently, primates. Although success has been 
evident in mammals, human derivation of pluripotent embryonic stem cells has been difficult to obtain. The difficulty stems from 
the premature activation of the oocyte and the improper reprogramming of the donated nucleus. This paper focuses on the 
development of human nuclear transfer embryonic stem cells (ntESC) and its application in regenerative medicine.  Studies done 
on primates provide information on the barriers of this procedure on humans and the proper modifications on regular SCNT 
protocol. The use of deacetylase inhibitor TSA, phosphate inhibitor caffeine, and HVJ-E for proper membrane fusion are only some 
of the recent methods found for proper nuclear reprogramming and embryonic development. Breakthroughs in the methylation of 
DNA and histones in mice provided insight to a barrier in human embryo development.  As a result, derivation of embryonic stem 
cells was successful and tested for pluripotency.  Insulin beta cells and cardiomyocytes have been produced using this modified 
SCNT protocol and hold great potential for the future of science.  The use of nuclear transfer embryonic stem cells is important 
in the development of stem cells that can differentiate into specialized cells, such as neurons, that can potentially be used to cure 
disease, like Parkinson’s.  Even more so, these cells will retain the genome of the patient and reduce immune incompatibility. The 
paper goes on to discuss the ethical issues that impede researchers from advancing in this area.
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Introduction
Somatic cell nuclear transfer (SCNT) is a laboratory technique in 
which the somatic cell nucleus is transferred into an enucleated 
oocyte.  The egg is developed into a blastocyst, an early embry-
onic stage where the opening of a cavity in the morula between 
the inner cell mass and the enveloping layer is filled with fluid. 
This procedure was first theorized in 1938 by Hans Spemann, a 
German embryologist, in his book Embryonic Development and 
Induction.  He proposed an experiment to replace the nucleus 
of an unfertilized egg with a differentiated embryo nucleus. He 
pondered on whether such a transplant of a differentiated nu-
cleus can give rise to an organism (Wellner, 2010). This was a 
start to the idea of cloning that was initially attempted in 1952. 
Scientists Robert Briggs and Thomas King transplanted nuclei 
from an advanced blastula cell into enucleated eggs of Rana pipi-
ens, also known as leopard frogs. They saw a normal development 
of embryo resulting in the first cloned organism. Their study pro-
vided a basis for the SCNT protocol. As well, they determined 
that success is attributed to the transfer of a nucleus from the 
same species of frog. Transplanting the nucleus of a bullfrog led 
to an arrest at the blastula stage and inevitably died (Briggs et. 
al, 1952). Alluding to the core principle in SCNT mechanics of 
donor nucleus and oocyte recipient compatibility. 
In 1996, the first cloned mammal using a fully differentiated 
adult cell was executed by Campbell et al. (1996) in Scotland. 
Dolly, the cloned sheep born in 1997, was a breakthrough in 
determining the nuances of SCNT. They figured out that the 
development of embryos reconstructed by nuclear transfer is 
highly dependent on the interaction of the donor nucleus and 
recipient cytoplasm (Campbell et al., 1996). Their findings aided 
in further successes of cloned organisms and nuclear transfer 
embryonic stem cells (ntESC) derivation. Such findings include 
the effects of cytoplasmic kinase activity and maturation pro-
moting factor (MPF) on chromosomal damage. The expression 
of cytokeratin and lamin A/C, markers associated with differen-
tiation, was also reported indicating the development of ESC. 
Research in this area after this incident paved the road to de-
velop human ntESC and the extensive studies done on primates 
contributed to a modified SCNT approach. 
The important application of this process is to produce 
a culture of embryonic stem cells that are created from the 
inner cell mass of the blastocyst. Stem cells are undifferentiated 
cells that can either produce cells that continue as stem cells 
or are differentiated into specialized cells.  The implications of 
this procedure of generating personalized embryonic stem cells 
is useful for disease mechanism, and development of therapies 
(Tachibana et al, 2013), i.e. regenerative medicine or replacing 
damaged cells in patients, like cardiomyocytes to replace dam-
aged heart tissue or insulin-producing beta cells for diabetic 
patients, by eliminating the prospect of immune incompatibility 
(Lanza et al, 1999). However, therapeutic cloning refers to the 
derivation of nuclear transfer embryonic stem cells without 
uterine transplantation that has been successful in mice and 
cattle, derived from ntESC lines in cloned blastocysts (Yang et. 
al, 2007). However, human ntESC has been notoriously difficult 
due to its failure to progress past the eight-cell stage because of 
inactivation of critical embryonic genes. Due to ethical and legal 
restrictions, further research in this area is moving at a slower 
pace. Therefore the question arises, can SCNT be used to pro-




The information gathered in this paper was collected from sev-
eral sources such as Touro College Online Library and NCBI. 
The searches for “Somatic cell nuclear transfer”, “Cloning”, 
and “Therapeutic Cloning” led to the majority of articles used 
obtained from PubMed and Nature. The articles discuss the 
experimental studies done at various times and an analysis of 
these studies provided material for this discussion. Some review 
articles were necessary in the development of this analysis.
Discussion: Nuclear Reprogramming
For successful embryonic development the proper nuclear and 
cytoplast-mediated reprogramming is necessary. Campbell and 
colleagues (1993) specified morphological events that occur in 
nuclear transfer at the merging of a nucleated blastomere or 
karyoplast into the cytoplast of an enucleated metaphase II ar-
rested oocyte (MII).  Oocytes in MII state have a higher success 
rate in nuclear reprogramming in the cytoplasm due to certain 
factors. In mammals, the fusion of the two specimens is induced 
by an electric pulse to promote fusion and activation of the 
enucleated egg. Studies in mice, pigs, and cattle display that cer-
tain morphological events occur at the point of fusion, including 
nuclear envelop breakdown (NEBD) followed by premature 
chromosome condensation (PCC), dispersal of nucleoli, refor-
mation of the nuclear envelope, and nuclear swelling (Campbell 
et. al, 1993). The induction of NEBD and PCC are important for 
the reprogramming of gene expression and increased embryo 
development. These events vary depending on both the species 
and nuclei at different cycle stages. In rabbits, blastocyst devel-
opment was found to be greater when the blastomeres were 
in G1 or early S phase than in late S phase or G2 (Collas et. al, 
1992). A possible explanation for such observations was found 
in the cell cycle regulation with an emphasis on cellular DNA 
replication by maturation promoting factor (MPF). 
A study showed the necessary implication of MPF activity at 
G1/S and G2 stages. MPF is a complex of two proteins, cyclins 
and p34cdc2. P34cdc2 is a protein kinase that is regulated by 
phosphorylation changes and interaction with cyclins. P34cdc2 
does not change during the cell division cycle while cyclin does. 
P34cdc2 kinase triggers the entry of the cell into the M phase 
that produces NEBD, chromatin condensation, and other mor-
phological changes in the cell. Therefore, MPF primary func-
tion is to promote nuclear breakdown, spindle formation, and 
chromatin condensation. Mammalian oocytes at the MII phase 
contain high levels of MPF. Upon fertilization or activation, MPF 
levels decline resulting in the decondensation of chromatin and 
formation of pronuclei. Therefore, NEBD and PCC occurrence 
in the donor nucleus suggests a correlation between MPF with 
NEBD and PCC activity. NEBD and PCC probably remove 
the nuclear membrane to allow ooplasmic remodeling factors 
access to the donor cell chromatin for the re-replication of 
previously replicated DNA and the synthesis of DNA in the 
donor nucleus at any cell stage. As well as, contributes to the 
reformation of the nuclear membrane. A problem arises when 
MPF activity is low at the time of fusion (Campbell et al., 1993).
When MPF is low at the time of fusion, from premature ac-
tivation of the enucleated egg, the nuclear membrane is main-
tained. G1 donor nuclei will replicate their DNA, however, G2 
nuclei will not rereplicate and a low frequency of development 
arises. However, interestingly enough, this suggests that, at slow 
MPF decline at the time of fusion, in any other phase other than 
G1, the DNA will rereplicate resulting in aneuploidy. This cor-
relates with the results of the study done by Collas et. al (1992) 
regarding the development of rabbit blastocyst. In rabbits, at G1, 
early S, and late S phases, metaphase plates, and spindles were 
detected but abnormalities, like incomplete spindle formation 
and incomplete chromosome condensation, was present in late 
S phases (Campbell et. al, 1993).
A study was done by Mitalipov et. al (2007) built on the aspect 
of MPF regulation in primates and nuclear remodeling through 
lamin A/C staining. Lamins, an intermediate filament super-
family of proteins, are part of the nuclear lamina found on the 
inner layer of the nuclear envelope. Lamin types A and C are 
expressed in many differentiated somatic cells. Lamins A/C are 
essential in size, shape, and strength determination of the nucle-
ar envelop as well as maintaining lamina structure. (Hutchison 
and Worman, 2004). These proteins tend to depolymerize 
during late prophase and become undetectable in the MI or MII 
oocytes. At fertilization, cytoplasmic lamins are gathered into 
the forming pronucleus (Prather et al., 1989). Lamin A/C has 
been used to assess the extent of nuclear remodeling following 
SCNT because of the changes in the nuclear lamina, as shown in 
this 1study, in monkeys.
MPF levels, as mentioned before, result from premature oo-
cyte activation and a failure to induce nuclear remodeling. In 
studies with mice and cattle, the fusion of a donor cell with an 
oocyte was done through electroporation. Electroporation in 
a calcium ion fusion medium increases the calcium levels that 
trigger a rapid decline of histone H1 kinase and even MPF activ-
ity. Using electrofusion with calcium ion or magnesium ion free 
buffers or performing all manipulations free of these ions can 
minimize premature activation of the oocyte (Mitalipov, 2007). 
An improvement in the in-vitro development of pig (Boquest et 
al., 2002) and primate blastocysts (Mitalipov et al., 2007), which 
was shown from lamin A/C profile under these modifications was 
similar to those detected in sperm-fertilized controls. To supple-
ment electroporation as a fusing agent in human SCNT, HVJ-E 
virus, hemagglutinating virus of Japan-envelope, a non-infectious 
vesicle used as an agent for cell fusion, showed a high rate of 
fusion. However, embryonic development past the compact mor-
ula failed, even though ionomycin and 6-Dimethylaminopyridine 
(DMAP) were used to activate the cell at the appropriate time. 
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Therefore, implementing electroporation, which is not necessary 
for cell fusion but rather for timely cell activation, increased blas-
tocyst development.  It is necessary as an activation stimulus in 
conjunction with ionomycin and DMAP (Tachibana et. al, 2013). 
Extended exposure of the chromatin to the non-activated MII 
cytoplast enhances embryonic development. An MII oocyte has 
high levels of MPF but enucleation, which also removes cyto-
plasm from the oocyte, reduces MPF levels (Lee & Campbell, 
2006). The disassembly of the nuclear lamina with the chro-
mosome condensation is attributed to the phosphorylation of 
MPF. To prolong the presence of MPF, use of caffeine, a pro-
tein phosphatase inhibitor, or MG-132, a proteasome inhibitor, 
increased nuclear remodeling in the donor nucleus. MG-132 
prevents spontaneous oocyte activation, as seen by the weak/
partial lamin A/C signal in C/C1 (figure 1). More exposure to 
MG-132 reduces the lamin A/C signal and increases the chro-
matin condensation, as seen by DAPI blue stain (Mitalipov et. 
al, 2007). However, proteasome activity impacts development 
events, in contrast to caffeine that has high cleavage rates and 
regular blastocyst formation. However, caffeine does not affect 
the frequency of blastocyst formation (Lee & Campbell, 2006; 
Mitalipov et. al, 2007). Embryos usually do not develop past day-
12. These conclusions suggest there is more than merely nuclear 
remodeling that affects the success of SCNT. 
Premature activation of the MII oocyte is a likely occurrence, 
especially in aged or overstimulated oocytes. Therapeutic clon-
ing or ESC derivation from discarded, aged, or failure-to-fertilize 
oocytes are unlikely to succeed (Mitalipov et al., 2007). Ovarian 
stimulation can also affect the quality of the oocyte, thus, tamper-
ing with the success of the procedure. A study was conducted to 
compare three groups of oocyte donation cycles, <10 oocytes 
per cycle, 11-15 oocytes per cycle, and >16 oocytes per cycle. 
Survival of the egg after spindle removal until embryonic cleavage 
was similar amongst the three groups. However, more >16 oo-
cyte/cycle groups arrested after the eighth cell stage. Additionally, 
the quality of the blastocysts correlated inversely with the num-
ber of oocytes collected per cycle. ntESC derived from these 
oocytes were mainly from the <10 oocyte/cycle group and none 
from the >16 oocyte/cycle group (Tachibana et al., 2013). This 
shows that both the donated nucleus and recipient oocyte con-
tribute to the success of ntESC derivation and development. 
Another challenge to SCNT embryonic development is the 
consequence of microtubule and centrosomal protein depletion. 
This is a result of enucleation of the oocyte that extracts the 
spindle with defective reformation of the spindle by the donor 
nucleus. However, when the somatic cell nucleus is transferred 
to an oocyte containing its own chromosomes it results in a 
functional polyploid blastocyst that can develop into ESC. This 
can mean that certain reprogramming factors, associated with 
the spindle apparatus, are present in the MII oocyte (Tachibana 
et al., 2013) and are removed upon enucleation.  Modification in 
the SCNT protocol of spindle removal is necessary to success-
fully execute nuclear reprogramming and blastocyst formation. 
The standard procedure of enucleation and spindle extraction 
is by adding bisbenzimide staining and UV exposure in mammals, 
such was executed in pigs (Polejaeva et al., 2000). However, if 
meiosis-specific factors are retained during spindle removal 
then only spontaneous activation of the cell causes its decline. 
By using the methods above to protect against premature ac-
tivation, SCNT embryo development increases and spindle-like 
structures are formed. This method increased ESC derivation 
in primates that displayed similarities to human IVF-derived 
blastocysts than the manipulated spindle transfer embryos 
(Tachibana et al., 2013). 
Epigenetic Regulation
Nuclear reprogramming is a crucial step for the success of 
embryonic development. However, it is not limited to the first 
steps of activation. Reprogramming gene expression in the inner 
cell mass (ICM) is a necessary component for the continua-
tion of embryonic development and especially for derivation of 
pluripotent ntESCs. Normal development requires epigenetic 
modifications, which includes DNA methylation and histone 
modification. The ICM and trophectoderm are distinguished in 
the blastocyst with a predominant increase of DNA and histone 
Figure 1: Lamin A/C signaling and DAPI staining for exposure of 




methylation in the ICM, affecting genomic imprinting and X 
chromosome activation in females (Yang et al., 2007). 
In normal embryonic development, methylation occurs prefer-
entially in the ICM, a process in which a methyl group is added 
to the 5th carbon of the cytosine ring next to a guanine base, 
through DNA methyltransferases (DNMT). In female mice, for 
example, demethylation occurs due to DNMT during subsequent 
cleavages. In male mice, it is demethylated in the pronucleus after 
fertilization.  Chromatin configuration establishes the ‘histone 
code,’ a cellular memory responsible for maintaining the identity 
of differentiated cells. Histones are proteins that contribute to 
the make-up of chromatin.  They have an exposed N-terminus 
end, which is either modified through methylation, acetylation, 
ubiquitinylation, or phosphorylation. For example, the acetylation 
of histone 3 Lys9 (H3K9) induces an open chromatin configura-
tion giving transcription factors access while the methylation or 
demethylation of H3K9 inactivates it (Yang et al., 2007). 
Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, 
has shown a significant impact on embryonic development in 
mammals and primates (Sawai et al., 2012; Mitalipov et al., 2007). 
A study was conducted on bovine animals using 5nM and 50nM 
of TSA. The group that was treated with 50nM of TSA showed 
significant blastocyst development. TSA increased histone H4K8 
and histone H3K9K14 acetylation, which activates gene tran-
scripts. However, FGF4 in bovine, required for ICM formation 
and trophectoderm differentiation, was still considerably low 
and did not change through the treatment of TSA. It is mainly 
affected by DNA methylation signifying that DNA methylation 
is an important factor for nuclear reprogramming (Sawai et al., 
2012). Therefore, it is proper to conclude that TSA is necessary, 
as Mitalipov’s study on primates and Tachibana’s study on human 
ntESC both come to the same conclusion, yet DNA methylation 
is another component to embryonic development. 
DNA and histone methylation is pertinent to improve the 
ntESC derivation. The first developmental defects of SCNT ap-
pears at the time of zygotic genome activation (ZGA) which 
occurs at the 4 to 8 cell stage in humans and bovine and at the 
2-cell stage in mice. Difficulties in ZGA are due to epigenetic 
barriers existing in the genome. Certain genomic domains re-
sistant to ZGA in SCNT embryos, known as reprogramming 
resistant regions (RRRs), have been identified.  Enrichment of 
mouse RRRs with histone H3, lysine 9 methylation (H3K9me3) 
in the donor genome results in a barrier to transcriptional re-
programming. They must be removed by specific demethylase 
or by ridding it of H3K9 methyltransferases. Kdm4d, H3K9me3-
specific histone demethylase, greatly reduces H3K9me3 levels. 
The injection of Kdm4d mRNA increased the blastocyst rate up 
to 88.6% (Matoba et al., 2014). 
In the study done by Chung et al. (2015), it was found that 
H3K9me3 also serves as a barrier in human SCNT. Using the 
same oocytes that failed to develop into blastocysts, they demon-
strated that Kdm4a overexpression significantly improved em-
bryonic development. Compared to the IVF derived embryos, 
of 707 genomic regions in SCNT embryos, 308 were termed as 
RRRs with the same enrichment of H3K9me3 as seen in mice. 
This study also showed that the injection of Kdm4a wild-type, 
not Kdm4d catalytic mutant used in the original study on mice, 
had a greater blastocyst rate, 90.3%, in SCNT embryos. To test 
the efficiency in this demethylase on humans, Kdm4a mRNA 
was injected at different stages of SCNT embryonic develop-
ment. Injecting it upon activation, after fusion by HVJ-E, showed 
no effect prior to ZGA completion. However, the effect was 
noticeable at the end when 8 blastocysts were developed, with 
no development of the control group. In a conventional ESC 
derivation medium, seven attached to the MEF feeder cell and 
four stable ntESC lines were derived. As shown in Figure 5, im-
munostaining revealed that NANOG, OCT4, SOX2, SSEA-4, and 
TRA1-60, transcription factors that maintain ESC differentiation, 
were all expressed similar to human ESC line derived by IVF. 
Likewise, these ntESC’s expressed pluripotency marker genes 
that were indistinguishable from IVF derived ESC. Additionally, 
these ntESCs underwent immunostaining of embryoid bodies 
(EB), aggregates of ESC, for two weeks in vitro giving rise to the 
Figure 3: TSA structure. Selleckchem.com
Figure 4 (Chung et al., 2015)
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differentiation into all three germ layers. Proving its differenti-
ation ability. Karyotyping, the process of chromosome pairing, 
demonstrated normal chromosomal number and the same sex 
chromosome of the donor nucleus, and Short Tandem Repeat 
(STR) analysis showed all 16 repeat markers on the genome is 
perfectly matched to the donor somatic cell. A sequence analy-
sis of mitochondrial DNA (mtDNA) demonstrated that the sin-
gle-nucleotide polymorphism of ntESCs matched the mtDNA 
of the donor oocyte and not the donor nucleus. A necessary 
analysis that demonstrates the idea that mtDNA is transmitted 
by the fertilized oocyte and not from the DNA in the cell’s 
nucleus (Chung et al., 2015).
Although blastocyst development in SCNT embryos was im-
proved, the success of humans, merely 27%, compared to the suc-
cess of mice, 90%, suggests that all modifications to SCNT protocol 
must be utilized, especially proper oocyte quality. That is a major 
factor for ntESC derivation. Human oocyte varies tremendously 
even from a single ovulation. Therefore, even some blastocysts 
formed through IVF were not supported (Chung et al., 2015). 
Fetal vs. Adult Somatic Cell
In order for SCNT to be regarded as having practical medical 
significance there must be a way to generate ntESC from adult 
somatic cells. Most experiments use various fetal fibroblasts as 
somatic nuclei donors. However, patients that are in need of this 
procedure are mainly aged. Therefore, a recent study done by 
Chung et al. (2014) determined whether dermal fibroblasts from 
35 and 75- year-old males can undergo successful SCNT proce-
dure. The debate on adult vs. fetal cells is regarding the age-re-
lated changes, such as shortened telomeres and oxidative DNA 
damage that can potentially obstruct nuclear reprogramming. 
Even though fetal fibroblasts were used in numerous researches, 
there were no clear claims of age impedance on SCNT. Using 
the non-modified, standard SCNT protocol, no aneuploidy was 
produced in the resultant human ESC. Therefore, the modi-
fied SCNT protocol established by Mitalipov et al. (2007) and 
Tachibana et al. (2013) on fetal fibroblasts was used, with two 
groups forming. One group was activated 2 hr after implantation 
and the other group was activated after 30 min. However, only 
two blastocysts hatched from the 2 hr group, one from each age 
subtype, leading to the generation of ESC lines. The difference 
in time duration can be explained by the possibility for the nec-
essary extra time needed for reprogramming that is dependent 
on the exposure of the donor nucleus to the recipient oocyte 
cytoplast. Both ntESC lines displayed the same sixteen STR 
markers located on the human autosomal and allosomal loci as 
the donor somatic cell and differed from the oocyte donor. The 
mtDNA was verified being inherited by the oocyte donor in 
both ntESC lines and expression of transcription factors OCT-4, 
SSEA-4, TRA-1-60, and TRA-1-81 was present. Pluripotency was 
confirmed through spontaneous differentiation into the three 
germ layers by immunostaining of embryoid bodies. Further 
confirmation of pluripotency was through teratoma formation 
assays that demonstrated outgrowth of tissue from the germ 
layers.  Despite the low success rate, this study portrayed the 
efficiency of the modified SCNT protocol and greatly implies 
the possibility of using SCNT to generate patient-specific ESC 
for medical use (Chung et al., 2014).
Application of Therapeutic Cloning on 
Regenerative Medicine
Therapeutic cloning holds great promise in regenerative medi-
cine and gene therapy. It has numerous research and clinical ap-
plications, such as producing a vector for gene delivery, creating 
animal models of human diseases, and cell replacement therapy 
in regenerative medicine. It can permanently cure Parkinson’s 
disease or diabetes mellitus. Barberi et al. (2003) conducted 
a study on mice using SCNT with nuclei from cumulus and 
tail-tip cells. Two ntESC lines were differentiated into motor, 
GABAminergic, serotonergic, and dopaminergic neurons, that 
displayed synapse formation and normal electrophysiological 
properties in vitro. Mice with Parkinson-like lesion were in-
jected with dopaminergic neurons into the cortical striatum 
induced by 6-hydroxydopamine. An 80% survival rate 8 weeks 
post-transplantation was observed from ntESC contrary to 40% 
for stem-cell derived neurons (Kfoury, 2007). 
Furthermore, SCNT can allow for organogenesis and pa-
tient-specific rescue of genetic mutations. In cell replacement 
therapy, therapeutic cloning has the potential to create various 
types of tissues such as osteoblasts to counteract osteoporo-
sis. Deshpande et al. (2006) transferred motor neurons derived 
from ESC to rats with a severed spinal cord showing SCNT 
application for spinal cord regeneration. A potential cure for 
paralysis in humans.  Therapeutic cloning eliminates the issue of 
immune rejection and organ shortage by engineering tissues and 
organs. Patient-specific cardiomyocytes, blood vessels, and skin 
can treat infarctus, atherosclerosis, and severe burns (Kfoury, 
2007). With the use of the modified SCNT protocols, diploid 
pluripotent stem cells that were derived from a patient with 
type 1 diabetes were produced (Yamada et al, 2014). Such ad-
vancements in medicine hold hope for cures of various diseases. 
iPSC vs. ntESC
IPSCs, induced pluripotent stem cells, is a laboratory tech-
nique that reprograms differentiated cells back to pluripotency 
using specific transcriptional factors. The medical application of 
human iPSCs has opened the door for rapid stem cell therapy. A 
set of essential transcription factors, called reprogramming fac-
tors, trigger the destruction of the existing state of somatic cells 
by changing their epigenetic status, leading to alterations in their 
gene expression. The changes in the gene expression induce 
secondary epigenetic changes, including DNA methylation and 
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alterations of the nuclear structure. However, there are road-
blocks to reprogramming that need to be removed because cel-
lular identity is stabilized. However, transcription factors such 
as Oct4, Sox2, Klf4, and c‐Myc are sufficient to destabilize the 
existing order in the original cells and re-construct a new order. 
Therefore, transcription factors associated with development 
may undertake important actions during the reprogramming 
process. This produces stem cells that are similar to embryonic 
stem cells but has a few disadvantages when compared to ntE-
SCs (Takahashi & Yamanaka, 2013). 
ESC is considered the ground state which is believed to have 
a greater chance of successful differentiation than iPSC. During 
reprogramming, iPSCs-specific methylation and transcriptional 
abnormalities in imprinted regions and X chromosomes were 
observed with such abnormalities less frequent in ntESCs 
(Nazor et al.,2012). In some instances, a number of highly pro-
liferative colonies appear that are not pluripotent and can form 
into tumors. Furthermore, iPSCs do not efficiently silence the 
expression pattern from where they are derived from and fail 
to induce some ESC specific genes (Bilic & Belmonte, 2011). 
A major advantage of SCNT-based ntESCs is the fact that 
it contains mtDNA originating from the oocyte.  Irrespective 
of the nuclear donor cell mtDNA, ntESCs have the potential 
to produce functional cells and tissues for cell therapies. Thus, 
SCNT offers a strategy for correcting mtDNA mutations and 
retaining the metabolic function of pluripotent cells from pa-
tients with inherited mtDNA diseases.
 MtDNA that is specific to the oocyte recipient of cloned 
embryos was first determined in the study done by Evans et 
al. (1999), with co-researcher Dr. John Loike. They showed nu-
clear transfer-derived sheep were homoplasmic. The random 
partitioning of mtDNAs does not occur. This may be due to 
the failure of the donor mitochondria to enter the ooplasm 
following electrofusion. It can be hypothesized that an active 
mechanism operates to destroy the donor mitochondria in the 
recipient ooplasm, similarly to what is thought to happen to 
sperm-derived mitochondria in fertilized ova in human repro-
duction. These results have implications for future attempts to 
correct maternally inherited mitochondrial genetic disorders 
by nuclear transfer involving a somatic or germline cell from a 
woman containing a pathogenic mtDNA mutation but normal 
nuclear DNA and a recipient enucleated oocyte. 
Ethical and Legal Issues
Research in this field has been held back due to controversial 
ethical issues. Legal constraints and lack of funding results in 
the impediment of therapeutic cloning (Lo & Parham, 2009). A 
major objection to SCNT is the belief that creating embryos 
for research, with the intention of mutilating these embryos, 
violates human respect and integrity. Sandel (2004) argued in his 
article on embryo ethics, “Although every oak tree was once 
an acorn, it does not follow that acorns are oak trees, or that 
I should treat the loss of an acorn . . . as the same kind of loss 
as the death of an oak tree.” This is an opinion based question 
whether an embryo varies in essence from a developed human 
being. Evaluation whether the use of embryos for medical re-
search justifies its destruction. Meanwhile, legislative actions, es-
pecially in Europe, hinders SCNT advancement that contributes 
to its slow progression.
Conclusion
Therapeutic cloning is feasible through modified SCNT proto-
col. Research in mammals and primates aided in the success 
of human ntESC derivation by establishing the correlation be-
tween oocyte and donor nucleus quality, nuclear reprogram-
ming, and proper gene expression. All steps led to the deriva-
tion of pluripotent ESC that were differentiated into various 
specialized cells, such as cardiomyocytes and insulin beta cells. 
The developed embryo harboring mtDNA from the recipient 
oocyte holds an advantage over iPSC cells by constituting met-
abolically functional cells from mitochondrial diseased cells. 
More research is needed to expand and apply this technique in 
medical practice; however, ethical and legislative actions repress 
the advancement in this area.
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Abstract
Until recently, relaxin has been known as a hormone that pertained to the female reproductive system. Its ability to remodel the 
extracellular matrix is responsible for its known reproductive effects. Current research has indicated that it may be useful as a 
drug to combat fibrosis. Relaxin has been proposed as an antifibrotic drug to target a variety of organs, including the skin, lung, 
kidney, liver, and heart. Studies done using the relaxin null knockout mouse have given scientists insight into the workings of this 
hormone. Human studies have also been done to test the efficacy of relaxin in its reversal of fibrosis. With more research, perhaps 
relaxin can be used as a drug in the future. 
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Introduction
Fibrosis is a hardening or scarring of tissue that results from 
the repair of injuries in the body.  It is estimated that 45-50% 
of deaths in the Western world are caused wholly or in part 
by fibrosis in various organs in the body. Currently, there is no 
available cure for damage caused by fibrosis (Summers, 2016).
Relaxin is a peptide hormone usually associated with the re-
productive system. Relaxin has been found to be pleiotropic, 
meaning that it is active in many varying roles in the body. It is 
produced in both pregnant and non-pregnant females as well 
as in males (Pallardy, 2016). It appears that relaxin can be ma-
nipulated to target injured organs in order to reverse fibrosis 
and prevent its further progression. There have been studies 
conducted that point to relaxin as a possible cure for fibrosis 
in various organs, including the skin, lung, kidney and heart (Tan, 
et. al. 2016). Fibrosis is a part of the pathology of many different 
human diseases and thus is said to account for 45-50% of deaths 
in the western world (Summers, 2016). 
Methods
Information in this paper is based primarily on research ac-
cessed through the Touro Library Databases. The peer reviewed, 
scholarly journal articles were retrieved through the Proquest 
or Pubmed databases. 
Fibrosis and its Causes
Fibrosis is an exaggeration of the scarring and hardening of tis-
sue usually caused by the body’s normal response to injury. It is 
characterized by a build-up of extracellular matrix (ECM) com-
ponents, or scar tissue, in place of normal tissue. Particularly, 
there is a buildup of fibrillar collagens, such as types I and III. 
Fibrogenesis is the body’s mechanism of healing and repairing 
wounds. What occurs in fibrogenesis is that myofibroblasts rush 
to the site of the injury and release cytokines. This causes fibro-
blasts to proliferate and build up the ECM producing fibrillar 
collagen creating a scar in place of the damaged tissue (Baum, et. 
al. 2011). Excessive build-up of connective tissue can be harm-
ful to underlying tissue and organs. This is because the ECM is 
the framework for the cells and extracellular structures in the 
body. Therefore, if the normal form of the ECM is disrupted, the 
tissue in which it is present will not continue to function as it 
should (Bathgate, et. al. 2003). Fibrosis is often caused by chronic 
inflammatory reactions that can be a result of various stimuli 
among which are persistent bacterial and viral infections, auto-
immune and allergic reactions, and tissue injury (Wynn, 2008).
The body has a system that works to clear accumulated ex-
tracellular matrix materials. Matrix Metalloproteinases (MMP’s) 
are a group of enzymes that break down extracellular matrix 
proteins, such as collagen. Part of the body’s normal way of 
repairing itself after tissue injury is to inhibit the production 
of these enzymes and to increase the secretion of Matrix 
Metalloproteinase Inhibitors (MMPIs), and more specifically, 
Tissue Inhibitors of Metalloproteinases (TIMPs).  Thus, scar tis-
sue replaces the injured tissue, and the body can heal itself. This 
too is favorable in a normal situation, but if this process contin-
ues unceasingly, it can result in disruption of normal organ func-
tion as the matrix builds up without anything present to break 
it down. An imbalance between collagen degrading enzymes will 
also cause fibrosis (Bennett, et. al. 2009). 
What is Relaxin?
Relaxin was first discovered in 1926 by Frederick Hisaw as a 
hormone present in pregnant guinea pigs. The function of re-
laxin observed at the time, was that it relaxed the pelvic liga-
ments and the cervix of the uterus to make it possible to carry 
the fetus and to prepare the area for parturition. Later, it was 
discovered that it was through collagen remodeling that relax-
in was able to play this important role in pregnancy and birth 
(Pallardy, 2016). Upon closer inspection of the relaxed ligaments 
it was seen that the collagen was remodeled from dense bun-
dles to looser, less structured fibers (Bennett, et. al. 2009).
Relaxin is produced by various structures in the female’s re-
productive tract including the placenta, corpus luteum and uter-
us, though this varies by species. During the first trimester of 
pregnancy, relaxin rises from practically undetectable levels to 
1ng/mL and then slowly wanes as delivery draws near. Relaxin is 
also present in non-pregnant human females and males (Pallardy, 
2016). In males, relaxin is produced by the prostate gland and 
can be found in the seminal fluid, though it is not usually detect-
ed in circulation (Bennet, 2009).
Relaxin is a peptide hormone whose two-chain structure is 
similar to that of insulin. In humans and higher primates, three 
genes for relaxin have been discovered, which include encod-
ing proteins known as H1, H2 and H3 relaxin. In rodents, only 
two relaxin genes have been discovered: relaxin-1 and relaxin-3, 
which are equivalent to the H2 and H3 in humans, respectively. 
The H3 relaxin gene was discovered in 2002 and is known to 
act mainly in the brain. H2 relaxin in humans- the product of the 
RLN2 gene, and relaxin-1 in rodents- the product of the RLN1 
gene, are the major circulating forms of relaxin and are the ones 
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that are thought to have an effect on fibrosis (reference to re-
laxin for the duration of the paper will refer to these forms of 
relaxin) (Samuel, et. al. 2007).
There has been a lot of research in the past few years that has 
tried to find more uses for relaxin in the body. There have been 
identified relaxin-binding sites in various places in the body in 
both males in females, including in the heart and brain. This sug-
gests that relaxin may also influence nonreproductive areas of 
the body and leads scientists to do further research into these 
possible uses (Samuel, et. al. 2016). 
Knockout Mouse Studies
To aid scientists in the understanding of relaxin, a relaxin-null 
nockout mouse was created by The Howard Florey Institute 
in Melbourne, Australia. A knockout mouse is a mouse that 
was genetically modified in order to remove or “knockout” a 
specific gene. Using such a mouse helps give scientists insight 
into the biology of a particular gene (Austin, et. al. 2004). The 
mouse established to research relaxin is the Rln1-KO mouse, 
meaning that the Rln1 gene, that codes for the major circulat-
ing form of relaxin in animals, was removed. However, the Rln3 
gene was not removed. Monitoring the development of these 
mice showed that the reproductive organs, in both males and fe-
males, were underdeveloped. In pregnant females, the mammary 
glands, nipples, and pubic symphysis were underdeveloped, and 
lactation was prevented. In the male mice, the testis, epididymis 
and prostate did not mature properly. Later, it was discovered 
that abnormal development in knock-out mice was due to ex-
cess collagen. In addition to this, as the mice aged, there was a 
buildup of interstitial collagen in the heart, lung, kidney, and skin. 
This eventually caused malfunction in these organs, appearing 
more prominently in the male mice. 
Scientists then administered recombinant human (H2) relaxin 
to the knockout mice and saw that it was helpful in reversing the 
fibrosis and restoring organ function. The relaxin was helpful in 
both early and late stages of the fibrosis, but worked to different 
extents depending on the organ. These findings point to a use of 
relaxin as a drug to reverse and prevent fibrosis in human patho-
logical situations (Bathgate, et. al. 2003 and Samuel, et. al. 2005b). 
In 2009 a study was done on relaxin null knockout mice to 
test the efficacy of using recombinant relaxin as a treatment 
for the fibrosis that developed in them. The study also aimed to 
test if it was significant when in the progression of the fibrosis 
the relaxin was administered. There were two groups of mice, in 
one group, relaxin was given to 9 month-old mice, during early 
stages of fibrosis. The other group was given relaxin when their 
fibrosis was more progressed, at 12 months of age. There was 
less fibrosis in the 9-month group, and no difference in the 12-
month group when compared to the untreated controls. This 
points to the fact that administered relaxin will be more effec-
tive in earlier stages of fibrosis (Giannakis, et. al. 2009).
Relaxin null knockout mice were used to test the effects of 
relaxin on scleroderma, a form of dermal fibrosis. It is a con-
nective tissue disease that causes fibrosis or various internal 
organs in addition to skin thickening. Untreated, scleroderma 
can cause irreversible damage. The study indicated that relaxin 
is more effective in treating dermal fibrosis in its early stages.  
(Samuel, et. al. 2005a).
How does Relaxin Help Reverse Fibrosis?
Relaxin binds with its endogenous receptor, relaxin family 
peptide receptor 1 (RXFP1), which is also known as LGR7. 
This inhibits the actions of major profibrotic factors such as 
transforming growth factor beta 1 (TGFb1), and angiotensin II 
in several organs. As a result of this, there will be a decreased 
expression of types I, III, and V collagens, interstitial collagens 
and type IV basement membrane collagen. There will also be 
an increase in the breakdown of collagen via the activation of 
MMP’s and an inhibition of the TIMPs (Samuel, et. al. 2016, fig 1)
Mechanisms
The mechanisms involved in the antifibrotic effects of relaxin 
are not currently well known by the scientific community. The 
primary receptor for relaxin is LGR7, or RXFP1, and was only 
recently discovered in 2002. Before this was known, the LGR7 
and LGR8 relaxin receptors were known as orphan G-protein 
receptors.  (Bennet, 2009). It is interesting to note that these re-
ceptors exist in organs outside the reproductive tract, pointing 
to the fact that relaxin has other functions than it was histori-
cally thought. Perhaps as the understanding of the pathway used 
by relaxin is enhanced, we will better be able to use relaxin as a 
drug for the treatment of fibrosis (Samuel, et. al. 2005a). 
Discussion: Clinical Trial for Relaxin
In the 1950’s, there was the emergence of the idea that relaxin 
could be used to treat fibrosis, and it was clinically tested then 
and again in the 1990’s. These studies failed to reach the lev-
els of effectiveness that were required for it to pass as a drug, 
but shed a lot of light onto the antifibrotic actions of relaxin 
(Samuel, et. al. 2005a).
A randomized, double-blind, placebo-controlled study was 
conducted using recombinant human relaxin in the treatment 
of systemic sclerosis. This was a phase III trial for testing relaxin 
as a possible drug to reverse fibrosis. Systemic sclerosis, also 
called systemic scleroderma, is a disease in which there is a 
buildup of collagen in various organs in the body. This is an ideal 
disease with which to test for the efficacy of relaxin, as the 
hallmark of this disease is ongoing fibrosis. The patients were 
divided into 2 random groups, one of which was given the actual 
drug, and the other group was given a placebo. In addition to 
this, neither those being treated, nor the researchers admin-
istering the medication knew who belonged to which group. 
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There was not a significant difference in the levels of fibrosis 
between the two groups. In addition, it seems that there were 
negative side effects to those that were administered the relaxin 
drug. The forced vital capacity in those patients given relaxin 
was decreased, and there were adverse renal effects primarily 
after they stopped giving them the relaxin. The study concluded 
that if relaxin is ever to be used in the reversal of fibrosis, there 
must be intensive monitoring of blood pressure and of renal 
function (Khanna, et. al. 2009). 
One proposed reason for why relaxin was not effective in this 
study was because the degree of scleroderma in the patients in 
this trial was quite advanced. In the relaxin-null mouse model it 
was also seen that relaxin was less effective in more advanced 
stages of fibrosis (Bennet, 2009).  Although this study is less opti-
mistic about the use of relaxin as a drug in the near future, it may 
be possible that as research continues, and we learn more about 
relaxin and how it works in the body, it will seem more plausible. 
Other Human Relaxin Studies
There was a study done to test the safety of administering re-
combinant human relaxin to people. The scleroderma patients 
were administered 200mcg/kg/day for 28 days. This is approx-
imately 50 times the relaxin present in a normal pregnant 
woman. The relaxin was unhelpful in reducing the fibrosis, but 
it was concluded that in these doses relaxin was safe and well 
tolerated. Some adverse side effects included; Development of 
a rash and pain at the site of infusion, minor bleeding in some 
cases, and decreased concentration of blood hemoglobin 
(Seibold, et. al. 1998).
It appears that the body itself uses relaxin as a mechanism to 
combat fibrosis. This was shown in a study of 50 patients with 
systemic sclerosis, an autoimmune disorder that causes fibrosis 
of the skin and internal organs, and 50 healthy patients in which 
normal relaxin levels were measured and the results were sta-
tistically analyzed. In the diseased patients, the measured levels 
of relaxin in the bloodstream was significantly higher than in the 
healthy subjects. It was hypothesized that this was the body’s 
response and effort to reverse the fibrosis (Giordano, et. al. 
2005). Thus, using relaxin as a drug for fibrotic patients is in 
accordance with the way nature would tackle the problem, and 
therefore worth further research. 
Pulmonary Fibrosis 
IPF or Idiopathic Pulmonary Fibrosis, is a lung disease in which 
there is fibrosis of the lungs for an unknown reason. It was 
found that the gene expression of the main relaxin receptor, 
RXFP1, is 2.9-fold less in lung samples taken from patients with 
IPF compared with lungs of normal control subjects. There 
was also a study done in an in vitro model, in which IPF fibro-
blasts were grown in media that was treated with transform-
ing growth factor TGFb1. It was found that the expression of 
the RXFP1 protein was decreased in immunoblots. It was thus 
hypothesized that relaxin treatments will not be too effective 
in patients with IPF. The authors also speculate that the loss 
of RXFP1 expression is a common factor in fibrotic diseases 
and therefore may have been part of the reason that the clin-
ical trials to treat scleroderma with relaxin failed (Tan, et. al. 
2016). Royce et. al. point out that these findings are surprising 
because relaxin has proved to be effective in reducing fibrosis in 
many human fibroblast culture models in which TGFb1 is used 
to stimulate collagen synthesis. They argue that the function-
al activity of the relaxin receptor cannot be determined using 
gene expression studies alone and point out that there may 
have been other factors involved that caused these results. 
Therefore, they conclude, more research must be done before 
relaxin-based therapies for fibrosis can be either ruled out or 
implemented clinically (Royce, at al, 2016).
Hepatic fibrosis
Fibrosis of the liver, like forms of fibrosis in other organs, is cat-
egorized by increased collagen deposition and decreased ECM 
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Fig.1 Mechanism for relaxin’s role in inhibiting fibrogenesis. (Modified 
from Samuel, et. al.2016.)
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vivo, scientists established fibrosis in mice using carbon tetra-
chloride. The mice were administered the carbon tetrachloride 
for 4 weeks, followed by 4 weeks of administration of relaxin in 
addition to carbon tetrachloride. Relaxin decreased the hepatic 
collagen expression, increased the expression of the MMPs, and 
decreased the TIMPs. This suggests that relaxin might be a possi-
ble treatment for established hepatic fibrosis (Bennet, et. al. 2014).
The common endpoint of many liver diseases caused by 
chronic liver injury is fibrosis. The major profibrogenic cell type 
that is activated in cases of chronic liver injury is the hepatic 
stellate cell-myofibroblast (HSC-MF). This cell produces scar tis-
sue and contributes to portal hypertension (PHT) by increasing 
the resistance within the hepatic vascular system. It was seen 
in past studies that the expression on RXFP1 was increased in 
human and rat HSC-MFs and in various studies on parts of the 
liver that were affected by fibrosis. In the model of rat fibrosis 
it was seen that the administering relaxin helped to reduce the 
fibrogenesis and reduce the PHT (McBride, et. al. 2017).
Relaxin has a short in vivo half-life. This is an obstacle to using 
it as a drug for treatment, especially in models of disease that re-
quire long-term administration of the drug, such as liver disease. 
In an effort to find a new drug to combat liver fibrosis, there 
was an attempt to find small molecules that are similar to relax-
in and that will act as agonists for the RXFP1 receptor. There are 
currently high throughput screening (HTS) technologies which 
allow scientists to explore vast libraries of compounds in a quick 
and efficient manner. This helps to identify molecules that can be 
used as starting points for creating new drugs. One compound, 
ML290, was found to be most promising. It binds with RXFP1 
and was therefore tested extensively. Although ML290 did ex-
hibit some relaxin-like activity, there were many differences in 
the way it bound to RXFP1 and its actions. Its effectiveness in 
combating liver fibrosis has not yet been tested and for now it 
does not seem that it will be a feasible replacement compound 
for the treatment of fibrosis. Also, being as the actions of RXFP1 
differ in various organs of the body, and are not well understood 
in general, more research must be done before such a drug can 
be produced (McBride, et. al. 2017). 
Cardiac Fibrosis
Fibrosis is a hallmark of hypertensive cardiac disease. The ECM 
has a great impact on the function of the heart, including regu-
lating ventricular diastolic and systolic function. It also provides 
the framework for the cardiomyocytes and coronary vessels. 
There are many cardiac pathologies that result in fibrosis. 
Among these are ischaemic injury, myocardial infarction, hy-
pertension, and many others. This results in a vicious cycle, as 
the accumulation of extracellular matrix via fibrosis leads to an 
increase in the amount of those negative cardiac events, which 
can in turn lead to more fibrosis. It was shown in relaxin knock-
out mouse studies that relaxin deficient mice have an elevated 
collagen content in their cardiovascular system which leads to 
diastolic dysfunction of the left ventricle (LV). 
Spontaneously hypertensive rats (SHR), in which fibrosis was 
not induced by having a lack of relaxin, rather it was the natu-
ral result of hypertension, were studied. When the rats were 
administered relaxin over a 14 day period the initially elevated 
collagen levels in the LV were now reduced. Fibroblast prolifera-
tion was inhibited, and MMP-2 expression increased. This means 
that there was a decrease in collagen synthesis as well as an 
increase in its breakdown. The study concluded that relaxin is a 
potent drug that can be used to combat hypertensive diseases. 
In addition to this, relaxin was compared to other hypertensive 
drugs such as angiotensin converting enzyme inhibitors and al-
dosterone inhibitors. These drugs have many side effects and 
only begin to help after prolonged periods of treatment. Relaxin, 
on the other hand, managed to work at a much faster rate to 
reduce fibrosis and did not have any notable side effects in this 
study (Lekgabe, et. al. 2005).
Renal Fibrosis
Renal fibrosis is the accumulation of collagen in the kidney. 
Specifically, in the renal resistance vessels, glomeruli and inter-
stitial space. There is a very strong relation between cardiovas-
cular diseases and renal diseases, as both diseases include high 
blood pressure. The SHR were also used to study renal involve-
ment. The experimental rats exhibited renal as well as cardiac 
fibrosis. Administration of relaxin over a 14-day period showed 
to reduce the fibrosis in the kidney cortex, thus halting renal 
failure. (Lekgabe, et. al. 2005).
Another study treated rats with bromoethylamine, or BEA, 
which causes severe renal interstitial fibrosis, one week later, the 
rats were administered relaxin via an osmotic pump for a period 
of 28 days. The aim was to see whether the relaxin would inhibit 
the fibrosis that was caused by the BEA. The structure of the renal 
tubules had been affected by much collagen deposition in the rats 
treated with BEA alone. The rats treated with BEA in conjunction 
with relaxin exhibited  a 75% decrease in collagen deposition and 
tubular structure was almost completely maintained.  In addition 
to this, it was seen that renal function was largely restored in the 
relaxin-treated animals. The levels of creatinine clearance were 
75% of those of the control mice. It is thus hypothesized that 
the reduction of the fibrosis by relaxin is the cause for the resto-
ration of renal function (Garber, et. al. 2001).
Conclusion
Fibrosis accounts for nearly half the deaths in the western world 
and yet there are no known cures. Relaxin’s natural antifibrotic 
properties make it a viable candidate for the treatment of fibrosis. 
Although much research has already been done, relaxin must be 
proven to be both safe and effective before it can begin to be im-
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Abstract
Music is an important part of cultures worldwide.  It has been used throughout the ages as a method of conveying emotions to 
the listener.  However, there is some confusion about exactly which areas of the brain are affected by music.  This study shows 
the general areas of the brain stimulated by music, explaining how these sections influence emotion and learning capability. In 
addition, this paper demonstrates that music therapy may be helpful in relieving stress or some neurological disorders, based on 
the areas activated by music.  Training in music has cognitive and motor coordination benefits, as well, because this training causes 
structural changes in brains of musicians.
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Introduction
According to the Merriam-Webster dictionary, music is the 
“vocal, instrumental, or mechanical sounds having rhythm, mel-
ody, or harmony (Merriam-Webster, 2018).” However, the word 
“music” suggests a much deeper meaning than the formal dictio-
nary definition implies. Music is known as the “language of the 
soul.” It speaks to its listener, conveying a message of emotions, 
such as a calming sensation of relaxation or intense feeling of ela-
tion or sadness. The language is universal; even people who have 
lost their ability to verbally communicate can understand the 
empathy inherent in music (Ridder, et al., 2009). When a musician 
plays his instrument, he is forming an emotional connection with 
his listeners. But music has effects beyond emotions. Learning to 
play music facilitates cognitive reasoning, motor coordination, and 
sensory perception. Because music has this unique combination 
of emotional connection and cognitive benefits, music therapy 
has been developed to alleviate emotional and physical hardship 
in a number of neurological illnesses. This analysis will discuss 
the varying effects of music on the brain, including the physical 
changes that manifest and the mechanisms through which music 
leads to enhanced learning and emotion. Additionally, through this 
study, the possible benefits of music therapy are revealed.
Methods
Research for this paper was gathered from Touro’s online library 
from databases including ProQuest and EBSCO. Articles found 
discuss the different areas of the brain affected by music, the use-
fulness of music therapy, differences in anatomy and processing 
of stimuli in the brains of musicians and non-musicians, whether 
music induces emotion, and the potential learning benefits to be 
gained through musical training. Review articles, case studies and 
experimental studies were used in forming the analysis.
Parts of the Brain Affected by Listening to Music
It is unclear, as of the research to date, exactly which parts of 
the brain are stimulated by music. The general mechanism for 
music that was heard travelling to the brain is as follows; music 
enters the ear and is received by the cochlea. It is then trans-
ferred to the thalamus, and then to the auditory cortex for 
processing (Boso, et al., 2006). If the person listening to the 
music is deciding whether to buy that music, there is a further 
association between the auditory cortex and the ventral stria-
tum, which processes enjoyment (Koelsch, 2014).
Although most reward stimuli do not activate the hippocam-
pal region, music does. The hippocampus’s main roles are the 
conversion of short-term memory into long term memory and 
spatial relations. It is also responsible for encoding information 
from the amygdala, which controls emotion, with the long-term 
memories. In other words, emotional memory becomes com-
bined and remembered with long-term memory through the 
hippocampus. This supports a growing theory that the hippo-
campus plays a role in emotional recollection that occurs when 
listening to music. Because music affects emotions in a way un-
like money, food or other reward stimuli, it couples emotion 
and the memory of a specific piece of music. This activates the 
hippocampus, leading to feelings of peacefulness, tenderness, joy, 
or even sadness when the piece is later recalled (Koelsch, 2014).
People can have varying parts of their brain stimulated, de-
pending on how they think of the song. For example, remem-
bering a song in one’s head can stimulate the visual cortex, while 
hearing the song stimulates the auditory cortex. Also, different 
parts of music affect different areas of the brain; pitch, melody, 
harmony and beat are usually processed in the right hemisphere 
of the temporal lobe, while lyrics, pacing, frequency, and intensity 
are analyzed in the left temporal lobe. The connection between 
music and thoughts, which will stimulate emotions or previous 
memories, is formed by the frontal lobe. The stimulation of the 
frontal lobe is activated by the limbic system which provides the 
emotions felt (Bennet, Bennet, 2008).
Although both speech and music utilize pitch, pitch seems 
to be used differently in the different circumstances. While 
speech cannot be “off-tune,” music can. It is possible, therefore, 
that coarse contour in speech and music are processed in one 
area, while a more finely-tuned pitch perception is analyzed in 
a different area. This argument is strengthened by the fact that 
there were cases of people who lost the ability to understand 
language prosody but retained musical pitch acuity. However, 
people who lost basic musical contour perception also lost 
their speech prosody awareness (Zatorre, Baum, 2012).
Music is also processed in different areas depending on 
whether the music is perceived as pleasant. Music that has dis-
sonance and disharmony is more likely to be processed in the 
temporal lobe, while music that is pleasant and has harmony will 
be processed in the frontal lobe (Boso, et al., 2006). 
Pleasant music is processed in the same way that primary 
and secondary pleasure stimuli are generally handled. Music 
activates the nucleus accumbens, ventral tegmentum area, hy-
pothalamus, orbitofrontal cortex, and the insula-frontal cortex. 
The nucleus accumbens is the center which processes pleasant 
stimuli, and then releases dopamine into the ventral tegmentum 
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area. In the brains of both musicians and non-musicians, listening 
to music activates the mesolimbic dopaminergic reward system 
(Herholz, Zatorre, 2012, Schlaug, et al., 2010, Menon, Levitin, 
2005). Pleasant music, such as music which gives the listener 
chills, or goosebumps, causes the release of dopamine both in 
the ventral tegmentum and in the ventral striatum. The antici-
pation of chills, itself, releases dopamine, as well. However, the 
exact area where dopamine is released when expecting such 
music differs from when the expectation is fulfilled. Expected 
chills activate dopamine in the ventral striatum. When the music 
causes the chills to actually happen, the dorsal striatum becomes 
activated with dopamine (Koelsch, 2014, Boso, et al., 2006). The 
hypothalamus, too, gets activated, which lowers the heart rate 
and breathing rate, leading people to feel calmed and relaxed by 
music (Menon, Levitin, 2005).
Music Therapy as a Useful Tool
Music therapy is unique in that listening to music sends signals to 
the visual, auditory and motor cortices simultaneously (Schlaug, 
et al., 2010, Walworth, et al., 2008). The fronto-temporo-parietal 
connection formed by music is a component of mirror neurons. 
Because mirror neurons are important for the coupling of per-
ceptional events and their motor response, listening to music, 
and thereby activating these areas, may help link cognition and 
perception, heightening concentration, memory and executive 
control (Schlaug, et al., 2010).
Connected to the general cognitive and perceptive benefits is 
the effect of music on reducing cognitive stress. This idea was 
proven through a study conducted on eighty-nine college stu-
dents. These students were given a cognitive stressor; they were 
told that they would have to present a complicated speech. Then, 
the control group worked on preparing their speech without 
background music, while the experimental group was exposed to 
music. The groups were given surveys to fill out before and after 
the stressor was given. Also, salivary IgA levels were measured 
to check if biologically, music can help boost the immune system. 
The IgA test and the stress surveys indicated that the group lis-
tening to music experienced less stress and had a more effective, 
boosted, immune system than the control group (Knight, Rickard, 
2001). A study of patients who were waiting to undergo surgery 
showed that music can return heart-rate, cardiac output and 
blood pressure values to normal, non-stress levels. Additionally, 
blood glucose levels and skin temperature will be overcompen-
sated in the return to normal status when listening to music. Not 
only will the brain restore blood glucose levels and skin tem-
perature to the normal levels in response to listening to music, it 
will establish levels corresponding to a state of relaxation. Music, 
therefore, can relieve its listener of feelings of stress and induce 
calmness in its place (Miluk-Kolasa, et al., 2002).
The stress-relieving benefits of music are helpful clinically 
as well. Music can destress a patient before a difficult surgery. 
Research done by Walworth et al. demonstrated that music 
therapy can have psychological effects on patients undergoing 
brain surgery. In their experiment, twenty-seven subjects who 
were scheduled for a surgery were divided into two groups. 
The control group did not receive any music therapy prior to 
surgery, while the experimental group received twenty to fifty 
minutes of therapy. Surveys taken by the subjects before and 
after the surgery analyzed mood level, perception of hospital-
ization, and to what extent each subject felt anxious, stressed, 
or pain. The results indicated that subjects who had received 
the music therapy felt less anxiety and stress and were more 
relaxed before and during the surgery. They generally had a bet-
ter perception of their hospitalization. This is important since 
studies have shown that pessimism and anxiety correlate with 
worse outcomes in brain surgeries (Walworth, et al., 2008). 
Another study which focused on spinal epidurals, as opposed to 
brain surgery, concurs with Walworth et al. that music therapy 
can decrease stress in patients undergoing surgery. The patients 
having spinal anesthesia who listened to music throughout the 
surgery had a shorter induction time and required less medica-
tion than the control group. Interestingly, the patients listening 
to music did not recall hearing the music, suggesting that the 
effects of music occur subconsciously. A possible explanation 
for the reduction of necessary anesthesia is that the auditory 
and pain pathways inhibit each other. This can be an import-
ant method for decreasing the amount of anesthesia necessary 
non-pharmaceutically (Zhang, et al., 2005).
Music therapy can increase the quality of life for a patient with 
fronto-temporal dementia. Listening to familiar music can allow 
these patients to express themselves nonverbally, and thus allows 
for the building of social interactions and communication. After 
four weeks of music therapy, patients had less agitated behavior 
and were less distressed. Whether the patient actively participat-
ed in the therapy sessions did not diminish the benefit of the 
therapy, as both active and inactive participants clearly showed 
less agitation than before the sessions (Ridder, et al., 2015).
In addition to helping patients psychologically by reducing 
stress, music, and specifically musical training can help patients 
physically. In one study, stroke patients learned to play an elec-
tronic drum and MIDI keyboard. The results showed that the 
drum training improved gross motor skills, and the piano les-
sons honed fine motor skills. These patients began to recov-
er some of their motor coordination. Additionally, brain tests 
demonstrated that these patients had more success with motor 
planning and neuronal coherence with music therapy than other 
therapies. Interestingly, these skills were not limited to the mu-
sical instruments played. The coordination had improved overall, 
in every activity attempted (Schneider, et al., 2007 ).
Different Music Affecting the Brain Differently
Music is a very broad term. It includes many genres, styles and 
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pieces. Just as the varying aspects of music are processed in dif-
ferent areas of the brain, the various genres within music affect 
the brain in unique ways.
A network analysis was conducted, based on imaging from 21 
subjects, on different genres of music. Network imaging shows 
the connections of the brain, along with the important function-
ing parts at a given point. The analysis illustrated that different 
genres of music created “hubs” of activity in varying areas of the 
brain, depending on the music. Specifically, classical music made 
the largest hub in the auditory cortex. It is possible that the 
size of the hub is related to the complexity of the music being 
heard, and because classical music is often complex, its hub is 
the largest (Wilkins, et al., 2012).
In addition to the different genres affecting the brain, preferred 
music, as opposed to disliked music, shows different patterns in 
the brain. When comparing a subject’s favorite song with songs 
that the subject liked and disliked, all songs stimulated the de-
fault mode network, and particularly the precuneus. The precu-
neus is in the parietal lobe, anterior to the occipital lobe. This 
area is important in the processes of self-reflection and episodic 
memory, along with cognitive thinking and creativity. Although 
the precuneus was activated by every music heard, there was a 
strong correlation between the favorite song and liked song in 
activation of the lateral parietal and medial prefrontal cortices. 
The disliked song, however, had excitement that remained iso-
lated in the precuneus. Another difference between the favorite 
song and the liked and disliked songs is the involvement of the 
hippocampi. While all the songs showed some stimulation of the 
hippocampus, both the liked and disliked songs had auditory 
cortex “hubs” that included the hippocampi, while the favorite 
song had two separate hubs: one for the auditory cortex, and 
a second for the hippocampi. The activation of the hippocampi 
stimulates the encoding or retrieval of emotional memory. It 
is possible that the separation of hubs when listening to the 
favorite song leads to emotional memory retrieval, rather than 
inscription. The interconnection of the precuneus and the other 
areas contributes to the default mode network and causes the 
feelings of self-reflection and creativity, along with memory en-
coding, specifically of emotional memories (Wilkins, et al., 2014).
Although liked-music stimulates the default mode network 
and hippocampi leading to feelings of self-reflection and intro-
spection, if the liked music is unfamiliar, it may not necessar-
ily lead to the mesolimbic reward. Fourteen participants in a 
study listened to music to determine familiarity and preferences 
of songs. These participants listened to twelve songs in each 
category previously determined: familiar liked, familiar disliked, 
unfamiliar liked and unfamiliar disliked. Familiar music activated 
the anterior cingulate cortex, amygdala, thalamus, putamen, right 
nucleus accumbens, left hippocampus, temporal pole and orbi-
tofrontal cortex. Unfamiliar music either did not activate these 
regions altogether or activated them only slightly. There was an 
increased blood oxygen level dependence, indicative of a lot of 
activation, in the emotion-related areas, including the putamen, 
amygdala and nucleus accumbens. The high amount of stimula-
tion in the limbic and reward systems for familiar songs suggests 
that familiarity with a song will increase the liking of the song. 
The only difference in activation between the liked and disliked 
songs was in the right anterior cingulate cortex and the inferior 
frontal gyrus. This stimulation during liked songs correlates with 
the known functions of these areas, namely, judging beautiful 
stimuli (Pereira, et al., 2011).
Musicians vs. Non-Musicians
There are numerous differences between the way that musi-
cians and non-musicians process music, and therefore, differ-
ences in their brain structures. Firstly, as mentioned previously, 
music affects both hemispheres concurrently. However, while 
the right hemisphere usually processes the long-term patterns, 
such as pitch and melody, the left, usually dominant hemisphere, 
evaluates the short-term patterns, including changes in rhythm 
and frequency. Generally, while a musician is listening to music, 
he is examining the form. Therefore, his left hemisphere would 
be stimulated predominantly. On the other hand, a non-musi-
cian, who listens to music to enjoy the melody would be mainly 
stimulating his right hemisphere (Bennet, Bennet, 2008).
Although in each case there is largely one hemisphere that 
is excited, both hemispheres are stimulated each time music is 
heard. Besides for hearing the music, the musician often per-
forms complex hand sequences with his instrument, also excit-
ing both hemispheres with his actions. The information is trans-
mitted across both hemispheres through the corpus callosum. 
Neurons stimulated most often get the most strengthened by 
myelin sheath to allow for more efficient processing and faster 
reactions (Iusca, 2011). Because musicians listen to and practice 
playing music on a consistent basis, their neurons routinely fire 
across the anterior corpus callosum, leading to a larger anteri-
or corpus callosum with more myelinated axons and a greater 
number of neuronal fibers than that the non-musician (Iusca, 
2011, Herholz, Zatorre, 2012).
Another outcome of the need for musicians to use both hands 
is that musicians lose dominance in a single hand and become 
more ambidextrous. This is a necessary adaptation for the musical 
profession, which has underlying neuronal reasoning. Because the 
musicians use both hands to play complex musical sequences, the 
part of the motor cortex which stimulates both hands, rather 
than just the dominant hand, becomes strengthened with more 
myelin sheath and a greater number of synapses. This phenome-
non is especially true for a keyboard player (Iusca, 2011). 
Musicians have an enhanced short-term plasticity in the 
motor cortex, resulting in higher motor performance and syn-
chronization in intricate manual tasks. For example, pianists 
were able to learn a nonmusical finger tapping sequence quicker 
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than non-musicians, which correlated to an increased activity 
in their motor cortex. This, too, correlates with the notice-
ably larger finger area in a musician’s motor cortex (Herholz, 
Zatorre, 2012).
Besides for music affecting the cerebrum, musical training also 
affects the cerebellum. The cerebellum is used for fine motor 
skills. Playing an instrument requires these skills, and, therefore, 
learning to play them leads to more synapse connections, bigger 
capillaries to supply blood to these cells, and more glial cells to 
create a more effective support for the frequently used neurons 
in the cerebellum. Musicians’ cerebellums are larger than those 
of non-musicians because of the extra stimulation (Iusca, 2011).
Musicians can process simultaneous information more ac-
curately than non-musicians can. When fifteen non-musicians 
were told to report their touch sensations while simultaneous-
ly listening to two sounds, they had a hard time distinguishing 
between the auditory and sensory information and generally 
reported feeling two touches rather than one. However, musi-
cians who underwent the same test were more than twice as 
accurate at differentiating between the two stimuli. One reason 
for increased accuracy in musicians is that musicians are ac-
customed to reading sheet music, feeling their instruments and 
responding to the sounds produced. This balance of a combina-
tion of different stimuli enables the musician to better ignore 
one stimulus in favor of another (Sparks, 2013). In another study, 
musicians and non-musicians were presented with audio-visually 
incongruent stimuli. The non-musicians tended to react more 
to the visual stimulus, while the musicians relied on their au-
ditory perception. The likelihood of musicians relying on audio 
information is dependent on the length of time the musician 
has trained in his craft. (Abel, et al., 2016). Although the results 
of this experiment seem incongruent with first study, in which 
musicians relied on touch rather than sound to determine how 
many stimuli were before them, the studies are demonstrating 
different aspects of musicians’ skills. The first experiment aimed 
at establishing the accuracy of musicians’ sensory perception 
when coupled with incongruent auditory input. The musicians 
were successful in distinguishing between the two stimuli and, 
therefore, were able to accurately state the number of stimuli 
they touched. The second study, on the other hand, was not at-
tempting to determine accuracy. Rather, the goal was to discover 
which stimulus the musician would rely on when presented with 
two incongruent stimuli. Because the musician was not attempt-
ing to determine a specific stimulus, he was able to respond to 
whichever stimulus he perceived. This study proved that, given 
the option of two conflicting stimuli, musicians are more prone 
to relying on auditory perception than visual perception.
One reason that musicians rely more on auditory than vi-
sual stimuli when the two are conflicting is that the musical 
training process provides auditory feedback, strengthening the 
sensorimotor associations between the auditory and motor 
systems. Because of this continual strengthening, when the 
musician encounters inconsistent visual information, he has an 
easier time blocking it out and relying solely on his auditory 
perception. A non-musician, who never had such training, has 
poorer auditory perception, and therefore compensates with 
his visual perception (Abel, et al., 2016). Although this argument 
is compelling, the possibility remains that music does not, in 
fact, change perception preferences from visual to auditory in 
musicians. Perhaps people who naturally are inclined towards 
using auditory information, rather than visual, are inherently 
more disposed to becoming musicians, and that is the reason 
for the trend observed (Abel, et al., 2016, Banai, Ahissar, 2013).
Effects of Beginning Musical Training Young
Although musical training can affect the brain at any age, it has an 
extra impact when started at a young age. String instrument mu-
sicians who began training early have a greater representation of 
their left fingers in their motor cortex (Herholz, Zatorre, 2012). 
Another neuroanatomical change found in musicians who began 
training before the age of six or seven is found in the corpus cal-
losum. Because these children are practicing complex sequenc-
es daily, their brains need to accommodate a large transfer of 
information efficiently. This continual stimulation leads to an 
enlarged anterior corpus callosum (Iusca, 2011).
When studying the brains of forty-eight young adults who had 
at least one year of musical training in their youth, a researcher 
found that those who had begun training before the age seven 
had more developed brain areas connected to language and ex-
ecutive function (Sparks, 2013).
Starting musical training young seems to lead to improved visuo-
motor and auditory-motor synchrony, (Herholz, Zatorre, 2012). It 
is possible, however, that the children had exemplary visuomotor 
or auditory-motor coordination, which led them to begin music 
training young. If this is the case, the auditory-motor synchrony is 
the cause for early music training, rather than the reverse. 
Music Facilitates Learning
Music can facilitate learning in numerous ways. Firstly, music af-
fects the limbic system and subcortical regions, the areas that 
control long-term memory. Areas such as the hippocampus and 
cingulate cortex are stimulated through music. These areas con-
vert short-term memory into long-term memory. When learn-
ing while listening to music, the long-term memory areas are 
already stimulated, and the learning will become part of long-
term memory as an association of the music heard (Koelsch, 
2014, Wilkins, et al., 2014).
Listening to music seems to improve other cognitive tasks 
as well. A music director in North Carolina arranged for a 
woodwind quintet to play music three times a week to first 
grade, then first and second, and finally, first, second and third. 
Although the average IQ score for this school’s first through 
75
Music and the Brain
fifth graders had been below the national grade level, after the 
three years of listening to music the third-grade’s academic 
performance increased tremendously.  Eighty-five percent of 
the students were above grade level for reading and 89% for 
math. The improved math skills received from music is under-
standable. Music is inherently related to math because music 
measures beat and rhythm which are mathematical concepts 
(Bennet, Bennet, 2008).
Although relatively little musical training can improve basic per-
ceptional skills, especially among the originally poor performers, 
the larger population of musicians do not overall show improved 
verbal and cognitive skills. When children were given one year of 
after school music lessons, they did not show improved non-audi-
tory skills. In other words, the students had better pitch discrim-
ination, but the training did not generalize into verbal memory. 
The learning did not extend past the auditory perception the 
students gained directly from their music training. Possibly, with 
more time, other skills, such as verbal and cognitive skills, could 
emerge. Perhaps had the children had three years of music train-
ing, like the students from the previous study, the boost in reading 
and math skills would be evident as well.
Word decoding and reading comprehension were studied in 
six to nine-year-old musicians. The evidence showed no associ-
ation between length of training and word decoding, however, 
there was a close association between reading comprehen-
sion and musical training. Possibly, the reason that there was 
no significant difference between those with musical training 
and those without it with respect to word decoding is that the 
children in the control group were old enough that they cog-
nitively caught up on word decoding. If the children had been 
studied at a younger age, evidence may have shown a difference 
in word decoding ability. If musical training does in fact facilitate 
word decoding in younger children, perhaps the reason that the 
musical children tested had superior reading comprehension 
was because they had earlier and more proficient reading com-
prehension. According to this theory, the children did have a 
superior word decoding ability when they were younger, which 
led to an earlier reading comprehension. Because the musical 
children have been reading and effectively decoding, they show 
a higher reading comprehension than the non-musical children 
(Corrigall, Trainor, 2011).
In addition to reading comprehension, musical training facili-
tates improved reading skills in general, as well as the discrimina-
tion of small pitch variations in speech. Because pitch differentia-
tion is an important part of music, learning to play an instrument 
will improve pitch discrimination for both the instrument being 
learned and speech in general (Moreno, et al., 2009).
Since music training affects the motor cortex, which en-
ables the musician to play more complex pieces with greater 
dexterity, learning that involves the motor cortex is easier for 
musicians. Long-term musical training, specifically, augments 
short-term plasticity in the motor cortex. This is the reason 
that musicians have an easier time learning a nonsensical finger 
tapping sequence. Overall, motor performance and coordina-
tion are improved and, therefore, any learning that involves the 
motor cortex will be facilitated by musical training (Herholz, 
Zatorre, 2012).
Besides for the anatomical changes music effects, listening to 
music produces psychological benefits. Listening to music puts 
one in a good mood. When in a good mood, people are more 
productive and generate a higher quality of work. A study of 
employees listening to music in the workplace demonstrated 
that the weeks that the employees listened to music, higher 
quality of work was reported. However, it is possible that the 
higher review was an effect of the employees’ improved mood, 
and the quality of work was unchanged (Lesiuk, 2010).
The Mozart Effect
In the first study that correlated music and learning ability, par-
ticipants were placed into three groups and told to work out a 
spatial reasoning problem. The first group listened to Mozart’s 
music, the second practiced various relaxation techniques, and 
the third, the control group, did no preparation. The results 
showed that the group listening to Mozart performed the best. 
The phenomenon was coined the “Mozart Effect.” However, the 
benefit from the music lasted for a very short time, ten to fif-
teen minutes. Also, similar studies later showed that other music 
can achieve the same results. Therefore, it is possible that the 
result was not exclusively related to Mozart’s music but that 
music with an even tempo or rhythm may temporarily improve 
spatial relations (Bennet, Bennet, 2008).
Length of Training Needed to Effect a Change
Music training affects the brain’s structure. Some learning chang-
es are evident almost immediately, while others take longer. 
Temporarily improved auditory-motor coordination is evident 
after twenty minutes of instrument practice. However, the effects 
do not last long. More permanent improvement in this area hap-
pens after five weeks of training (Herholz, Zatorre, 2012).
Besides for length of training, the age that the musician be-
gins his lessons determines the extent of his brain’s structural 
changes. For example, string instrument musicians who began 
training young have a greater representation of their motor 
cortex dedicated to their fingers (Herholz, Zatorre, 2012). Also, 
musicians who began training before the age of seven had a larg-
er corpua callosum than musicians who began later in life. For 
example, the change in the corpus collosum of a six-year-old 
child would begin after about fifteen months of training (Iusca, 
2011, Herholz, Zatorre, 2012). The phenomenon is logical; the 
brain goes through the most changes during childhood, discov-
ering which areas require more synapses based on frequency of 
use. The younger the child begins music training, the earlier the 
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brain learns to accommodate the varying complexities needed, 
and the more prominent the resulting structural changes of the 
brain will be (Iusca, 2011).
Music Affecting Emotions
Although there is some controversy about whether music can 
induce emotions, there are some indications that music does 
play a role in stimulating emotion. There are six mechanisms 
which can explain the emotions generated by listening to music. 
The first is a brain stem reflex. The brain stem reacts to sounds 
that are loud and discordant with an arousal mechanism de-
signed to protect the person from possible danger. Listeners 
who enjoy arousal will be stimulated by jarring music.
A second mechanism is conditioned response learning. When 
music is heard for the first time in an emotional environment 
the emotions become connected to the music heard. Later, 
when the music is replayed, the emotional feeling is regenerated.
Another mechanism is emotional contagion. The mirror neu-
rons in the brain react by imitating stimuli in the environment. 
The tone, frequency or pitch of music will be mirrored by the 
listener by eliciting either calm or excitement.
A fourth mechanism through which music stimulates emotions 
is visual imagery. Often, while the listener is hearing the music, his 
brain conjures up images associated with the sounds he hears. 
It is possible for those images to lead to emotions. The images 
recalled may or may not be from memory. However, when the 
images are from the listener’s episodic memory, a different mech-
anism provides the emotions associated with the memory.
Finally, momentary surprise or confusion will occur when the 
listener anticipates a particular sequence of chords. For exam-
ple, if a listener hears a C sharp, D sharp, and then E sharp, he 
naturally expects the next note to be an F sharp. If the music 
breaks the rhythm, the listener is temporarily put off balance 
and may be confused. Although this will not lead to emotions 
such as joy or sadness, it can cause brief surprise or confusion 
(Juslin, Västfjäll, 2008).
Besides for these mechanisms, specific areas of the brain re-
lated to emotion are stimulated by music. One area activated 
by music is the amygdala. Because the amygdala controls the 
processing of emotions, stimulation to that area leads to feel-
ing emotion. Joyful music stimulates the superficial amygdala, 
leading to happiness. Both happy and sad music stimulate the 
latero-basal amygdala, which is associated with positive and neg-
ative reinforcement. This reinforcement can activate the me-
solimbic reward system in both musicians and non-musicians 
(Koelsch, 2014).
Pleasant music activates the nucleus accumbens and ventral 
tegmental area, which controls motivation through reward. 
The “reward” feeling is in the form of dopamine being released 
into the brain. Performing an action that leads to reward is 
enjoyable. Because listening to music stimulates the nucleus 
accumbens and ventral tegmentum which send the dopamine 
reward as a response, the listener appreciates the music 
(Koelsch, 2014, Schlaug, et al., 2010, Boso, et al., 2006, Menon, 
Levitin, 2005, Pereira, et al., 2011). Reward feelings are enjoyable, 
and therefore, improve the listener’s mood and affect his emo-
tions. Besides for activating the dopaminergic reward system, 
listening to music causes the release of endorphins into the 
blood stream. Endorphins reduce pain and stress and can lead 
to feelings of happiness (Koelsch, 2014, Herholz, Zatorre, 2012, 
Boso, et al., 2006).
Conclusion
Music affects a variety of areas in the brain, including areas that 
control cognitive learning, coordination and emotion. Not all 
music affects the brain in the same way. Different genres of 
music cause different size “hubs” of activation in the auditory 
cortex. Similarly, music that the listener likes is processed in a 
different way from music that he dislikes. Based on areas of acti-
vation in the brain, music therapy can be a useful tool for treat-
ing neurological disorders, such as stroke, cerebral palsy, and 
fronto-temporal dementia, as well as calming stress. Because 
musicians practice playing their instrument, and in general have 
more exposure to music, there are distinct differences in the 
structural anatomy of a musician’s brain, as opposed to that of 
a non-musician. Musicians tend to have a larger anterior corpus 
callosum, as well as greater representation of their fingers in 
the motor cortex, especially when musical training had been 
started at a young age and continued for at least fifteen months. 
Because playing an instrument requires complex multitasking, 
musicians develop superior multitasking skills, such as the ability 
to distinguish between conflicting auditory and visual stimuli. 
Additionally, since music affects areas of the brain connected 
to learning, people who listen to music or train in music show 
higher reading comprehension and math ability compared to 
non-listeners and non-musicians. Listening to music can be an 
emotional experience, in addition to the learning benefits, be-
cause of specific mechanisms associated with emotion which 
are stimulated by listening to music, as well as activation in areas 
which control underlying emotions, such as the amygdala and 
the mesolimbic reward system. Music is more than just sounds 
strung together. The effects of music are broad and should con-
tinue to be studied to determine the full extent of the benefits. 
References
Abel MK, Li HC, Russo FA, Schlaug G, Loui P. Audiovisual 
interval size estimation is associated with early musical 
training. PLoS One. 2016;11(10). https://search.proquest.com/
docview/1830383991?accountid=14375. doi: http://dx.doi.
org/10.1371/journal.pone.0163589.
Alves-Pinto A, Turova V, Blumenstein T, Lampe R. The 
Case for Musical Instrument Training in Cerebral Palsy 
77
Music and the Brain
for Neurorehabilitation. Neural Plasticity [serial on-





Banai K, Ahissar M. Musical experience, auditory perception 
and reading-related skills in children. PLoS One. 2013;8(9). 
https://search.proquest.com/docview/1435971856?accoun-
tid=14375. doi: http://dx.doi.org/10.1371/journal.pone.0075876. 
Bennet A, Bennet D. The human knowledge system: Music and 
brain coherence. Vine. 2008;38(3):277-295. https://search.pro-
quest.com/docview/232112779?accountid=14375. doi: http://
dx.doi.org/10.1108/03055720810904817.
Boso M, Politi P, Barale F, Emanuele E. Neurophysiology 
and neurobiology of the musical experience. Funct 
Neurol. 2006;21(4):187-91. https://search.proquest.com/
docview/233312810?accountid=14375. Herholz S, Zatorre R. 
Musical training as a framework for brain plasticity: Behavior, 
function, and structure. Neuron. 2012;76(3):486-502. https://
search.proquest.com/docview/1503847401?accountid=14375. 
doi: http://dx.doi.org/10.1016/j.neuron.2012.10.011.
Corrigall K, Trainor L. Associations between length of music 
training and reading skills in children. Music Perception. 
2011;29(2):147-155. https://search.proquest.com/
docview/911787394?accountid=14375.
Herholz S, Zatorre R. Musical Training as a Framework for 
Brain Plasticity: Behavior, Function, and Structure. Neuron. 
2012;76(3):486-502.
Iusca D. Brain plasticity as a consequence of musical education. 
Review of Artistic Education. 2011(1):73-79. https://search.
proquest.com/docview/1519062123?accountid=14375.
Juslin PN, Västfjäll D. Emotional responses to music: The 
need to consider underlying mechanisms. Behav Brain Sci. 
2008;31(5):559-75; discussion 575-621. https://search.proquest.
com/docview/212200357?accountid=14375. doi: http://dx.doi.
org/10.1017/S0140525X08005293.
Knight, W, Rickard N. Relaxing music prevents stress-induced 
increases in subjective anxiety, systolic blood pressure, and 
heart rate in healthy males and females. Journal of Music 








Lesiuk T. The effect of preferred music on mood and per-
formance in a high-cognitive demand occupation. J Music 
Ther. 2010;47(2):137-54. https://search.proquest.com/
docview/750430860?accountid=14375.
Menon V, Levitin DJ. The rewards of music listening: Response 





Merriam-Webster Web site. https://www.merriam-webster.
com/dictionary/music. Published 1898. Updated 2018. Accessed 
May 16, 2018
Miluk-Kolasa B, Kłodecka-Różka J, Stupnicki R. The ef-
fect of music listening on perioperative anxiety levels in 
adult surgical patients. Polish Psychological Bulletin [se-





Moreno S, Marques C, Santos A, Santos M, Castro S, Besson M. 
Musical training influences linguistic abilities in 8-year-old chil-
dren: More evidence for brain plasticity. Cerebral Cortex [seri-
al online]. March 2009;19(3):712-723. Available from: PsycINFO, 




Pereira CS, Teixeira J, Figueiredo P, Xavier J, Castro S, 
Brattico E. Music and emotions in the brain: Familiarity 
matters. PLoS One. 2011;6(11). https://search.proquest.com/
docview/1312156859?accountid=14375. doi: http://dx.doi.
org/10.1371/journal.pone.0027241. 
Ridder H, Wigram T, Ottesen A. A pilot study on the effects 
of music therapy on frontotemporal dementia -- develop-
ing a research protocol. Nordic Journal Of Music Therapy 
[serial online]. September 2009;18(2):103-132. Available from: 
CINAHL Complete, Ipswich, MA. http://web.b.ebscohost.com/
ehost/pdfviewer/pdfviewer?vid=23&sid=22757ec4-352e-4e2c-
8f92-ab402328a92b%40pdc-v-sessmgr01. Accessed February 
10, 2018
Schlaug G, Altenmüller E, Thaut M. Music listening and music 
making in the treatment of neurological disorders and impair-
ments. Music Perception. 2010;27(4):249-250. https://search.
proquest.com/docview/89194453?accountid=14375.
Schneider S, Schönle ,P.W., Altenmüller E, Münte ,T.F. Using 
musical instruments to improve motor skill recovery following 





Sparks S. Studies highlight brain benefits from music training. 
Education Week. 2013;33(13):6. https://search.proquest.com/
docview/1465898396?accountid=14375.
Walworth D, Rumana C, Nguyen J, Jarred J. Effects of live music 
therapy sessions on quality of life indicators, medications 
78
Maddie Nierman
administered and hospital length of stay for patients un-
dergoing elective surgical procedures for brain. Journal Of 
Music Therapy [serial online]. 2008;45(3):349-359. Available 




Wilkins R, Hodges D, Laurienti P, Steen M, Burdette J. Network 
science: a new method for investigating the complexity of 
musical experiences in the brain. Leonardo [serial online]. 
June 2012;45(3):282-283. Available from: Academic Search 




Wilkins R, Hodges D, Laurienti P, Steen M, Burdette J. Network 
science and the effects of music preference on functional brain 
connectivity: From beethoven to eminem. Scientific Reports 
(Nature Publisher Group). 2014;4:6130. https://search.pro-
quest.com/docview/1898156577?accountid=14375. doi: http://
dx.doi.org/10.1038/srep06130.
Zatorre RJ, Baum SR. Musical melody and speech intonation: 
Singing a different tune. PLoS Biology. 2012;10(7):e1001372. 
https://search.proquest.com/docview/1303741552?accoun-
tid=14375. doi: http://dx.doi.org/10.1371/journal.pbio.1001372.
Zhang XW, Fan Y, Manyande A, Tian YK, Yin P. Effects of 
music on target-controlled infusion of propofol require-






There is a clear correlation between excessive sun exposure and the development of skin cancer. UVB radiation from the sun 
is potent, and as the ozone layer gets depleted, more UVB can reach Earth and cause cell damage. UV radiation causes DNA 
lesions, such as 6-4 photoproducts and cyclobutane pyrimidine dimers. Cyclobutane pyrimidine dimers are more abundant and 
take longer to be repaired and therefore are responsible for most of the mutation and DNA damage. These DNA lesions lead to 
mutation of the p53 gene. The signature mutation on p53 from UV radiation is a CC to TT mutation, which generally occurs at 
the binding site of p53. As a result, of the mutation, p53 is inactivated and can no longer perform its tumor suppressive functions. 
As a result, cancerous or damaged cells in the skin can proliferate and form tumors. P53 is an early step in skin carcinogenesis, 
and p53 mutation is found in abundance in actinic keratosis, a precancerous lesion of Squamous Cell Carcinoma. Experiments 
conducted on mice prove the effectiveness of sunscreen. Mice treated with UVB blocking sunscreen had significantly decreased 
percentage of mutation, compared to mice without the sunscreen.
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Introduction
When summer comes around, it is quite challenging to find a 
place to sit at the beach. The sands are covered with people sun-
bathing and basking in the sunlight. Although it is widely known 
that excessive sun exposure directly correlates to the onset of 
skin cancer, many people feel that they are immune to the sun’s 
harmful rays and therefore will not develop skin cancer. However, 
this is not the case, and as they lie there, in denial of the harmful 
effects of the sun’s radiation, they are hurting their bodies. Tanning 
may cause a more appealing appearance , but in just a few years 
the harmful effects can emerge and cause a quite dangerous con-
dition, long after the beauty wears away. Sitting directly in the sun, 
especially without sunscreen, is understandably harmful, but what 
many people do not realize is that even in cloudy weather eighty 
percent of the sun’s rays can penetrate through the clouds and 
can still affect the skin (Bowes, 2012). No matter the weather, 
spending too much time outdoors without the proper protection 
is detrimental to a person’s skin. 
In the United States alone there are approximately 500,000 
cases of basal cell carcinoma (BCC) and 100,00 to 150,000 cases 
if squamous cell carcinoma (SCC) reported every year (Kanjilal 
et al., 1995). Sun exposure proves to be the major factor in the 
formation of these cancers. Melanoma generally is caused by 
short incidents of high intensity ultraviolet (UV) radiation. On 
the other hand, BCC and SCC, known as the non-melanoma 
skin cancers (NMSC) are generally caused by incidents of ex-
posure to UV radiation which gradually build up. Since NMSC 
is a result of the collective UV radiation absorption, it is more 
commonly found in older people (Armstrong and Cust, 2017). 
Generally skin cancer is more prevalent among fair skinned 
people, who have less melanin, pigment, which acts as a barrier 
to UV radiation. Moreover, people who live close to the equator 
are also at a greater risk for solar UV induced skin cancer, as the 
sun’s rays hit Earth most directly at equator. 
No matter the skin tone, too much sun exposure can lead 
to various issues, such as inflammation, photoaging, erythema, 
sunburn, eye damage, DNA damage and skin cancer (Benjamin 
et al., 2007). UV radiation causes damage to DNA, specifically 
on the p53 gene, a gene with tumor suppressive functions. Once 
this gene is mutated, it can no longer act as an anti-oncogene, 
and cancerous skin cells can metastasize. 
Methods
The research discussed in this paper was obtained from various 
published articles from the Touro Library and Google Scholar. 
Most of the articles present original information from studies 
and experiments of tissue and DNA
Discussion: Ultraviolet Radiation
The electromagnetic spectrum is a range of all forms of light, 
based in their frequency and wavelength. Visible light has wave-
lengths between 400 and 750 nanometers. UV radiation has 
shorter wavelengths and therefore higher frequency than visible 
light. Wavelengths of UV rays are 100 to 400 nanometers (US 
EPA, 2018). UV radiation is divided into 3 categories, UVA, UVB, 
and UVC. UVA has wavelengths between 320 to 400 nanometers, 
and can penetrate through the ozone layer, a protective layer of 
gas that surrounds earth and protects from harmful UV rays. UVB 
ranges from 290 to 320 nanometers, and is mostly blocked by the 
ozone layer, but some rays do come through the ozone and reach 
Earth. UVC ranges from 100 to 290 nanometers, and is almost 
entirely blocked by the ozone (Chouinard et al., 2001). 
Although UVB is mostly blocked by the ozone, as the strato-
spheric ozone layer is depleted, UV radiation is more potent 
and can raise the instances of skin cancer (Nakazawa et al., 
1994). UVB has been proven to be the major factor to induce 
DNA damage, because that specific wavelength can be absorbed 
by the nucleotide bases that make up DNA (Ichihashi et al., 
2003). Wavelengths below 290 nanometers usually get absorbed 
on the surface of the epidermis, and thus do not cause BCC and 
SCC (Radosevich, 2014).
Only ten percent of sunlight is UV radiation, as the rest 
comes from visible and infrared light. Of the ten percent, ninety 
five percent of it is UVA radiation, and only five percent is UVB 
(Bowes, 2012). A little bit of UVB is essential for the produc-
tion of Vitamin D, however, excessive exposure to it can cause 
erythema, cataracts, or skin cancer (Radosevich, 2014). Even 
small amounts of UVB exposure can be dangerous if there are 
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repeated incidents, as it will affect the cell formation in the skin 
by attenuating the basement membrane structure (Chouinard 
et al., 2001). The weakened membrane allows the UV radiation 
to reach a person’s DNA, specifically that of the p53 gene, a 
gene with tumor suppressive functions. Once this gene is mu-
tated, it can no longer act as an anti-oncogene. 
Function of p53
The p53 protein is made from a 20 Kb gene on the short arm 
of chromosome 17, which codes for a phosphoprotein involved 
in transcription and regulation in the cell cycle (Benjamin 
and Ananthaswamy, 2007). It has been dubbed the name “the 
guardian of the genome” and “the cellular gatekeeper” (Zilfou 
and Lowe, 2009). P53 is known this way because of its tumor 
suppressive functions. P53 gets activated via phosphorylation 
at a serine residue, at either the amino or carboxyl terminus 
(Benjamin et al., 2007). Then, it can inhibit the growth of cancer-
ous causing cell cycle arrest, apoptosis, and DNA repair (Ouhtit 
et al., 1998). Cell cycle arrest gives the cell the opportunity to 
correct DNA complications before the DNA gets replicated. 
Since the cell is not continuing mitosis at that point, no new 
cells will be formed with the incorrect DNA. On the other 
hand, when p53 causes apoptosis, the cancerous cell gets killed 
and destroyed, and therefore cannot proliferate and become a 
cancerous growth(Benjamin et al., 2007). Moreover, it can pre-
serve the correct form of the DNA (Einspahr et al., 1999). This 
is accomplished by “negative growth regulation,” which essen-
tially means that p53 stops cell division and proliferation of cells 
with abnormal DNA (Benjamin and Ananthaswamy, 2007).
Mutation of p53 is usually a missense mutation, a mutation 
which switches nucleotide in the DNA sequence. Therefore, the 
codon in the DNA will code for a different amino acid. Such a 
change affects the protein’s function if the mutation results in 
an amino acid change in the binding site of the protein, which is 
the case in the p53 missense mutations (Einspahr et al., 1999). 
When p53 is mutated it loses its ability to act as an anti-on-
cogene and suppress tumors, so growth of tumors are then able 
to grow and form. Tumorigenesis gets inhibited when p53 binds 
DNA and triggers a different gene to make p21. Once p21 is 
made, it reacts with a cell division stimulating protein(cdk2), and 
forms a complex with it. As a result, cdk2 is inactivated and the 
cell cannot continue with cell division. By stopping cell division, 
the cells cannot multiply and grow to form a tumor. However, 
when p53 gets mutated, it can no longer interact with DNA 
the same way, so p21 is not produced, cdk2 is not inhibited 
and cancerous cells can continue multiplying and form a tumor 
(National Center for Biotechnology Information (US), 1998).
UV Damage Adducts: Cyclobutane Pyrimidine 
dimers and 6-4 Photoproducts
BCC and SCC are mainly caused by UV radiation(You et al., 2001). 
Studies have shown that 58% of SCC has a mutation on the p53 
gene(Benjamin et al., 2007).UVB specifically causes bulky linkages 
between pyrimidine dimers(Sarasin and Giglia-Mari, 2002). DNA 
is made up of nucleic acid, which is a linear polymer of nucleo-
tides. Each nucleotide contains a ribose sugar, phosphate group 
and a nitrogen base. There are four different nitrogen bases found 
in DNA: adenine, guanine, cytosine and thymine. Adenine and 
guanine have similar ring structures and are classified as purines. 
Cytosine (C) and thymine (T) have a similar ring structure (differ-
ent than that of the purines) and are classified as pyrimidines. A 
pyrimidine dimer can form when two pyrimidine nucleotides are 
adjacent to each other on a DNA strand.
These pyrimidine dimer linkages can mainly be corrected 
by nucleotide excision repair. (Sarasin and Giglia-Mari, 2002). 
Nucleotide excision repair can repair UV induced pyrimidine 
dimer linkages before DNA replication, or after replication by 
using a specific DNA polymerase which corrects DNA. The re-
pair process begins with recognizing the damage on the DNA 
.The DNA is then cut on either side of the lesion on a single 
strand of DNA, and the damaged area is extracted. Next, the 
removed segment is replaced with new nucleotides to recreate 
the DNA properly. The process is complete when ligation oc-
curs, and the newly formed DNA segment is linked to rest of 
the strand. Two approaches to nucleotide excision repair are 
transcription coupled repair, which is done on DNA strands that 
are actively transcribed, and global genome repair which occurs 
on the non-transcribed strand of DNA. Transcription coupled 
repair requires is generally faster than global genome repair in 
DNA repair (de Gruijl and Rebel, 2008). Global genome repair 
deals with damage recognition and correction of pyrimidine 
dimer linkages. The damage recognition stage takes some time, 
depending on the effect of the damage on the structure of the 
DNA helix, and is the rate limiting aspect in repair, which makes 
global genome repair slower than transcription coupled repair 
(Ichihashi et al., 2003).The significance of nucleotide excision 
repair can be understood by studying patients with Xeroderma 
Pigmentosum, a genetic disease in which DNA repair from UV 
radiation, nucleotide excision repair, is impaired. Individuals with 
this disorder have a much higher rate of developing skin cancer, 
since they have more uncorrected pyrimidine dimer linkages 
that lead to mutation (de Gruijl and Rebel, 2008). Early growth 
of skin cancer is noted in Xeroderma Pigmentosum patients 
with a frequency of approximately 4000 more than regular peo-
ple (Sarasin and Giglia-Mari, 2002).
UVB can cause two types of DNA lesions on the p53 protein, 
cyclobutane pyrimidine dimers (CPD) and pyrimidine 6-4 pyrim-
idone photoproducts (6-4PP). Both of these linkages lead to C 
to T or CC to TT mutations, known as “signature mutations,” on 
gene p53 in DNA (You et al., 2001). In a study of tissue with 
different levels of sun exposure and sun damage, it was noted that 
74% of the mutation of p53 occurred at dipyrimidine sites, and 
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54% were C to T, or CC to TT mutations (Einspahr et al., 1999).
CPDs are the cause of 80% of the DNA mutations, since 6-4 
PP can be repaired more efficiently (You et al., 2001). The repair 
of 6-4PP can occur within less than 24 hours of the UV exposure 
(de Gruijl and Rebel, 2008). In fact, 56% of keratinocytes correct-
ed the 6-4 PP within 24 hours. Conversely, only 11% of CPDs 
were remedied within the first 24 hours after UVB exposure 
(Chouinard et al., 2001). CPDs are less effectively repaired and 
can lead to mutation of p53 and then skin cancer. Moreover, there 
are generally CPDs are 3 to 4 times more commonly formed 
than 6-4 PP (de Gruijl and Rebel, 2008). Experimentally it has 
been observed that 6-4 PP were formed significantly less often 
than CPD overall, and even more rare in experiments with solar 
UV simulation. Therefore, in natural sunlight, 6-4 PP are found at a 
much lower percentage than CPDs (You et al., 2001).
UVB from sunlight will cause CPD formation, especially at 
pyrimidine dimers which have methylated cytosine nucleotides 
(You, 2000). A CCG sequence with a methylated cytosine is a 
common place for mutation, since a methylated cytosine is less 
stable than regular cytosine and can be deaminated easily. The 
deamination of a methyl cytosine yields a thymine nucleotide, a 
DNA mutation (Sarasin and Giglia-Mari, 2002). CPDs only can 
cause mutations to develop after the deamination of a methyl-
cytosine in adduct (You et al., 2001). The CCG sequence codes 
for the amino acid arginine, and when the cytosine nucleotide 
gets converted to thymine, the sequence now codes for tryp-
tophan. This switch of amino acids is extremely important to 
the p53 gene since that arginine is found at p53’s binding site 
(Sarasin and Giglia-Mari, 2002). Since arginine and tryptophan 
have different side chains they react differently and thus will 
affect the binding of p53 to the target DNA. Arginine contains 
a second amino group on its side chain, which can act as a base 
and get protonated. Tryptophan side chain is two fused aromatic 
rings, and the nitrogen in its side chain is an extremely weak 
base, as it loses its aromaticity when protonated. Therefore, mu-
tation and transition of the nucleotide at this sequence greatly 
affects the function and capabilities of p53. 
Mutation of p53 and Carcinogenesis
Genetic mutations of p53 have clear correlations with the 
growth of cancer. When p53 is inactivated or mutated, the skin 
becomes more vulnerable to carcinogenesis (de Gruijl and 
Rebel, 2008). UV radiation provokes the growth of skin tumors, 
mostly SCC and BCC(You et al., 2001). Basal cells are on the 
bottom layer of the epidermis and rise slowly as new layers 
grow beneath them. As a result, these cells stay in the epidermis 
the longest, until the rise from the bottom layer until they even-
tually reach the top and die, Therefore UV damage to these cells 
has a long term capability to cause cancer, since they are in the 
skin for the longest time (de Gruijl, 2002).
 P53 mutation is found in about 50% of all types of cancer. UV 
radiation causes specific mutations in p53 which can result in 
skin cancer. It causes cancerous growths by stimulating different 
growth factors and activating their receptors. Moreover, each 
instance of UV exposure helps mutated cells reproduce and 
take over healthy epidermal cells, even if it does not induce new 
mutations. Although the cell has protective mechanisms against 
DNA mutation, UV sometimes can still cause DNA damage. 
Buildup of mutations on critical genes leads to carcinogenesis 
of the skin. Many mutations of p53 are even noted in normal 
looking skin which has been exposed to the sun (Benjamin and 
Ananthaswamy, 2007). Most of the mutations found in p53 in 
people with skin cancer, prove to have UV radiation as the cause. 
Once p53 is mutated, it affects the availability for apoptosis to 
occur in keratinocytes, as a response to UV radiation. Apoptosis 
is a programmed cell death. In tissues that are constantly re-
newing, apoptosis is involved in homeostasis , as more cells are 
reproducing, others are destroyed through apoptosis. When a 
gene which deals with apoptosis is mutated, it can result in too 
much growth, since cells are not dying as new cells are being 
formed. Moreover, p53 maintains “genomic integrity” by repair-
ing the DNA or causing apoptosis in a cell with mutant DNA. 
However, when p53 is mutated, it can no longer function in this 
way. In cancer, generally the mutation of p53 occurs further into 
the tumorigenic process. In contrast, in NMSC the mutation 
in p53 is an early step in carcinogenesis (Einspahr et al., 1999).
Mutated cells have overexpression of the p53 protein and form 
“p53 patches.” Most p53 patches had signature UVB damage. The 
mutation spectrum observed is quite similar to the mutation 
spectrum of SCC. As a result of the damage, the functions of p53, 
like apoptosis and cell cycle arrest, are interrupted. Since these 
processes generally occur to prevent cancerous growth, UV in-
duced damage which impacts them likely occurs early in cancer 
development. Although all p53 have the potential to become SCC, 
only a few do actually become cancerous. Approximately 8000 to 
40000 p53 patches are around by the time the first tumorous 
growth begins (de Gruijl and Rebel, 2008). 
UV induced mutations in p53 most likely occur as an early 
step in the process of skin carcinogenesis. However in other 
cancers, like colon cancer p53 mutations generally occur 
later in the development of the cancer, particularly related to 
the change from an adenoma to a carcinoma (Benjamin and 
Ananthaswamy, 2007). This phase of cancer is much later in the 
development as cancer progresses from normal epithelium, to 
abnormal epithelium, to a small adenoma, to larger adenoma, 
and finally to a carcinoma.
Actinic keratosis (AK) is a precancerous lesion which can lead 
to SCC. The frequency of a p53 mutation has been studied with 
different conditions of skin. In a particular study, the frequency 
of a p53 mutation in SCC was 53.8%, in AK it was 62.5%, in sun 
damaged skin it was 38.5%, and in normal skin it was 14.3%. 
The mutation is observed to have a higher frequency in skin 
82
Raizy Berger
from an AK lesion. This could be because the tissue samples 
obtained from AK lesions are closer to the surface of the skin, 
and the tissue samples of SCC are deeper in the skin and could 
be contaminated from the stromal tissue(Einspahr et al., 1999).
 Approximately 89% of the mutations found in AK, were UV 
signature mutations. Therefore, it is believed that AK is the 
growth of mutated, cancerous cells. Moreover, the UV does not 
only cause great increase in reproduction of the mutated cells, 
but also causes apoptosis of normal cells in the area of hyper-
proliferation (Benjamin and Ananthaswamy, 2007). Various stud-
ies of skin have found a lot of p53 mutations in BCC and SCC. 
Samples of 342 tissues from patients with aggressive and nonag-
gressive cases of SCC and BCC were studied for p53 changes. In 
BCC, 66% of the aggressive cases and 38% of the non-aggressive 
cases had p53 changes. In SCC, p53 mutations were observed 
in 35% of the aggressive cases and 50% of non-aggressive cases 
(Benjamin and Ananthaswamy, 2007). 
In a study of eight samples of NMSC, from the head and neck, 
7 of the samples (88%) had p53 mutation. Six of the tissues had 
at least two amino acid changes as a result of the mutation, which 
were mainly at the binding site of p53 (Kanjilal et al., 1995). 
In Approximately 38-50% of patients with NMSC, a second 
tumor grows within five years of the first one. A patient with 
skin cancer needs a lot of medical intervention, surgical proce-
dures, and sometimes radiotherapy (Kanjilal et al., 1995). 
Prevention
Since NMSC can be caused by UVB from sunlight, protection 
from the sun’s powerful rays would be a great means of pre-
vention. DNA damage and mutation of p53 are the beginning 
steps of the development of skin cancer, by preventing them 
skin cancer can be prevented as well (El-Deiry, 2007). Sunscreen 
can effectively protect the skin from UV induced DNA damage 
and p53 mutation, since it can absorb or reflect the harmful 
UV rays so they do not penetrate the cells (Radosevich, 2014). 
Sunscreens have been proven to protect against DNA damage, 
skin aging, sunburn, immunosuppression, and skin carcinogene-
sis. Although it can be obviously observed that sunscreen pre-
vents erythema and sunburn, experiments and studies must be 
conducted to see if it is useful in preventing deeper damage, like 
p53 mutation (Benjamin et al., 2007).
The effectiveness of sunscreen in preventing mutations, can 
be proven based on a murine experiment. After conducting 
experiments to prove that UV radiation causes p53 mutation, 
another experiment was conducted to understand if sunscreen 
can prevent the p53 mutations from happening. Both sunscreens 
used in this experiment had an SPF (sunburn protection factor) 
of 15. One sunscreen had only UVB protection, and the other 
had protection for UVB as well as protection from UVA. The 
mice who had the UVB sunscreen, developed p53 mutations 
88% less than mice without sun protection, and those with UVB 
+UVA sunscreen had 92% less mutations. Therefore, this exper-
iment clearly displayed the capability of sunscreen to inhibit p53 
mutation. Since p53 mutation is an integral step in carcinogene-
sis, if mutation is prevented, skin cancer is less likely to develop 
(Ananthaswamy, Ullrich and Kripke, 2002).
Another strategic tactic to avoid or delay carcinogenesis is 
to minimize sun exposure. Some UV exposure is necessary for 
the body, as it plays an important role in the synthesis of vitamin 
D , excess exposure can cause skin cancer (Radosevich, 2014). 
Studies have proven that p53 patches grow more when exposed 
to additional UV exposure. Although reducing UV exposure 
cannot eliminate the possibility of skin cancer, it can delay its 
progression and development(Benjamin et al., 2007).
The Environmental Protection Agency (EPA) notes that at noon 
the sun’s rays are most powerful as they travel the least distance 
to reach Earth. Therefore, it would be wise to avoid unnecessary 
UV exposure at that time. The EPA also recommends applying 
sunscreen, seeking shade when possible, keeping aware the UV 
index, and being exceptionally cautious around areas that can re-
flect the sun’s rays, such as water, snow, and sand (US EPA, 2018). 
Conclusion
UVB induced mutation of p53 leads to the development of skin 
cancer. UV radiation causes the formation of pyrimidine dimers 
on the p53 protein. P53 is an anti-oncogene, which prevents tu-
morigenesis by causing cell cycle arrest or apoptosis. When p53 
is damaged by UV mutation it can longer function and cancerous 
basal and squamous cells can proliferate and grow. Cancerous 
areas show overexpression of p53 and are referred to as “p53 
patches.” These patches will grow more when exposed to more 
UV radiation, even if the radiation will not cause a new mutation 
to form in that instance. Sunscreen usage and minimization of 
sun exposure are affective approaches to prevent UV damage of 
p53 and skin carcinogenesis.
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